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ABSTRACT OF DISSERTATION 
 
 
 
BIOCHEMICAL APPROACHES FOR THE DIAGNOSIS AND TREATMENT OF 
LAFORA DISEASE 
 
 
Glycogen is the sole carbohydrate storage molecule found in mammalian cells 
and plays an important role in cellular metabolism in nearly all tissues, including 
the brain. Defects in glycogen metabolism underlie the glycogen storage diseases 
(GSDs), genetic disorders with variable clinical phenotypes depending on the 
mutation type and affected gene(s). Lafora disease (LD) is a fatal form of 
progressive myoclonus epilepsy and a non-classical GSD. LD typically manifests 
in adolescence with tonic-clonic seizures, myoclonus, and a rapid, insidious 
progression. Patients experience increasingly severe and frequent epileptic 
episodes, loss of speech and muscular control, disinhibited dementia, and severe 
cognitive decline; death usually ensues in the second decade of life. LD, like one-
third of all epilepsy disorders, is intractable and resistant to antiseizure drugs.  
A hallmark of LD is the accumulation of intracellular, insoluble carbohydrate 
aggregates known as Lafora bodies (LBs) in brain, muscle, and other tissues. LBs 
are a type of polyglucosan body, an insoluble aggregate of aberrant glycogen 
found in some GSDs and neurodegenerative disorders. Like most GSDs, LD is an 
autosomal recessive genetic disorder. Approximately 50% of LD patients carry 
mutations in the epilepsy, progressive myoclonus 2A (EPM2A) gene encoding 
laforin, a glycogen phosphatase. Remaining patients carry mutations in EPM2B, 
the gene that encodes malin, an E3 ubiquitin ligase. Laforin and malin play 
important roles in glycogen metabolism. In the absence of either enzyme, 
glycogen transforms into an insoluble, hyperphosphorylated and aberrantly 
branched polysaccharide reminiscent of plant starch. This abnormal 
polysaccharide precipitates to form LBs and has pathological consequences in the 
brain.  
Since a definitive LD diagnosis requires genetic testing, whole exome 
sequencing has been increasingly used to diagnose LD. As a result, numerous 
cases of more slowly progressing or late-onset LD have been discovered that are 
     
 
associated with missense mutations in EPM2A or EPM2B. Over 50 EPM2A 
missense mutations have been described. These mutations map to many regions 
of the laforin X-ray crystal structure, suggesting they produce a spectrum of effects 
on laforin function. In the present work, a biochemical pipeline was developed to 
characterize laforin patient mutations. The mutations fall into distinct classes with 
mild, moderate or severe effects on laforin function, providing a biochemical 
explanation for less severe forms of LD.  
LBs drive LD pathology. As a result, LBs and glycogen metabolism have 
become therapeutic targets. Since LBs are starch-like, and starch is degraded by 
amylases, these enzymes are potential therapeutics for reducing LB loads in vivo. 
However, amylases are normally secreted enzymes. Degradation of intracellular 
LBs requires a cell-penetrating delivery platform. Herein, an antibody-enzyme 
fusion (AEF) technology was developed to degrade LBs in vitro, in situ in cell 
culture, and in vivo in LD mouse models. AEFs are a now putative precision 
therapy for LD, potentially the first therapeutic to provide a significant clinical 
benefit. 
Prior to this work, LD was considered a homogenous disorder and treatments 
were only palliative. The data herein support a spectrum of clinical progression, a 
potential therapy for LD, and mechanistic insights into LD pathophysiology. This 
work illustrates how personalized medicine, both in diagnosis and treatment, can 
be achieved through basic biochemical approaches to human disease. 
 
KEYWORDS: Lafora disease, glycogen, epilepsy, neurodegenerative disease, 
phosphatase, personalized medicine. 
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  BRAIN GLYCOGEN STRUCTURE AND ITS ASSOCIATED 
PROTEINS  
1.1 Introduction 
 In the 1840s, the French physiologist Claude Bernard made an astonishing 
observation: that sugar could be synthesized de novo by the liver of a dog that 
was exclusively fed meat (1). In 1857, he described the isolation of this sugar-
forming substance, which he aptly called la matière glycogène (2). Soon afterward, 
glycogen in muscle was reported, shown to diminish with exercise, and discovered 
to "ferment" into lactic acid. Over the century that followed, the structure and 
regulation of glycogen were extensively characterized in the context of liver and 
muscle, leading to multiple Nobel prizes throughout the 20th century. Although the 
mechanisms governing glycogen metabolism have been deeply studied, the work 
is not yet complete. Meticulous investigations of Nobel laureates Otto Meyerhof, 
Carl and Gerty Cori, Luis Leloir, Edwin Krebs and Edmond Fischer, and countless 
others have paved the way for a profound understanding of glycogen metabolism, 
even in organs where glycogen constitutes a smaller fraction of total weight, such 
as the brain. Despite glycogen metabolism being a mainstay in textbooks, new 
aspects of glycogen structure, metabolism and tissue-specific roles are still being 
defined, aided by modern technologies and the mechanistic investigations of 
glycogen storage diseases.  
This chapter discusses the historical progression of glycogen research and its 
current condition with particular emphasis on how it has benefitted the overarching 
field of biochemistry, why the study of brain glycogen has lagged, and what gaps 
remain in our understanding of glycogen metabolism. There are aspects of 
glycogen structure and metabolism that are applicable to all types of glycogen, but 
some aspects are specific to organisms, tissues, and/or nutritional state, and 
insights can be gleaned through study of the other types of carbohydrates, 
particularly plant starch. Given the similarities and connections, it is useful to 
review the literature on glycogen (and starch) to understand what can be 
extrapolated to brain glycogen. This chapter provides a detailed overview of our 
current understanding of glycogen structure, architecture, associated proteins, 
tissue-specific properties and subcellular distribution. Glycogen storage diseases 
inform our studies of glycogen in ways that would not otherwise be possible; 
insights gained from Lafora and Pompe disease in particular are discussed. An in-
depth understanding of glycogen metabolism and the basic mechanisms of these 
diseases pave the way for more effective diagnoses and therapies, as discussed 
in later chapters.  
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1.2 Discovery of glycogen and its associated proteins 
1.2.1 Claude Bernard and early reports of brain glycogen 
Glycogen constitutes up to 8% of liver volume and up to 2% of muscle volume, 
and its content is higher in these tissues than in any other tissue of the adult 
mammal (3). It is not surprising that the fundamental study of its structure and 
metabolism began in liver and muscle. Claude Bernard, through a series of 
fundamental experiments, discovered the primary role of the liver in supplying 
glucose to other organs through the bloodstream (reviewed by (4-6). In 1848, 
Bernard noticed that after death, a large amount of glucose was released from the 
hepatic veins of a dog, even when the dog had not been fed any carbohydrates 
(6). He concluded that the liver could produce glucose, and by 1857, reported that 
he could extract glycogen (a term that literally means "sugar-former") by plunging 
the tissue in boiling water shortly after death and precipitating the material with 
alcohol (Figure 1.1) (2). Through fermentation with yeast and basic chemical 
tests, he confirmed that its main constituent was glucose (5). He also noticed that 
the glycogen yielded a red wine color in the presence of iodine, which facilitated 
its histological observation in other tissues (7, 8). Very shortly afterward, Sanson 
reported the isolation of "a glycogen-like substance analogous to dextrin" from the 
spleen, muscle and kidneys of a horse (translated, (9) (Figure 1.1). By 1875, 
Bernard and others reported glycogen in mammalian muscle, embryos, and trace 
amounts in other tissues, but it was difficult to know for certain that those trace 
amounts were indeed glycogen (10).  
Soon after Bernard's discovery of glycogen, it was noted that glycogen in 
muscle diminished upon contraction, and Bernard reported that "muscle glycogen 
always undergoes a lactic acid fermentation, and this is the only change that 
muscle glycogen ever undergoes, either in the living animal or after death" (5, 10). 
In the early twentieth century, a landmark paper from Fletcher and Hopkins 
demonstrated that lactic acid was formed in muscle under anaerobic conditions 
(11). Then, a German physician named Otto Meyerhof published a series of 
experiments demonstrating that the lactic acid produced by frog muscle was 
derived from glycogen, and that in the presence of oxygen, it could be either 
oxidized, or reconverted to glycogen (Figure 1.1) (12-14). "Meyerhof's brilliant 
analysis of the glycogen-lactic acid cycle and its relation to respiration explained 
the course of the heat production and, for the first time, established the cyclic 
character of energy transformations in the living cell" (15). For this discovery and 
his seminal work on glycolysis, Meyerhof and his colleague A.V. Hill were awarded 
the 1922 Nobel Prize in Physiology or Medicine.  
The German physiologist Eduard Pflüger is credited as the first to establish a 
method for obtaining pure fractions of glycogen (Figure 1.1), and modifications of 
his method are still used today (4, 16, 17). While Pflüger, Bernard and most others 
were unable to detect glycogen in the nervous system, traces of brain glycogen in 
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the normal and diabetic human brain were reported by Cramer in 1880 and Pavy 
in 1881 (18). Similar findings were published in an 1890 edition of The Lancet: "Dr. 
Fütterer has examined various organs of a diabetic person, finding glycogen in the 
medulla oblongata, spinal cord, and kidney in large quantities, and a little in the 
liver. A careful examination of the cerebral cortex showed that the vessels were 
full of glycogen. He concluded that extensive disturbances of nutrition were bound 
to result from this" (19).  
Although nearly all studies of glycogen in the early 1900s were in the liver and 
muscle of various organisms, as well as in yeast, a few groups reported glycogen 
in the central nervous system (CNS) of animals by staining tissues with an iodine 
solution. Glycogen was observed in the CNS, often in the retina, of the lancelet, 
lamprey, frog, pigeon, rabbit, and dog (18, 20). Gage asserted its presence in the 
CNS of lower organisms, in the dorsal root ganglia of the pig, and in the choroid 
plexus of human embryos (Figure 1.2). He validated the identity of the 
"mahogany-red substance" by incubating the sections with saliva, which contained 
amylases that digested the glycogen so that it no longer stained. "With the higher 
vertebrates, glycogen in demonstrable amount is not found in the nervous system 
after the embryonic period, the liver and muscles then assuming the main 
glycogenic function." Gage was hopeful that with the proper techniques, glycogen 
would also be found in the adult human CNS (18). 
With the relationship between glycogen and lactic acid demonstrated in muscle 
by Meyerhof, a few groups began investigating this relationship in brain. However, 
brain glycogen and lactic acid remained difficult to isolate and detect, and results 
were variable. Some groups reported a reduction in glycogen with insulin-
stimulated convulsions or anesthetics, while others reported a rise in glycogen 
after convulsions produced by methylguanidine; Holmes and Holmes in reviewing 
these studies argued that the low values reported for brain glycogen were within 
the normal range of variation, and that brain glycogen is unlikely to produce lactic 
acid under normal conditions (20). They astutely commented that "it is possible 
that the low values which we, in common with other workers, find for the glycogen 
content of the brain, may be due, not to a slow or inadequate breakdown 
mechanism, but to an extremely rapid one." This was indeed the case, and 
methods for capturing brain glycogen improved over the years; however, it was 
not until the end of the 20th century that the most sophisticated methods for 
measuring brain glycogen emerged. "It seemed to us, therefore, that it is quite 
possible that glycogen plays a comparatively unimportant (or at least quite 
obscure) part in the carbohydrate metabolism of mammalian brain" (20). This 
sentiment prevailed for many years, and it did not become clear until the following 
century that the role of glycogen in brain was more obscure than it was 
unimportant. Meanwhile, studies on glycogen enzymology had just begun, which 
led to a series of fundamental discoveries with major impacts on the wider field of 
biochemistry.  
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1.2.2  The Cori years: advances in glycogen enzymology and glycogen 
structure 
Soon after Meyerhof's Nobel prize was awarded, Carl and Gerty Cori, Czech-
born medical doctors who had emigrated to the United States, started working on 
the effects of insulin and epinephrine on liver glycogen. They reported that the 
hyperglycemia observed in the blood after epinephrine injections could not be 
accounted for solely by liver glycogen, and that lactic acid, which would be derived 
from muscle, could give rise to newly formed liver glycogen (21). They theorized 
that there was a "cycle of carbohydrates" linking liver glycogen and muscle 
glycogen, with the intermediates between the two being glucose and lactic acid 
(Figure 1.3a). Their subsequent work demonstrated this theory to be true, and it 
became known as the Cori cycle.  
The Coris made a series of major discoveries in the 1930s (Figure 1.1). In 1936 
they isolated a novel ester, glucose-1-phosphate, from a mixture of glycogen, 
inorganic phosphate, and aqueous muscle extract (22). So significant was this 
discovery that the compound became known as the Cori ester (7). In subsequent 
years, the Coris showed that a phosphorylating enzyme found in muscle, heart, 
liver, brain, and yeast extracts catalyzed the release of glucosyl moieties from 
glycogen by esterifying them with inorganic phosphate. The resulting glucose-1-
phosphate was converted to glucose-6-phosphate by an enzyme they named 
phosphoglucomutase (23, 24). In a 1939 article in Science, they reported that the 
enzyme producing the Cori ester (which they aptly named phosphorylase) could 
also catalyze the reverse reaction, in order to synthesize polysaccharide (25). 
Almost simultaneously, phosphorolytic enzymes catalyzing polysaccharide 
synthesis were being described in the extracts of peas and potatoes and in yeast 
(26, 27). In 1943, Cori, Cori and Green crystallized glycogen phosphorylase and 
published a series of seminal papers on its properties (28-31). In reward for their 
pioneering work, the Coris shared the 1946 Nobel Prize in Physiology or Medicine 
with Bernardo Houssay, who also made important contributions to the field of 
carbohydrate metabolism through his study of the role of the pituitary gland in 
hormonal regulation.   
The discovery of phosphorylase in mammals, plants and yeast was a major 
breakthrough in the overarching field of biochemistry (7). Phosphorylase was the 
first enzyme demonstrated to synthesize polysaccharide, and glycogen was the 
first macromolecule to be synthesized in vitro (32, 33). However, while mammals 
and yeast utilize glycogen as an energy source, plants synthesize starch, a 
glucose polymer with very different properties. Investigations of plant starch had 
been underway years before Bernard's discovery of glycogen and were 
progressing in parallel with those of glycogen. By the 1940s it had become clear 
that starch was composed of two distinct polymeric fractions: amylose, which was 
composed of long linear chains of glucose and gave an intense blue-black color 
with iodine, and amylopectin, which was a branched macromolecule and gave a 
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purplish to reddish color (34). While the Coris were working out glycogen 
enzymology, others were studying the polymeric nature of both glycogen and 
starch. Haworth and Percival established a method for identifying the chemical 
linkages in glucose polymers through methylation of the free hydroxyls of the 
glucose polymer prior to hydrolysis with acid (35). They found that since most of 
the product had unmethylated hydroxyls at the 1- and 4- positions, the majority of 
the glucose units in glycogen must be linked by α-1,4 glycosidic bonds. A small 
proportion of glucose was methylated at the 4-hydroxyl position, which would 
represent what is called the non-reducing end of a glucose chain (i.e. the end 
lacking an aldehyde group). Based on the proportion of the methylated products, 
the average linear chain in glycogen was proposed to contain 12 glucose units. 
Similar work was done on several varieties of plant starch, and the average chain 
length in starch was estimated to be 24-30 units (36). In 1947 and 1949, the α-
1,6-linked disaccharide isomaltose was isolated from hydrolyzed starch and 
glycogen, providing definitive evidence for the chemical identity of the branch 
points (37, 38).  
For many years it was believed that phosphorylase catalyzed both the 
synthesis and degradation of glycogen and starch, although synthesis by 
phosphorylase always required a primer, i.e. the addition of a small amount of 
carbohydrate upon which phosphorylase could act (7, 39). Curiously, 
phosphorylase from brain, heart and liver extracts produced branched 
polysaccharides that yielded a similar color to glycogen when stained with iodine, 
while the enzyme from potato and muscle extracts synthesized a linear, 
unbranched polysaccharide resembling amylose (31). It was hypothesized that the 
former preparations contained a contaminating enzyme that was capable of 
introducing the α-1,6-linked branch points. A branching enzyme had been 
identified in potato, and in 1953, Larner characterized the branching enzyme from 
rat liver and muscle extracts. Using isotopic labeling, he showed that potato, liver 
and muscle branching enzymes transferred a 1,4-linked chain of 6-11 glucose 
moieties to create the 1,6-linked branch. Thus, branching enzyme is considered a 
transglucosidase (40). His approach was novel in that he utilized radioactive 
isotopes rather than measuring branching by a shift in iodine color, susceptibility 
to phosphorylase, or change in end-group. With the combination of phosphorylase 
and branching enzyme, glycogen could be synthesized in vitro, and for the most 
part, it resembled the glycogen purified from tissues (41). 
Similarly, it was observed that while muscle phosphorylase could completely 
digest glycogen, recrystallized preparations of muscle phosphorylase and potato 
phosphorylase degraded glycogen only partially, stopping at the branch points, 
and leaving what was called a limit dextrin (42). A second enzyme must be present 
in the crude extracts that could remove the branch points. In 1951, Cori and Larner 
discovered the contaminating enzyme, showing that it cleaved α-1,6 linkages and 
released free glucose (42). Walker and Whelan later found that the phosphorylase 
limit dextrin contained not one, but four glucose units attached to branch points 
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(43). It was then discovered that the enzyme they had identified, which they called 
amylo-1,6-glucosidase, also had transglucosidase activity, favoring the transfer of 
three glucose units from one chain to another (44). It is now well established that 
when phosphorolysis terminates four units away from a branch point, the glycogen 
debranching enzyme, which possesses both transferase and glucosidase 
activities, moves three glucose units to another chain and then releases the single 
branched glucosyl moiety (45).  
It appeared at that time that all of the enzymes required for glycogen synthesis 
and degradation had been identified: glycogen phosphorylase, branching enzyme, 
and debranching enzyme. Enzymes that were either analogous or distinct to these 
had also been identified in plants. It became possible to utilize these enzymes to 
more precisely understand the structure of the glycogen and amylopectin 
molecules. With such useful tools and insights in common, the fields of starch and 
glycogen metabolism continued to progress together and overlapped 
considerably. In 1940 a tree-like structure for glycogen and amylopectin was 
proposed by Meyer and Bernfeld based on serial degradation with various 
enzymes (Figure 1.1) (46). This model varied from the prior structures proposed 
by Staudinger and Haworth, which were based solely on data obtained by 
chemical methods. The Cori group used stepwise enzymatic degradation of 
various glycogens and amylopectins with phosphorylase and debranching 
enzyme to test the various models. It was evident that glycogen was composed of 
"tiers," and each successive tier could only be accessed by phosphorylase after 
removal of the branch points by the debranching enzyme; degradation of multiple 
tiers required alternating treatments of the two enzymes. "The Staudinger and the 
Haworth models would yield a constant percentage of the total branch points in 
each tier during successive enzymatic degradation, while the Meyer model would 
yield a diminishing percentage as one progresses from the outer to the inner tiers, 
such as is actually indicated by the data in Table II. Only one kind of model could 
be made to fit this arrangement of branch points; namely, one which represents 
the polysaccharides as multibranched, tree-like structures" (39) (Figure 1.3b). It 
was also noted in this paper that the average chain length of liver and muscle 
glycogen (15 glucose units) were shorter than those of wheat and corn 
amylopectin (18 and 24 glucose units, respectively). We now know that chain 
length is one of the major features that distinguish glycogen from amylopectin. 
Meyer's model was the accepted model for glycogen and amylopectin until 
experiments from Whelan's group in 1970 showed the absence of very long chains 
and refined the model (Figure 1.1) (47, 48). The currently accepted model for 
glycogen is based on Whelan's work, but recent data indicates this model requires 
further refinement (see Section 1.3.1). 
 
1.2.3  Emerging technologies with staying power  
 
When the Coris began their work, the most common procedure for purifying 
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glycogen was based on the 1909 Pflüger method. The protocol is similar to what 
Bernard used and involves boiling tissue in hot concentrated alkali and then 
precipitating the glycogen with alcohol (16). Modifications of this procedure, 
especially those of Somogyi (49), were used by the Coris and are still the most 
commonly utilized protocols for glycogen extraction. Another frequently used 
method, introduced in 1934 (50), is extraction with cold trichloroacetic acid (TCA); 
however, it has been observed that not all glycogen can be extracted by this 
method (see Section 1.6.2), and a slightly different molecular weight is observed 
for the purified glycogen (51, 52). In 1936, the first reliable procedure for extracting 
brain glycogen was established utilizing Somogyi's method (53). Kerr found that 
he obtained the highest yields when the brains of dogs were rapidly excised under 
amytal anesthesia and crushed directly into 60% potassium hydroxide. He also 
obtained high yields when the brains were frozen in situ in liquid air. Importantly, 
he showed that the purified brain glycogen "is indistinguishable from liver glycogen 
prepared by Somogyi’s method. It dissolves readily in water to form a transparent 
solution, which is opalescent in reflected light. This when treated with iodine 
solution gives a Burgundy red color identical with that obtained with a solution of 
liver glycogen." The similar chemical properties of brain and liver glycogen were 
important to establish, and made it reasonable to extend the principles of glycogen 
structure and regulation that were being so thoroughly defined in liver and muscle 
to brain glycogen.  
Quantifications of brain glycogen were now reproducible. Kerr and other groups 
showed that brain glycogen levels dropped during hypoglycemia in dogs, cats and 
rabbits (54). Once a robust method for quantifying low levels of brain lactate was 
also established (55), informative experiments on the effects of various stimuli on 
brain glycogen and lactate could begin. Using a circular saw to rapidly excise the 
brains of mice, Chance and Yaxley showed that lactate was elevated with both 
subconvulsive and convulsive levels of various seizure-inducing stimulants, while 
glycogen was only elevated when a convulsion was reached (56). They also 
carefully defined the rapid decrease of glycogen and lactate levels after death in 
both normal and convulsed mice, demonstrating that most of the glycogen was 
lost after five minutes (Figure 1.4a). Based on their own measurements and those 
of their contemporaries, they estimated that "a large number of vertebrates 
normally possess between 10 and 30 mg of glycogen per 100 g of brain tissue" 
and that glycogen distribution within the brain was heterogeneous. These values 
are in agreement with current estimates (3). A few groups also began studying 
glycogen metabolism in isolated cerebral tissues and the effects of sleep on brain 
glycogen (57-59). 
As glycogen quantification methods improved, so did microscopic techniques. 
Glycogen had long been visualized with iodine using the light microscope, but the 
stain was not sensitive enough to detect the small amounts found in the normal 
adult brain. Additionally, alcoholic fixation was also critical, as glycogen would 
dissolve in aqueous solutions (18). Some attempts were made to visualize 
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glycogen with Best's carnitine or the Bauer reaction, but these methods were also 
criticized for their lack of sensitivity (53, 60, 61). In 1946, McManus introduced the 
periodic acid-Schiff (PAS) technique as a delicate and convenient way to stain 
carbohydrates, including glycogen, in tissue sections: the periodic acid reacts with 
the 1,2 glycol linkage of carbohydrates, producing an aldehyde that can be colored 
with Schiff reagent (62, 63) (Figure 1.1). Although PAS stained most 
polysaccharides, including glycoproteins and mucins, its specificity for glycogen 
could be tested by incubation with diastase (a general term for amylase) or saliva 
(which contains amylase) to digest the glycogen and distinguish it from other types 
of polysaccharides, which were left intact after digestion (60). Using PAS and a 
modification of this stain (lead-tetra-acetate-Schiff), Shimizu and Kumamoto 
published a series of papers in the 1950s on glycogen deposition in the normal 
brain and with pathological insults (64-67). Glycogen was detected in the area 
postrema (an area populated primarily by glial cells) in mammalian brains, 
particularly around blood vessels, and in ependymal cells of the supraoptic crest 
in rodents; it could also be detected in nerve cells of the hypothalamic nucleus and 
other regions when the brain was perfused with appropriate fixatives (Figure 1.4b) 
(65). The PAS technique, usually in combination with diastase (PASD), is now the 
most widely used histochemical stain for glycogen detection in tissues (68).  
Another extremely useful technology in visualizing glycogen structure and 
distribution was born with the invention of the electron microscope in 1931 by Ernst 
Ruska (69). The electron microscope achieved superior resolution to that of the 
light microscope. In 1934, Marton developed a histological technique that  allowed 
biological specimens to be visualized by the electron microscope without 
destruction (70). With this technique, the fine structure of subcellular organelles 
could be visualized. The first report of glycogen using electron microscopy (EM) 
was from Husemann and Helmut Ruska, Ernst Ruska's brother, in 1940 (71) 
(Figure 1.1). The spherical particles, which were derivatized to produce better 
scattering of the X-ray beam, were about 15-30 nm in diameter. But visualization 
of glycogen was difficult for a number of reasons. Firstly, polysaccharides contain 
primarily light atoms (carbon, oxygen and hydrogen) and are intrinsically not very 
electron dense. Secondly, after the identification of ribonucleoprotein particles by 
EM, particulate components with a diameter of ~150 Å free in the cytoplasm or 
associated with the endoplasmic reticulum were typically interpreted as 
ribonucleoprotein (72, 73). Unknown tissue components were sometimes 
identified by comparing the thin EM sections with thicker, stained sections viewed 
under the light microscope, but this too had its limits.  
The ultracentrifuge, invented by Theodor Svedburg in 1925, became a very 
powerful tool in the field of biochemistry and allowed glycogen to be isolated its 
native form. Lazarow showed in 1942 a species which he called "particulate 
glycogen" could be isolated from liver via ultracentrifugation without the use of 
harsh chemicals (Figure 1.1) (51). Its sedimentation constant suggested a 
molecular weight much larger than previous reports for Pflüger-purified glycogen, 
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and the particle, which he showed was made of pure glycogen, could be dispersed 
by heating, trichloroacetic acid (TCA), or potassium hydroxide treatment. Lazarow 
concluded that "clearly, then, particulate glycogen is an aggregate of smaller 
glycogen units." In 1962, Drochmans, combining these two state-of-the art 
technologies and utilizing a negative staining technique with phosphotungstate, 
elegantly described the ultrastructure of glycogen particles purified by differential 
ultracentrifugation (74) (Figure 1.1). He defined three levels of glycogen structure 
in the rat liver visible by EM: the largest structure was the α particle, which was 
60-200 nm in diameter and had a rosette like appearance; the β particle, 20-40 
nm in diameter, which associated to form α particles; and the γ particle, which 
referred to the 3 nm fine filaments comprising the β particle (Figure 1.5a,b). The 
α particles could be dispersed into β particles in low pH. It became clear that 
Drochmans's α particle was equivalent to Lazarow's particulate glycogen, and that 
these particles represent the primary native form of glycogen in the liver. This 
helped to explain the discrepancies in molecular weights that others had observed 
for glycogen purified by different methods. In 1968, Wanson and Drochmans also 
visualized differentially centrifuged glycogen from rabbit skeletal muscle, showing 
the presence of solely β particles (Figure 1.5c) (75). Dozens of EM studies on 
glycogen in various tissues and organisms followed.   
The use of EM on sections of the mammalian brain in the 1960s and later years 
made it clear that the vast majority of brain glycogen was present in the form of β 
particles in astrocytic processes (Figure 1.5d) (76, 77). Multiple groups showed 
striking accumulations of glycogen in reactive astrocytes in response to various 
traumas (Figure 1.5e) (66, 67, 76). Most groups reported that in the adult 
mammalian brain, neurons and microglia contained virtually no glycogen except 
under certain pathological conditions; however, in a few studies of normal tissue, 
glycogen was found in nerve cells (reviewed by (78)). During this time, numerous 
groups began using PAS and EM to visualize the microscopic characteristics of 
polyglucosan bodies, abnormal carbohydrate structures found in a variety of 
tissues. Polyglucosan bodies were identified in both astrocytes and neurons, in 
the context of glycogen storage diseases, epilepsy, neurodegenerative disorders, 
and aging (79, 80). Although glycogen still received little attention in the brain 
compared to other tissues, its significance was becoming increasingly evident. In 
1961, A.W. Merrick stated, "A substantial amount of Russian work within the past 
decade has been directed toward brain glycogen changes during various function 
and biochemical states of the animal. The opinion is offered by many of these 
investigators (several of whom are cited in this paper) that glycogen takes an 
active part in brain metabolism" (81). 
 
1.2.4  Sugar nucleotides, reversible phosphorylation, and a glycogen primer  
In 1950, the Argentinian chemist Luis Leloir discovered the first sugar 
nucleotide: uridine-diphosphate (UDP) glucose (82). It soon became apparent that 
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the sugar nucleotides were found throughout nature and were essential for the 
interconversion of carbohydrates, occupying "a central position in carbohydrate 
metabolism" (83). In 1957, Leloir made the shocking discovery that the true 
catalyst of glycogen synthesis was not glycogen phosphorylase, but a glucosyl 
transferase utilizing UDP-glucose as a glucosyl donor, which became known as 
glycogen synthase (84) (Figure 1.1). In the words of Larner, "Nature seems to 
have found a new more powerful glucose donor by making a pyrophosphate 
derivative of the Cori ester" (7). Leloir's group went on to show that glycogen 
synthesized in vitro using glycogen synthase in combination with branching 
enzyme was identical to natively purified glycogen β particles from muscle; in 
contrast, glycogen synthesized by phosphorylase and branching enzyme was not 
exactly equivalent to native glycogen: it differed in its stability and response to 
various types of degradative treatments (85, 86). These results were confirmed 
and expanded upon by numerous groups, and Leloir was awarded the 1970 Nobel 
Prize in Chemistry for his discovery of the sugar nucleotides.  
It became apparent that both glycogen phosphorylase and synthase are 
peculiar enzymes. The Coris observed that glycogen phosphorylase existed in two 
forms, an active a form, and inactive b form, which were differentially activated by 
adenylic acid (87). The Coris had identified another enzyme capable of converting 
the a form to the b form, calling this the "prosthetic-group-removing" enzyme (29). 
Kinase activity, the covalent addition of phosphate to one protein by another, was 
first described in 1954 (88), and in 1955, Fisher and Krebs showed that 
phosphorylase a could be converted to phosphorylase b in the presence of 
adenosine triphosphate (ATP) by an enzyme from muscle that became known as 
phosphorylase kinase (PhK) (89). Concurrently, Wosilait and Sutherland also 
demonstrated the presence of an equivalent converting enzyme in liver (90). 
These were the first ever demonstrations of reversible phosphorylation, a 
momentous discovery that has reverberated throughout the life sciences. Fischer 
and Krebs published a series of papers on the details of this novel mechanism 
that earned them the 1970 Nobel Prize in Physiology or Medicine, and Sutherland 
received the 1971 Nobel Prize for his discovery of cyclic adenosine 
monophosphate (cAMP) and its role in hormonal regulation (91). A few years later, 
Larner and others showed that glycogen synthase is also subject to allosteric 
control, that it exists in two forms, and that the interconversion of these forms 
requires phosphorylation by another kinase (92). In fact, unlike phosphorylase, 
which has one phospho-site and one kinase, synthase is hierarchically 
phosphorylated at multiple sites by multiple kinases, inextricably linking glycogen 
metabolism to hormonal regulation, energy status, and a milieu of intracellular 
signals (93). One of the kinases discovered to phosphorylate synthase, glycogen 
synthase kinase 3 (GSK3), was later found to regulate a much greater array of 
cellular processes and play an important role in many pathologies including 
cancer, Alzheimer's disease, Parkinson's disease and diabetes (94, 95). Many of 
the roles of GSK3 are quite unrelated to glycogen metabolism, leading to an 
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unfortunately misleading keyword in literature searches.  
While more pieces in the puzzle of glycogen regulation had fallen into place, 
other pieces were not even known to be missing. One enzyme must be mentioned 
at this point that has received insufficient attention despite its discovery in 1963. It 
was discovered as the deficient enzyme in Pompe disease, one of the glycogen 
storage diseases (GSDs). GSDs, also known as glycogenoses, are a group of 
diverse pathologies characterized by glycogen accumulation in various tissues. 
GSDs were first described in the early 1900s, and over the decades, the enzyme 
deficiencies causing many of these disorders were identified through biochemical 
analyses of patient tissues. Typically, patients were lacking one of the basic 
enzymes involved in glycogen metabolism (reviewed in (45)). However, in one of 
the most severe GSDs, Pompe disease, all of the known glycogen-related 
enzymes had normal activity. Lysosomes had been recently discovered by de 
Duve with the use of the ultracentrifuge (96), and in 1963, Hers demonstrated that 
Pompe patients were lacking an enzyme called acid α-glucosidase or maltase, 
which was found in lysosomes and converts glycogen or maltose to glucose (97). 
He identified Pompe disease as the first of the lysosomal storage diseases, now 
known to have a combined incidence of 1 in 5,000-10,000 (98, 99). Brown, Brown 
and Jeffrey demonstrated that the lysosomal enzyme discovered by Hers could 
cleave both 1,4 and 1,6 glycosidic linkages (100-102). The role of this enzyme in 
the degradation of glycogen was unclear, but presumably it was important since 
its absence resulted in a fatal condition. It is now well established, but not broadly 
known, that glycogen can be degraded within lysosomes, but the details of this 
pathway are still being defined (see Section 1.5).  
The discoveries of Leloir, Krebs and Fischer spurred a major wave of glycogen-
related research in the decade that followed (Figure 1.1). By 1970, these fervent 
investigations were waning, as it seemed to most that the work on glycogen was 
virtually complete. In 1971, Ryman and Whelan synthesized an exhaustive review 
of glycogen metabolism, which spanned 158 pages and cited nearly 900 
publications. They stated in their introduction: 
 
"The field of glycogen metabolism is one that to the outside observer 
has long seemed in a settled condition, with new discoveries being only 
likely to add gloss to existing facets. This is because it has been possible 
since the early 1940's to draw metabolic maps that seem to explain the 
process fully and satisfactorily, these maps being based on highly 
satisfactory in vitro experiments carried out with purified or semi-purified 
enzymes. This has been the polymer par excellence as far as in vitro work 
is concerned.  
This apparently settled condition is, in fact, illusory, and this has 
probably worked to the detriment of progress, since potentially interested 
investigators have almost certainly turned to other pursuits, feeling that no 
more major advances would be forthcoming. The true situation is the exact 
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opposite, and the ferment of activity now going on testifies to the growing 
realization that studies of glycogen metabolism have thrown up key 
discoveries that have the widest implications throughout biochemistry" 
(103). 
 
One aspect that remained unclear was how glycogen synthesis was initiated in 
vivo. Both the Coris and Leloir observed that in vitro glucose polymerization by 
glycogen phosphorylase or glycogen synthase required the addition of a pre-
formed carbohydrate primer (84, 104). Some investigators believed that glycogen 
synthesis could be initiated in vivo by glycogen synthase (105); others reported 
that a protein acted as the priming factor (106). In 1977, Whelan's group 
discovered a protein covalently bound to glycogen in liver, and later showed that 
the protein, which became known as glycogenin, was linked to glycogen via a 
novel tyrosine-glucose linkage (107, 108) (Figure 1.1). At first, Whelan's discovery 
was doubted, but his subsequent work and work from the laboratories of Cohen 
and Roach provided very strong support for this protein acting as the true primer 
of glycogen biogenesis. These groups established that glycogenin was a 
glucosyltransferase using UDP-glucose, and that after glycosylating itself, it could 
also extend the glucose chain to ~8 glucose residues, which would then be acted 
upon by glycogen synthase and branching enzyme (109-112). The initiation of 
glycogen synthesis by glycogenin is now widely accepted and has been 
extensively characterized, and similar protein primers for starch synthesis have 
also been described (reviewed by (113-115). 
 
1.2.5 Reviving interest in brain glycogen metabolism  
In recent years there has been a growing interest in studying brain metabolism, 
in part due to some important technological advancements. Firstly, in the 1970s, 
neurochemists began using focused microwave irradiation to rapidly and 
irreversibly inactivate enzymes in rodent brains in order to more accurately 
measure labile metabolites (reviewed by (116, 117). This technique was elegantly 
applied to determine the regional distribution of glycogen in the rat brain in the 
1980s (118, 119) and more recently in the mouse brain (120). Secondly, after it 
was suggested that elevated glycogen in a GSD patient could be observed by 1H 
NMR, Choi et al. introduced the use of NMR spectroscopy to noninvansively 
measure the turnover of 13C-labelled glycogen in vivo in rodents (121, 122). Öz 
and colleagues applied this technique to humans, publishing a series of studies 
on the role of glycogen in normal human brain metabolism and during 
hypoglycemia (123-125). 
Another reason for the growing interest in brain glycogen is the emerging theme 
of metabolic coupling of astrocytes and neurons, particularly involving the transfer 
of lactate. These interactions are fascinating, complex, and highly debated. They 
have been recently discussed by multiple excellent reviews (126-130). The 
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coupling between astrocytes and neurons is reminiscent of the Cori cycle and the 
shuttling of lactate between liver and muscle; however, these interactions are 
more complicated and difficult to study. Glycogen metabolism is intimately linked 
to granule size, architecture, and its various associated proteins, which are still 
being investigated. Such topics are not frequently discussed in the context of brain 
glycogen metabolism. These nuanced aspects of glycogen regulation, in addition 
to its surprisingly dynamic nature, subcellular distribution, and alternative 
degradation pathways, are introduced in the next sections. 
1.3 Glycogen Structure 
1.3.1 Basic structure of glycogen and other glucose polymers 
Glycogen is one of many types of polysaccharides that exist in biology. A 
polysaccharide refers to any large polymer comprised of many covalently linked 
monosaccharides; the bonds between them are known as glycosidic linkages. 
Glycogen and the two primary constituents of plant starch, amylopectin and 
amylose, are all homopolymers of glucose designed for energy storage in various 
organisms. We and others refer to these glucose homopolymers as polyglucans. 
Glycogen and amylopectin contain branches, while amylose is almost exclusively 
composed of linear chains. The linear chains of glucose are connected by α-1,4 
glycosidic linkages, and the branch points are comprised of α-1,6 glycosidic 
linkages (Figure 1.6a). Because of the tree-like arrangement of branching, 
glycogen and amylopectin contain fewer reducing ends (i.e. ends with a free 
aldehyde group) than nonreducing ends, which are oriented outward. The α 
configuration of the glycosidic linkage causes a linear α-1,4 linked chain to twist, 
and when the chains are long enough, and uninhibited by branch points, they can 
form single or double helices (Figure 1.6b) (131). An alternative β-linked 
configuration of glucose polymers favors very straight chains that can associate 
into tight fibrils; this is characteristic of structural polyglucans such as cellulose. 
Mammals do not synthesize or hydrolyze β-glycosidic linkages, so they cannot 
digest cellulose, but they are well equipped to degrade glycogen and starch (132). 
Although the models of glycogen and amylopectin structure are both based on 
the tree-like arrangement originally proposed by Meyer and Bernfeld, the models 
were individually refined as it became increasingly evident that the arrangement 
and length of the branches of these glucose polymers were quite different. 
Glycogen contains a high degree of branching and short linear chains. By 
enzymatic analyses, there are, on average, 13 glucose units per α-1,4-linked 
linear chain, and 8% of the total glycosidic linkages are α-1,6 branch points (114, 
133-136) (Figure 1.6c). Branching in glycogen is believed to be continuous, 
meaning the branch points are evenly distributed within the molecule. The 
presently accepted model for glycogen is based on the revisions of Whelan's 
group (52), but high resolution studies of chain length distribution (CLD) suggests 
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this model may still not be completely accurate (discussed below). Typically, a 
single glycogen is depicted as originating from a single chain covalently attached 
to a glycogenin molecule, which gives rise to all subsequent chains (Figure 1.6c) 
(114, 137). Enzymatic experiments indicate 3 to 4 glucose units between each 
branch point, so each linear chain would yield two branches (52, 133). Each new 
set of branches is referred to as a tier (Figure 1.6c), and since the number of 
linear chains doubles with each successive tier, the outermost tier would 
theoretically contain about one-third of the total glucose in the molecule, which is 
consistent with empirical observations (39, 136). Mathematical modeling has 
demonstrated that due to physical constraints, glycogen molecules can 
theoretically contain up to 12 tiers, corresponding to ~55,000 glucose molecules; 
beyond this size, the outer chains would become so crowded they would be 
inaccessible to enzymes (134). Indeed, the empirically observed upper limit of 
glycogen β-particles (44 nm) is consistent with the theoretical maximal diameter 
of a 12-tiered glycogen molecule (42 nm) (137, 138). The continuous branching 
within glycogen prevents, or dramatically limits, the formation of double helices, 
which would lead to insolubility of glycogen and inaccessibility of the glucan chains 
to enzymatic degradation (139). Mathematical modeling studies have also 
demonstrated that the empirically observed average chain length and branching 
degree are optimal for maintaining solubility and structural homogeneity (140).  
Amylopectin is also a branched polyglucan, but it contains longer chains of 20-
25 glucose units per chain with infrequent and clustered branching (Figure 1.6d) 
(141, 142). The clustering of branch points means there are regions of long, 
unbranched chains that associate to form crystalline, water-excluding double 
helices (Figure 1.6b). How these crystalline regions are arranged is still debated, 
but the most recent data suggests they are arranged along a polyglucan 
"backbone" (143). The alternating crystalline and amorphous layers within starch 
are advantageous as it allows for very dense glucose packing within starch 
granules, which can be as large as 100 μm in diameter (139). Amylose is believed 
to be interspersed among amylopectin molecules (Figure 1.6d). Glycogen, 
amylopectin, and amylose have diverse structural properties due to differences in 
chain length and degree of branching. Glycogen has the shortest average chain 
length and the highest degree of branching, usually 8%. The degree of branching 
in amylopectin is nearly half that of glycogen, only 4-6% (142, 144). Amylose is 
generally considered to be entirely composed of very long, linear chains, although 
infrequent branching has been reported (141).  
 
1.3.2 Glycogen architecture 
It is well established that amylopectin and glycogen differ in chain length and 
degree of branching. But a diverse array of polyglucans exist in nature with 
structures that vary beyond these two simple parameters. It is becoming 
increasingly apparent that the distribution of chain lengths and the arrangement of 
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branch points within a polyglucan are variable, producing distinct biological and 
physiochemical properties. Furthermore, not only do amylopectin and glycogen 
differ significantly from each other, but each polyglucan comes in a variety of 
shapes and properties based on species, tissue of origin, and even the nutritional 
state of the tissue. Polyglucan diversity in the context of starch has been 
exhaustively studied and thoroughly parameterized (145, 146). We will use the 
term "architecture" to refer to the unique chain length distribution, branching 
frequency and arrangement, and quantity and distribution of non-glucose moieties 
(notably phosphate) characteristic of a certain type of glycogen or amylopectin.  
Since the days of Bernard, investigators have utilized iodine to study 
polyglucan architecture. Bernard observed in 1877 that newly synthesized 
glycogen in rabbit muscle following exhaustive exercise gave a bluish coloration 
with iodine, in contrast to the reddish color of glycogen from rested muscle or well-
fed liver (4). This colorimetric test can be made quantitative by an absorbance 
spectral scan: the wavelength of maximal absorption (λmax) increases with longer 
chains and less branching, reflected by the staining color (147-149). Glycogen 
from different sources yields a range of colors from yellow to reddish brown with 
iodine and produces a λmax of 420-490 nm; amylopectin gives a more intense color 
ranging from red to lavender with λmax of 490-570 nm; and amylose yields a blue 
to green color with a λmax of 580-640 nm (150-152). The iodine method is not 
perfectly quantitative, due to the various effects of the iodine and salt 
concentrations, temperature, and polysaccharide structure and source (151, 153). 
Additionally, although chain length and degree of branching describe different 
aspects of glycogen architecture, both parameters are related to λmax (150, 151, 
154). It is difficult to deconvolve the various architectural parameters of 
polyglucans using just iodine, but it remains a convenient technique that yields 
useful information. 
High-performance anion exchange chromatography (HPAEC) was introduced 
in the 1990s to determine the chain length distribution (CLD) of enzymatically 
debranched polysaccharides with very high resolution (155). The CLD for various 
glycogens is asymmetrically unimodal: in bovine and rabbit liver glycogens, chains 
ranged from 3 to 35 degrees of polymerization (DP), peaking at DP 6-10 or 7-15, 
respectively (Figure 1.7a) (155, 156). This range of chain lengths suggests the 
architecture of glycogen may be intermediary between the Meyer and Whelan 
models. Amylopectin CLD profiles display a strikingly different bimodal CLD, with 
distinct groupings of short and long chains, further evidence for amylopectin 
chains being organized very differently than glycogen (Figure 1.7b) (157). CLD 
profiles for skeletal muscle and brain glycogen from mice have also been 
described recently. The Minassian group showed that the CLD profiles of mouse 
skeletal muscle and brain glycogen are nearly identical, ranging from DP 2-35 or 
more, with most chains being DP 4-15 (158, 159). Additionally, gradual 
isoamylolysis of muscle glycogen suggests that the internal chains are longer than 
the external chains (158). The Roach group showed a CLD for mouse skeletal 
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muscle glycogen ranging from DP 3-45, with most chains being 7-15 units long 
(160). After exercise and a 1 hour recovery, the CLD shifted toward long chains 
(Figure 1.7c). Similarly, muscle glycogen had an increased λmax after exercise 
and recovery, which was gradually restored over the course of 6 days. These data 
suggest that newly synthesized glycogen is less branched with longer chains that 
are remodeled over time (Figure 1.7d).  
It appears that glycogen molecule is not as homogenously structured as the 
Whelan model suggests, and chain length and branching appear to fluctuate 
based on nutritional state. Gerty Cori stated in a 1952 lecture that "the relationship 
of structure to nutritional state has not yet been fully explored, but it seems that 
glycogen freshly deposited after a fasting period is least branched and has long 
outer chains whereas the opposite is true of 'old' glycogens" (135). Additionally, 
mammalian and non-mammalian glycogens with similar average chain lengths 
produce differences in iodine spectra, suggesting that mammalian glycogens 
contain long chains in the interior of the granule that are not present in non-
mammalian glycogens (161). Whole glycogen particles also display a continuum  
of sizes, and their size and ultrastructure vary with tissue type (see Section 2.6.1).  
 
1.3.3 Glycogen structure and phosphate: insights from Lafora disease 
Fontana first demonstrated that [32P]-labeled glycogen could be purified from 
the livers of rats after the administration of radioactive phosphoric acid (162). 
Whelan's group subsequently reported that mammalian muscle glycogen contains 
about 0.064% phosphorus by weight (163, 164). However, much like Whelan's 
reports of a proteinaceous component of glycogen that were later substantiated 
with the discovery of glycogenin, phosphate was initially treated as a contaminant. 
The physiological relevance of glycogen phosphate became evident through basic 
scientific investigations of Lafora disease (LD), a fatal, inherited childhood 
epilepsy characterized by accumulations of abnormal polysaccharides known as 
Lafora bodies (LBs). Historically, LD has not always listed among the glycogen 
storage diseases (GSDs) since a neurological phenotype predominates rather 
than a phenotype of muscle or liver dysfunction. However, like all other GSDs, LD 
is caused by genetic defect(s) leading to aberrant glycogen metabolism; it has 
therefore been included in recent reviews of GSDs and may be considered a non-
classical GSD (165, 166). LBs have been shown to be the underlying cause of 
neurodegeneration and epilepsy in mouse models (recently reviewed by (167) 
(Figure 1.8a). In the 1960s and 1970s, it was demonstrated that LBs contain high 
levels of phosphorus and histologically resemble plant amylopectin (168, 169). In 
1998 and 2003 the genes associated with the disease were identified, and it is 
now well established that virtually all LD patients carry recessive mutations in 
either the EPM2A or EPM2B gene (170-172). EPM2A encodes laforin, a glycogen 
phosphatase (173, 174), and EPM2B encodes malin, an E3 ubiquitin ligase (175, 
176). Epm2a-/- and Epm2b-/- mouse models recapitulate the disease with respect 
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to LB formation and neurodegeneration (Figure 1.8b) (177-182). Purified 
polysaccharides from LD mice have a shifted λmax reminiscent of amylopectin 
(180), and their CLD profile shows a higher proportion of long chains than wild-
type mice, most prominently in brain tissue (Figure 1.8c) (159). Unlike glycogen, 
purified LBs are quite large (>1 μm in diameter) and insoluble; they are presumed 
to be aggregates of a polysaccharide with abnormal architecture resulting from 
aberrant glycogen metabolism (167).   
Laforin and malin regulate two aspects of glycogen architecture that may be 
intertwined: chain length and phosphate level. Through studies of its role in LD, 
laforin was discovered to be the founding member of a class of enzymes known 
as glucan phosphatases that directly dephosphorylate carbohydrate substrates 
(173, 183-187).  Laforin is the only known glucan phosphatase in mammals, and 
decreased laforin activity results in glycogen hyperphosphorylation. Malin 
ubiquitinates enzymes involved in glycogen metabolism, but the effects of 
ubiquitination are not clear (see Section 1.5.2). Surprisingly, the absence of malin 
also leads to hyperphosphorylation, and the absence of either enzyme leads to 
the accumulation of glycogen with abnormally long chains, which is puzzling (188). 
Recent results from mouse models overexpressing a catalytically inactive laforin 
demonstrate that the inactive laforin rescues the LD phenotype in the Epm2a-
deficient mouse model (159, 189). As a result, the relevance of laforin's catalytic 
activity has been questioned, despite the very high conservation of its catalytic 
residues and the presence of glucan phosphatases across multiple kingdoms 
(183, 190). It has also been suggested that laforin and malin form a ubiquitination-
targeting complex involved in the disposal of glycogen molecules with aberrantly 
long chains that could crystallize and cause the molecule to precipitate (188). A 
growing body of evidence suggest that laforin and malin are an integral part of an 
alternative route for glycogen degradation known as glycophagy, involving 
members of the autophagic pathway and lysosomal α-glucosidase (see Section 
1.5.2). However, glycophagy is probably not reserved only for aberrantly 
structured glycogen molecules, since the accumulated lysosomal glycogen in acid 
α-glucosidase deficiency (i.e. Pompe disease) is of normal structure based on 
iodine staining (191, 192). Additional evidence for a physiological role of glycogen 
phosphate comes from the Roach lab and a substantial body of work from the field 
of starch metabolism.  
The Roach lab analyzed glycogen CLD and phosphate levels of laforin-
deficient mice pre- and post-exercise. When muscle glycogen phosphate was 
depleted, phosphate levels remained suppressed even after total glycogen and 
CLD returned to normal (160). Laforin-deficient mice displayed exercise-induced 
glycogen depletion identical to wild- type mice, but phosphate levels remained 
elevated and iodine spectra suggested a delay in glycogen remodeling post-
recovery. This study demonstrated that laforin dephosphorylates glycogen during 
exercise-induced cytosolic glycogeolysis, providing strong evidence for its 
physiological role as a glycogen phosphatase. Whelan suggested in 1994 that 
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phosphate was a marker for the age of a glycogen molecule; the suppression of 
glycogen phosphate after exhaustive exercise in wild-type mice does indeed 
suggest that phosphate accumulates with age, possibly from multiple cycles of 
glycogen degradation and re-synthesis (160, 163). The role of phosphate in 
glycogen metabolism is not clear, but studies from the starch field demonstrate 
that phosphate plays an important physiochemical and biological role in starch 
architecture and metabolism (193-195). 
In plants, phosphorylation is necessary for the proper synthesis of starch, and 
reversible phosphorylation is an integral part of starch breakdown. Only 
amylopectin contains significant amounts of phosphate, which is enriched in the 
amorphous regions (196, 197). Root and tuber starches, which exhibit less 
densely packed crystalline helices than other types of starches, have high 
phosphate levels (198, 199). Starch phosphate is covalently linked to the C3 and 
C6 hydroxyls of glucose moieties; about 70-80% of the phosphate is esterified to 
C6 (200).  Phosphate, particularly at the C3 position, disrupts the crystalline 
helices in amylopectin by introducing steric hindrance, promoting their 
solubilization (201). Starch degradation is believed to be a cyclic process involving 
reversible phosphorylation and the concerted action of multiple enzymes: glucan 
dikinases, amylases, and glucan phosphatases (139). Two dikinases that 
respectively phosphorylate the C6 and C3 position in that order are glucan, water 
dikinase and phosphoglucan, water dikinase. Phosphorylation promotes 
solubilization of the glucan chains and facilitates their access by plant amylases. 
However, the amylases cannot proceed past a phosphate, so phosphate removal 
is achieved by the glucan phosphatases Starch Excess 4 (SEX4) and Like Sex 
Four 2 (LSF2), named after the plant phenotype that results from their deficiency 
and part of the same family as the glycogen phosphatase laforin (202-206). Crystal 
structures and structure-function studies of SEX4 and LSF2 preceded those of 
laforin (186, 187, 190, 207) and the cooperative study of both systems has led to 
a wealth of insight about polyglucan architecture and phosphorylation (139, 205, 
208).  
Through studies of LD, the Roach and Minassian groups determined that 
normal glycogen contains about 1 phosphate moiety per 600-2500 glucose units, 
depending on species and tissue type (174, 181, 209-211). Phosphates are 
present as monoesters linked to the C2, C3 and C6 hydroxyls of glucose moieties, 
in approximately equal quantities (158, 210, 212).  Data from multiple groups using 
various approaches strongly suggest the phosphate is concentrated at the interior 
of glycogen molecules (158, 160, 174). Liver glycogen contains less phosphate 
than muscle glycogen, while C6 phosphate has been detected in brain glycogen 
at similar levels to C6 phosphate in muscle glycogen (159, 163, 174, 211). The 
source of glycogen phosphate remains a mystery: although it has been reported 
that glycogen synthase can incorporate the β-phosphate of UDP-glucose into 
glycogen in a rare side reaction, this mechanism could only account for C2 and 
C3 phosphate, and the rate of incorporation is very low (1 in 10,000 catalytic 
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cycles) compared to the actual levels observed in glycogen (212, 213). Although 
no glucan dikinase has been identified in mammals, the physiological role of 
glycogen phosphate will eventually be defined, likely through the continued 
investigations of starch metabolism and the molecular mechanisms of LD.  
 
1.3.4 Glucosamine 
Glycogen also contains small amounts of covalent glucosamine. In the 1960s 
and 70s, Maley et al. reported the incorporation of glycosidically linked 
[14C]glucosamine into glycogen from [14C]galactosamine, and showed that 
glycogen synthase could catalyze glucosamine incorporation in vitro by using the 
substrate UDP-glucosamine instead of UDP-glucose (214, 215). Whelan also 
reported that intraperitoneal injection of [14C]galactosamine led to the 
incorporation of [14C]glucosamine into glycogen, replacing as much as 10% of the 
glucose residues (216). Covalently linked glucosamine in glycogen apparently 
would not block phosphorolysis, since it could be released as glucosamine-1-
phosphate by phosphorylase. Whelan reported that normal pig and rabbit liver 
contained 86-266 nmol glucosamine per g glycogen, which was randomly 
distributed throughout the molecule (217). It is worth noting that an earlier study 
also demonstrating the incorporation of [14C] into glycogen from injected 
[14C]glucosamine showed that glucosyl residues were labeled, indicating 
[14C]glucosamine was converted to [14C]glucose through a deamination reaction 
prior to glycogen incorporation (218).  
Additional links between glycogen and glucosamine have been reported. 
Glycogen synthase can be modified by N-acetyl-glucosamine (GlcNAc), and it has 
been suggested that glycogenin could also be modified by GlcNAc (219, 220). 
Furthermore, studies have suggested that glycogen could be a carbohydrate 
source for protein glycosylation, for which glucosamine is a major precursor, and 
hypoglycosylation has been reported in GSDs (221-224). A physiological role for 
glycogen in protein glycosylation and the relevance of covalently linked 
glucosamine await further investigation. 
1.4 Cytosolic glycogen synthesis and degradation 
1.4.1 Glycogenin 
Glycogen synthesis begins with glycogenin [UDP-α-glucose:glycogenin α-
glucosyltransferase, EC 2.4.1.186], a member of glucosyltransferase family 8 
(225) (www.cazy.org). The enzyme possesses two distinct enzymatic activities: 
self-glucosylation and chain elongation, both requiring UDP-glucose as a glucosyl 
donor and both occurring at the same active site, though the chemistries of the 
reactions are different (226, 227). For this reason the two activities were initially 
believed to belong to separate enzymes, until Whelan and Cohen discovered that 
both were accomplished by glycogenin (109, 110). Crystal structures and 
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biochemical studies show that glycogenin functions as an obligate dimer and 
requires Mn2+ for activity (228, 229). Autoglucosylation on tyrosine creates a 
glucose-1-O-tyrosyl linkage, a chemical linkage rarely found in nature, then 
glycogenin synthesizes a short oligosaccharide primer of at least 7-8 glucose units 
(226, 230). Even if this tyrosine is mutated, glycogenin is still capable of 
glucoslyation, just not of itself (231, 232). Whether glucosyl additions occur via 
intra- or intersubunit reactions has been debated, but recent studies suggest that 
the first four glucosyl units may be added via an intrasubunit reaction, and longer 
chains require intersubunit interaction (229). It has been suggested that although 
glycogenin functions as a dimer, at low enough concentrations the two subunits 
would dissociate after chain initiation, giving rise to two separate glycogen 
molecules (233). The presence of a single chain giving rise to an entire β-particle 
is supported by structural studies of glycogen (52). 
In most mammals, there is only one isoform of glycogenin that is widely 
expressed, but humans have two isoforms: glycogenin-1 (GYG1), expressed in all 
tissues, and glycogenin-2 (GYG2) which is primarily expressed only in liver, with 
minor expression in heart, pancreas, and adipose tissue (113, 234) 
(www.proteinatlas.org). There is some evidence that glycogenin is 
phosphorylated, but it has not been corroborated (227). Glycogenin can interact 
directly with glycogen synthase, and a crystal structure of the interaction provides 
evidence for their cooperation in the initiation of the glycogen granule (235, 236). 
Additionally, insufficiently glucosylated glycogenin does not serve as an efficient 
primer for glycogen synthase, and phosphorylase can reduce the glucosylation 
state of glycogenin, making it a less effective substrate for synthase (237, 238). 
Phosphorylase induces the dissociation of glycogen synthase from a proteoglycan 
fraction in hepatocytes, presumably containing glycogenin (219).  Thus, priming 
through glycogenin may be regulated indirectly by the signals that govern 
glycogen synthase and phosphorylase activity, rather than by direct regulation of 
glycogenin. Glycogenin interacting proteins (GNIPs) have been suggested to 
stimulate the activity of glycogenin (239). Paradoxically, glycogenin mutations in 
humans and mice lead to glycogen accumulation in some tissues and muscle 
weakness, indicating that without glycogenin, glycogen synthesis can still occur, 
but in a dysregulated and pathogenic manner (240, 241).  
 
1.4.2 Glycogen synthase and phosphorylase 
Glycogen synthase [UDPglucose:glycogen α-4-glucosyltransferase, EC 
2.4.1.11] is a member of the glycosyltransferase family 3 that catalyzes the 
addition of alpha-1,4-linked glucosyl units to a glycogen chain, using UDP-glucose 
as the donor and releasing UDP as product  (www.cazy.com). Two isoforms of 
synthase exist in mammals: GYS1, encoding muscle glycogen synthase, highly 
expressed in all tissues including brain, and GYS2, restricted to liver (114) 
(www.proteinatlas.org). Muscle glycogen synthase has nine phosphorylation sites 
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and was one of the first examples of a hierarchically phosphorylated protein (93). 
Although liver glycogen synthase is also multiply phosphorylated, its activity 
appears to be regulated by only one phospho-site (242). Phosphorylation inhibits 
synthase activity, although activity can be fully restored in the presence of the 
potent allosteric activator glucose-6-phosphate. Numerous kinases are 
responsible for phosphorylating synthase, including protein kinase A, protein 
kinase C, AMP-activated protein kinase (AMPK), caseine kinase 2, and glycogen 
synthase kinase 3 (GSK3). Thus, control of glycogen metabolism is inextricably 
linked to intracellular energy status, glucose homeostasis, insulin signaling, and 
other external signals through diverse signaling cascades (93, 114, 243).. 
Glycogen phosphorylase [1,4-α-glucan:orthophosphate α-glycosyltransferase, 
EC 2.4.1.1] is a member of the glycosyltransferase family 35, and catalyzes the 
transfer of glucose moieties from the glycogen molecule to inorganic phosphate, 
releasing the product glucose-1-phospate (www.cazy.com). Glucose-1-phosphate 
is converted to glucose-6-phosphate by phosphoglucomutase, facilitating its entry 
into glycolysis. In the presence of excess glucose-1-phosphate, phosphorylase 
can catalyze the reverse reaction (31). There are three isoforms of phosphorylase 
corresponding to the tissues in which they are enriched, but not restricted: muscle 
(PYGM), liver (PYGL) and brain (PYGB) (www.proteinatlas.org). Only the brain 
isoform is expressed in fetal tissues, and all are expressed to some extent in adult 
brain (244). A single site on phosphorylase is phosphorylated by only one kinase: 
phosphorylase kinase (PhK), a multisubunit enzyme with muscle, liver and brain 
isoforms. Both phosphorylase and PhK are activated by phosphorylation and 
allosteric modulators, and an excellent review on their regulation in brain has been 
published recently (245). Crystal structures of all phosphorylase isoforms have 
been determined (246-248).  
 
1.4.3 Glycogen branching and debranching enzymes 
Like glycogenin, and unlike synthase and phosphorylase, glycogen branching 
enzyme (GBE) and debranching enzyme (GDE) do not appear to be regulated by 
phosphorylation or allosteric modulation. There is only one isoform of each, and 
both are highly expressed ubiquitously (www.proteinatlas.org). Due to their 
abundance, these enzymes are not considered to be rate-limiting under normal 
circumstances (114, 136, 249). However, they are clearly essential for maintaining 
proper glycogen structure, as deficiencies in either enzyme result in GSDs 
characterized by distinctly abnormal glycogen deposits with pathological 
consequences (165). Crystal structures of human GBE and yeast GDE have been 
determined and the effects of GSD-causing mutations defined, providing 
molecular level insights into how they affect glycogen structure (250, 251). 
GBE (α-1,4-glucan:α-1,4-glucan 6-glycosyltransferase, EC 2.4.1.18) belongs 
to the subfamily 8 of the GH13 family of glucosyl hydrolases. Like other members 
of this subfamily, it contains a carbohydrate binding module, CBM48 (252) 
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(www.cazy.com). Two reaction steps occur successively in its central catalytic 
core: hydrolysis and transglucosylation (250). In the first step, the enzyme cleaves 
an α-1,4 linkage on a glucan chain, forming a covalent enzyme-glycosyl 
intermediate; in the second step, an α-1,6 linkage is formed from the same chain 
or one nearby. The minimum length transferred is 6 or 7 glucosyl units (253, 254), 
and the average distance between chains is 3 or 4 glucose units (52, 255). This 
chain length requirement is supported by the crystal structure of GBE in complex 
with a heptasaccharide (250).  
Mammalian GBE can convert amylose or amylopectin to a glycogen-like 
polysaccharide. Krisman showed that incubation of amylopectin or amylose with 
GBE purified from rat liver led to a displacement of λmax to a value that coincided 
with that of glycogen (147). However, GBE did not change the λmax of rabbit liver 
glycogen, suggesting the molecule already had been maximally branched. Indeed, 
comparative studies on mammalian and plant branching enzymes indicate that the 
branching degree in polysaccharides is determined by intrinsic properties of the 
branching enzyme used to synthesize them (256, 257). In other words, the optimal 
structure of the mammalian glycogen molecule may be primarily attributed to the 
inherent "equilibrium" of the mammalian branching enzyme. Not surprisingly, 
synthetic glycogens produced in vitro by branching enzymes from different 
organisms have similar, but not identical, structural properties to natural glycogens 
(258-260).  Perhaps these observations explain the delay in glycogen remodeling 
reported by the Roach lab after exercise (160): glycogen super-compensation, 
characterized by high glycogen synthase activity, results in longer chains because 
branching enzyme has not yet introduced the appropriate branch points. Only over 
time does branching enzyme act so that glycogen structure returns to an 
equilibrium, with CLD and λmax at basal levels. Indeed, it has been suggested 
that a chronic imbalance of glycogen synthase and GBE activities leads to 
abnormal polysaccharide formation in pathological conditions (209, 261, 262). 
Also, the ubiquitous expression of a single GBE isoform may help to explain why 
brain glycogen has a similar CLD to muscle glycogen (159). Presumably all 
healthy tissues in a single species would reach the same CLD at "equilibrium."  
GDE is required for cytosolic glycogen degradation since phosphorylase 
terminates four glucosyl residues away from a branch point. Mammalian GDE has 
two catalytic activities: 4-α-glucanotransferase activity (EC 2.4.1.25) involves 
transfer of a chain of three glucosyl units from the branch to a nearby nonreducing 
end, leaving a single α-1,6 glucosyl unit. Its amylo-α-1,6-glucosidase activity (EC 
3.2.1.33) follows, and the α-1,6 linkage is hydrolyzed to release free glucose (103). 
The release of free glucose instead of glucose-1-phosphate makes it very 
convenient to compare the levels of α-1,6 and α-1,4 linkages in polysaccharides. 
GDE is considered an indirect debranching enzyme; direct debranching enzymes 
such as isoamylase exclusively cleave α-1,6-linkages and release intact 
oligosaccharide chains. Direct debranching enzymes occur in plants, bacteria and 
yeast but not in mammals (103). These enzymes are very useful in polysaccharide 
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analysis, especially in determining CLD. 
GDE catalytic mutants display a loss of either glucosidase or transferase 
activity, but not both, strongly suggesting disparate catalytic sites (263). This was 
confirmed when the crystal structure of yeast GDE was determined, revealing an 
elongated structure with catalytic domains at either end of the molecule (251). 
Structures of both the free wild-type enzyme and a transferase-deficient mutant in 
complex with maltopentaose were reported. Maltopentaose molecules were 
bound at both catalytic domains and other sites, illustrating the specificity of GDE 
transferase activity for a glucan of five units or less and the necessity of non-
catalytic binding sites for glycogen association. The data also suggested that the 
product of the transferase reaction, a chain containing a single α-1,6-linked 
glucosyl unit, completely dissociates from GDE prior to recruitment to the 
glucosidase catalytic site. Multiple binding sites are a recurring theme among 
glycogen- and starch-associated proteins (187, 190, 250, 251, 264). In observing 
that oligosaccharides were bound both to catalytic and non-catalytic sites in the 
crystal structure of GBE, Froese et al. stated: "[Non-catalytic binding sites] may 
provide GBEs the capability to anchor a complex glycogen granule and, as 
proposed previously, determine the chain length specificity for the branching 
reaction as a ‘molecular ruler’. This agrees with the emerging concept of glycogen 
serving not only as the substrate and product of its metabolism but also as a 
scaffold for all acting enzymes" (2015) (see Section 1.7).  
1.5 Glycophagy  
1.5.1 Lessons from Pompe disease 
Phosphorolysis is not the sole means of glycogen degradation in cells. This 
became evident through studies of Pompe disease, a lysosomal storage disorder 
characterized by the buildup of vacuole-bound glycogen in virtually all tissues (97, 
98). The deficient enzyme in Pompe disease is lysosomal acid α-glucosidase 
(called GAA or acid maltase) [EC 3.2.1.3] which hydrolyzes both α-1,4 and α-1,6 
linkages, optimally at low pH (265). It is a widely expressed enzyme, with a 
promoter characteristic of a housekeeping gene (266). GAA is synthesized as a 
precursor protein in the endoplasmic reticulum and undergoes extensive 
processing before it achieves optimal catalytic activity and reaches its lysosomal 
destination (265, 267). It can fully hydrolyze glycogen as well as short 
oligosaccharides, maltose and other polyglucans to glucose (97, 268, 269). GAA 
is exo-acting, cleaving single glucosyl units successively from the non-reducing 
ends of glycogen. However, rather than releasing glucose-6-phosphate like 
phosphorylase, GAA liberates free glucose, which can translocate into the cytosol 
via glucose transporters in the lysosomal membrane (270).  
How glycogen gets into the lysosome is not well defined, but recent work 
demonstrates that it involves the autophagic machinery. Autophagy, or 'self-
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eating,' refers to multiple cellular pathways converging on the lysosomal 
breakdown of cellular components such as long-lived proteins and organelles 
(reviewed by (271-273). Autophagy is critical both for general cellular maintenance 
and for nutrient release in times of energy stress. It is especially critical for turning 
over worn or damaged cellular components in neurons and other post-mitotic cells 
(271, 272, 274). The best characterized autophagic pathway is macroautophagy, 
activated in response to starvation; 'autophagy' and 'macroautophagy' are 
frequently used interchangeably. Macroautophagy is a highly conserved pathway 
in eukaryotes involving a family of autophagy-related (Atg) proteins and the 
formation of a structure with a characteristic double membrane known as the 
autophagosome, which engulfs substrates and fuses with the lysosome. 
Microautophagy and chaperone-mediated autophagy are alternative pathways in 
which cellular components are targeted directly to lysosomes in the absence of 
autophagosome formation. In recent years, numerous terms for the selective 
degradation of specific substrates (via any of the autophagic pathways) have been 
introduced; e.g. mitophagy (of mitochondria), pexophagy (of perioxisomes), 
nucleophagy (of nuclear components), reticulophagy (of ER), and xenophagy (of 
pathogens) (271, 275). In 2011, the Roach group introduced the term 'glycophagy' 
to refer to the selective autophagic degradation of glycogen (276). Ironically, the 
term 'glycogenosome' had already been used by some investigators to refer to the 
glycogen-laden lysosomes found in newborn rat liver, aged neural tissue, and 
glycogen storage diseases (277-279), but the term did not gain traction. 
In addition to glycogenosomes, which have a single membrane characteristic 
of a lysosome, Pompe (GAA-/-) tissues also display accumulated 
autophagosomes filled with ubiquitinated proteins and cellular debris. In order to 
study the effect of autophagy on lysosomal glycogen, Raben and colleagues 
generated a muscle-specific knockout of a critical autophagosome gene, Atg5, on 
the GAA-/- background. These mice had just as many glycogenosomes as the 
GAA-/- mice, but they had a reduced number of autophagosomes and no 
improvement in pathology. Ubiquitinated proteins were increased, but they were 
not surrounded by the double membrane as in the GAA-/- mice (280, 281). The 
study suggested that the autophagy defect was caused by inefficient fusion of the 
autophagosomes with the glycogen-laden lysosomes, which formed by an 
independent pathway. In a later study, the group selectively inactivated a closely 
related gene, Atg7, in fast-twitch GAA-/- muscle (282). No autophagosomes were 
formed, glycogenosomes were still present, and there was no change in 
pathology; however, the glycogen level was reduced. These two studies 
demonstrate that macroautophagy contributes to some, but not all, of the delivery 
of glycogen to the lysosome (282). The group also illustrated that the muscle 
pathology of Pompe disease resulted largely from defective autophagic flux. The 
observation that Atg7, but not Atg5, abrogated glycogen accumulation may be 
explained by the fact that there are two primary conjugation systems in autophagy, 
and while Atg5 is only involved in one, Atg7 is required for both (283). 
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In 2002, Janeček identified a putative CBM20 in a protein of unknown function 
called starch binding domain-containing protein 1 (Stbd1, also called genethonin 
1) (284). The only other proteins in mammals with a CBM20 are laforin and a 
glycosyltransferase (glycerophosphocholine phosphodiesterase 1, GPCPD1). It 
was known that the laforin CBM facilitates laforin binding to glycogen (285). The 
Roach group later showed that Stbd1 is highly expressed in glycogen-rich tissues 
such as muscle, liver, and heart, with trace amounts in brain, kidney and pancreas, 
and that Stbd1 levels mirrored glycogen levels in fed, fasted and transgenic mice 
(286). Stbd1 binds glycogen in vitro and co-localizes with the lysosomal-
associated membrane protein LAMP1 and the Atg8 homolog GABARAPL1 in cell 
culture, but not with the microtubule-associated light chain 3 (LC3), a marker for 
auotophagosomes (276, 286). Demetriadou et al. later showed that when 
overexpressed in HeLa cells, Stbd1 was N-myristoylated, and this modification 
facilitates its recruitment with glycogen to subcellular domains associated with 
autophagy (287). The Sun group showed that Stbd1 is elevated in muscle tissue 
of GAA-/- mice, but not in liver or heart, but shRNA-mediated knockdown of Stbd1 
did not alter glycogen levels in any tissues (288). A full knockout of Stbd1 in the 
Pompe mice (Stbd1-/- GAA-/-) did not change lysosomal accumulation of 
glycogen in muscle or heart tissue, but reduced liver glycogen by 73% (289). 
Glycogen accumulation could be restored by exogenous expression of human 
Stbd1, but not a mutant lacking the CBM20. Their study demonstrated that Stbd1 
may significantly participate in glycophagy in the liver but not in the heart or 
skeletal muscle, and that the CBM20 is essential for its function.  
 
1.5.2 Lessons from Lafora disease 
Another link between glycogen and autophagy emerged through studies of LD. 
Laforin- and malin-deficient mouse models were generated and analyzed by six 
different groups. Most observed autophagy defects in the brain of these mice (179, 
182, 189, 290). Some groups observed reduced conversion of LC3 from its 
cyotosolic form (LC3-I) to lipidated form (LC-II), which is associated with its 
recruitment to autophagosomal membranes (179, 189). Both mouse models also 
displayed an increase in p62 (179, 182, 290), a protein that normally binds to both 
ubiquitinated cargo and LC3, is incorporated into the autophagosome, and 
degraded (271). Reduced LC3-II and increased p62 levels strongly suggested 
defects in autophagic flux. Similar defects were also observed in liver of laforin-
deficient mice, but not in muscle (160, 291). In contrast, the Minassian group did 
not observe autophagy defects in muscle or brain in either mouse model (159, 
292).  
The Roach, Minassian and Guinovart groups generated LD mouse models with 
genetically reduced glycogen synthesis and found that LB formation was reduced 
and neuropathology was abrogated (182, 293-295). The Guinovart group 
elegantly demonstrated that the autophagy impairment was secondary to 
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polyglucosan accumulation by crossing malin-deficient mice with mice specifically 
lacking muscle glycogen synthase in the brain, which eliminated cerebral glycogen 
synthesis, LB formation, autophagy defects, gliosis, and susceptibility to epilepsy 
(182). These studies indicate that polyglucosan accumulation drives the 
autophagy impairment and neurological phenotype in LD. Although some groups 
have argued that laforin and malin regulate autophagy independent of glycogen, 
this is unlikely to be the case in vivo (167). However, as was demonstrated with 
the Pompe mice, insufficient clearance of glycogen via glycophagy may indeed 
provoke pathological damage by obstructing overall autophagic flux. This is a very 
prominent theme among lysosome storage disorders, which frequently have 
severe neurological phenotypes; this disease class is reviewed in depth elsewhere 
(296, 297). Corroborating this, recent studies from the Sanz group showed that in 
LD, mitophagy is impaired due to a global autophagic defect, and endocytic 
recycling of the astrocytic glutamate transporter GLT1 is altered (298, 299), likely 
also resulting from impaired autophagy.  
The possibility that laforin and malin are involved in glycophagy builds on work 
from many labs showing that malin, typically in concert with laforin, ubiquitinates 
glycogen-associated substrates. Malin is an E3 ubiquitin ligase that was initially 
demonstrated to bind and ubiquitinate laforin in cell culture (175, 176). Malin also 
promotes the ubiquitination of multiple proteins that bind to glycogen molecules: 
glycogen synthase, protein targeting to glycogen (PTG), R6, AMPK and GDE (see 
Section 1.7). In most of these studies, ubiquitination was shown to require laforin, 
which is believed to act as a scaffold for malin interaction with its substrate (300-
304). Although ubiquitination led to the degradation of these substrates in cell 
culture, PTG, R6 and AMPK levels were unchanged in LD mouse models; in 
contrast, glycogen synthase accumulated in the insoluble glycogen fraction, as did 
laforin in malin-deficient mice (178, 180, 181, 305) (Gentry, Sun, Dukhande, 
unpublished results). Importantly, whenever the ubiquitin linkages incorporated by 
malin are defined, they are K63-linked (302, 303, 306, 307). K63-linked 
ubiquitination is a substrate for p62 binding and specifically linked to selective 
autophagy (308, 309). The presence of a laforin-malin ubiquitination complex has 
been highly debated (167, 188, 310).  
 Interestingly, the Roach group reported that there was no change in the levels 
of GABARAPL1 (a member of the Atg8 family and a homolog of LC3; see (311)) 
and LAMP1 in laforin-deficient fibroblasts, but these proteins were decreased in 
malin-deficient fibroblasts and in fibroblasts with both laforin and malin knocked 
out (312). These results suggest laforin is upstream of malin in the path from 
glycogen to the lysosome. The Sanz group showed that laforin, malin and p62 
form a complex, and that malin mediates the interaction between laforin and p62, 
likely through ubiquitination (307). Additionally, malin and p62 do not co-localize 
in cells without the expression of laforin. It is well known that laforin binds to and 
co-localizes with glycogen in vitro, in cell culture, and in vivo. 
A model to explain these studies that is compatible with available data posits: 
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laforin binds to glycogen and recruits malin; the laforin-malin complex promotes 
K63-linked ubiquitination of various glycogen-bound proteins; p62 binds to K63-
linked ubiquitin moieties, recruiting LC3 (or its homolog GABARAPL1) and the 
autophagosome machinery, which engulfs the glycogen particle and fuses with 
the lysosome. Since glycogen synthase and laforin expression parallel glycogen 
levels and these proteins accumulate with glycogen in LD mouse models, they 
may also be turned over inside the lysosome. The fact that a catalytically inactive 
form of laforin rescues laforin-deficient mouse models supports this scaffolding 
role for laforin (159, 189), but does not exclude the possibility that glycogen 
dephosphorylation by laforin is still relevant, as during cytosolic glycogenolysis 
(160). Also, phosphorylation of laforin by AMPK has been shown to enhance the 
interaction of laforin with malin (313); this regulation event could be one way to 
stimulate glycophagy in times of energy stress, when AMPK becomes activated. 
Finally, it is well established that laforin preferentially binds to polysaccharides with 
long chains and localizes to LBs in malin-deficient mice (179, 190, 314). Thus, 
laforin would selectively recruit the glycophagy machinery to precipitation-prone 
glycogen molecules with precariously long chains, as has been proposed (188).  
It is worth noting that delivery of glycogen to lysosomes may involve multiple 
pathways, possibly with cell-specific relevance. Perhaps Stbd1 and laforin, each 
containing a CBM20, function as distinct receptors for glycophagy. It is interesting 
that although LBs occupy most tissues in LD, they are enriched in certain cell types 
within these tissues. For example, in LD mice, 97% of LBs in skeletal muscle are 
found in fast-twitch type IIb muscle fibers and 2% in slow-twitch type I fibers (315). 
In human skin biopsy, LBs are only found in duct cells, but not secretory cells 
(316). In human liver, LBs are enriched in the periportal regions, but not the 
perivenous regions (317). All of these cell types appear to make glycogen (318-
320), but the differences in whether or not they make LBs suggest the glycogen is 
handled differently. Cell-specific glycogen metabolism and polyglucosan body 
formation are of particular interest in the brain. LBs were first reported in neurons 
(321), and historically were believed to occupy this cell type almost exclusively 
(322). However, this observation has been perplexing since the vast majority of 
brain glycogen is stored in astrocytes. Recent work has demonstrated that 
neurons possess an active glycogen metabolism (300, 323), and LD mouse 
models accumulate both LBs in neurons and a distinct polyglucosan body known 
as corpora amylacea in astrocytes (324, 325). Early literature on human patients 
corroborate these findings. Corpora amylacea in addition to LBs have been 
reported in multiple studies (326). Small inclusions, which may also correspond to 
corpora amylacea, have been identified in astrocytes and oligodendrocytes (327). 
Recently, it has been asserted that the striking appearance of neuronal LBs left 
glial LBs largely overlooked over the years; upon careful review of the literature, 
small LBs that were assumed to be in neuronal processes are likely to actually be 
astrocytic (328).  
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1.5.3 The benefits of glycophagy 
The lysosomal glycogen pool plays an important role in circumstances when a 
burst of glucose is needed, such as during the neonatal starvation period (329-
331). Glycogen-rich autophagosomes have been observed in the neonatal liver, 
muscle and heart, but they are depleted within hours after birth. A unique role for 
glycophagy in the heart is also emerging (332, 333). While liver and muscle 
normally deplete their glycogen stores with fasting, cardiac tissues accumulate 
glycogen and upregulate glycogen autophagy under nutrient stress (333). An 
advantage of lysosomal glycogen is that it can be mobilized independently or in 
parallel with cytosolic glycogen by a distinct set of cellular stimuli. For example, 
glycophagy could be specifically regulated by lysosomal uptake of Ca2+, which 
enhances GAA activity (330, 332). Very little is known about the role of glycophagy 
in brain tissue, besides the report of glycogenosomes in the aging brain (277). It 
has been suggested that glycogen of large molecular weight (i.e. α particles) is 
specifically degraded in lysosomes, and proceeds by a random, rather than an 
ordered degradation mechanism (334, 335). Based on glycogen degradation 
patterns it has been speculated that brain glycogen is degraded primarily by 
phosphorolysis and not by lysosomal hydrolysis (336).  
1.6 Glycogen ultrastructure and subcellular distribution 
In over a century of glycogen-related research many researchers have debated 
the existence of multiple forms of glycogen that differ in size, structure, associated 
proteins, and metabolic activity. The distinction between glycogen α and β 
particles came into focus with studies using the electron microscope and 
ultracentrifugation, and some progress has been made on defining the nature of 
these particles. Acid-soluble and acid-insoluble fractions of glycogen have also 
been observed, but the physiological relevance of these distinct pools has been 
highly debated. These topics, as well as a possible role for glycogen metabolic 
enzymes in the nucleus, are discussed in the next sections.  
 
1.6.1 Glycogen α, β, and γ particles 
Drochmans and colleagues were the first to describe the various levels of 
glycogen structure in native glycogen isolated from liver and muscle, and their 
observations were corroborated by others (72, 74, 75, 337). The largest glycogen 
particle, named the α particle, is a rosette-shaped association of several smaller 
units, known as β particles. An α particle is usually more than 108 Daltons in 
molecular weight and up to 300 nm in diameter (137, 338). Glycogen β particles 
have a molecular weight of 106-107 Daltons and typically range in size from 10-44 
nm (339, 340). It is generally accepted that a β particle corresponds to a single 
molecular unit of glycogen that can reach up to 12 tiers as modeled by Whelan 
and others (Figure 1.6c, see Section 1.3.1). Drochmans designated the 3 nm 
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filaments making up the β particles as γ particles (74). However, 'γ particle' has 
also been used to refer to protein-rich subunits on the glycogen β particles (see 
Section 1.7) (137). Generally speaking, glycogen is primarily stored as α particles 
(or a mixture of α and β particles) in the liver and as β particles in muscle, brain, 
and other tissues (reviewed below). Recent work has demonstrated a mixture of α 
and β particles in cardiac tissue (341). It is apparent that these norms become 
disrupted in pathological conditions.  
It is estimated that liver α particles contain, on average, 20 to 40 β particle 
subunits (342). Liver glycogen is typically cytoplasmic and often reported to closely 
associate with smooth endoplasmic reticulum (343, 344). In muscle, β particles are 
associated with sarcoplasmic reticulum, concentrated either in subsarcolemmal 
regions, between myofibrils, or within the myofibrils; these pools respond 
differently to metabolic cues (239). Aggregates up to 60 nm in diameter, apparently 
composed of 4-6 β particles, were also observed via EM by Wanson and 
Drochmans in muscle, and others have reported α particles in rat muscle and 
insect flight muscle (52, 75). In skin and adipose tissue, β particles appear as 
cytoplasmic granules interspersed between ribonucleoprotein particles (345, 346). 
In adipose tissue, they are only prominent after refeeding following a fast (347). In 
leukocytes and thymus, β particles are scattered throughout the cytoplasm and are 
fairly homogenous in size (348, 349). In the retina, cytoplasmic β particles and 
occasional small α particles (60 nm) have been observed in the cone, but not rod, 
photoreceptor cells, and in Müller cells (350).  
In the brain, glycogen exists primary as cytoplasmic β particles in the cell 
bodies and processes of astrocytes (76, 77, 351, 352). Normally, they are sparse 
to nonexistent in neurons, microglia, or oligodendrocytes, but β particles have 
appeared in neuronal axons and dendrites following fasting or trauma (77, 351). 
Astroglial β particles become apparent in early embryos and increase in both 
abundance and diameter with development (353). Small α particles (80-100 nm in 
diameter, composed of 4-8 β particle subunits by EM) have also been reported in 
rat astrocytes (352). Biochemical studies of glycogen isolated via a mild cold-water 
extraction method show significant heterogeneity in molecular weight: a fraction 
of particles had molecular weights suggestive of small α-particles composed of 3-
6 β particle subunits (336). In several cases of human glycogenoses, small (60-
120 nm in diameter) and large (150-350 nm in diameter) α particles have been 
reported in astrocytes or neurons (354-356). Aggregates of α or β particles have 
also been reported in Alzheimer's disease and the aging brain (357, 358), which 
are distinct from polyglucosan bodies (79). Reactive astrocytes are known to 
accumulate glycogen β particles in response to various pathological stimuli, 
including: brain infarction (359), methionine sulfoxide (351, 360), X-ray irradiation 
(76), and barbiturates (351). Occasionally, intramitochondrial glycogen has also 
been observed in rat retinal cells (361), in the human and canine myocardium 
(362, 363), and in astrocytes (352, 364). 
β particle size exists around a normal distribution, with most granules being 20-
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30 nm (Figure 1.9a) (52, 365). Since each additional tier is estimated to contribute 
3.8 nm to the diameter (134, 365), the observed size distribution implies that most 
β particles have only about 7-9 tiers (Figure 1.9a,b,c). It is still not clear why most 
β particles do not reach the maximum diameter, since such large granules can 
store a significantly greater amount of glucose (239). A growing body of evidence 
suggests that glycogenin regulates β particle size. In cell culture and in tissue, 
glycogenin does not appear to exist in a free form; it is always attached to glycogen 
(226, 241, 366). Overexpression of glycogenin in cell culture did not change total 
glycogen levels, but it increased the total number of glycogen molecules, which 
were of a smaller size (366). The Guinovart group showed that mice lacking 
glycogenin display reduced exercise endurance and an accumulation of glycogen 
particles in muscle that were larger than those in wild-type mice (241). Also, crystal 
structures and data from the Sicheri lab suggest glycogen particle size is regulated 
by the length of the linker between the glycogenin catalytic domain and the region 
that binds to glycogen synthase; this region is alternatively spliced and varies in 
length across species (236, 367).  
In healthy organisms, α particles seem to be a unique feature of the liver. It is 
well established that total liver glycogen depletes with fasting and exceeds basal 
levels upon refeeding, a phenomenon known as glycogen super-compensation 
that is also observed in muscle and brain (368-370). Additionally, hepatic glycogen 
levels and the activities of glycogen metabolizing enzymes undergo a diurnal 
rhythm (371, 372). The Gilbert lab analyzed glycogen particles by size exclusion 
chromatography and EM and proposed a model for diurnal glycogen cycling in 
liver based on their data and earlier work (373). Starved livers maintain low 
glycogen in the form of small β particles. Upon refeeding, glycogen is quickly 
synthesized on these preexisting β particles, which provide optimal surface-to-
volume ratio for rapid resynthesis. Once glycogen levels peak, the β particles are 
assembled into α particles. The α particles persist as glycogen levels begin to 
gradually fall, but they are gradually disassembled into β particles, which are 
preferentially degraded. Thus it appears that the primarily role of α particles is to 
facilitate a slower release of glucose than β particles (374). This indeed seems 
optimal for the organ whose primary role is to maintain blood glucose 
homeostasis. Additionally, α particles in diabetic livers are more fragile than those 
of healthy mice, suggesting they could more easily be broken into β particles and 
contribute to hyperglycemia (375, 376).  
The nature of α particle assembly has remained elusive for decades. 
Drochmans observed that purified α particles could be dissociated into β particles 
under acidic conditions (74). Lazarow, Orrell and Bueding previously showed 
using ultracentrifugation that acid, alkali and heat drastically changed the 
sedimentation of liver glycogen, suggesting these treatments disrupt α particle 
structure (51, 377). The Gilbert lab has devoted a significant body of work to 
elucidating the nature of the α particle bond due to its relevance to diabetes (340, 
376, 378-380). The lack of significant dissociation of normal α particles in dimethyl 
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sulfoxide, 2-mercaptoethanol, or sodium dodecyl sulfate suggested the 
association is not through hydrogen or disulfide bonds or weak protein-protein 
interactions (340, 378). It was reported that unexpectedly high levels of glycogenin 
were found in a proteomic study of liver glycogen, suggesting that glycogenin was 
present on the granule surface in addition to the granule core (381). The Gilbert 
lab then used proteomics to identify glycogenin as the molecular "glue" holding α 
particles together (379) (Figure 1.9d). 
 
1.6.2 Proglycogen and macroglycogen 
There is a lot of controversy surrounding proglycogen and macroglycogen, 
which have gone by different terms over the years and have been discussed in 
great detail by others (226, 339, 382, 383). Although the precise nature of these 
pools is debated, there does appear to be sufficient evidence for their distinct 
physiological roles in glycogen turnover (239, 339). The relationship between 
proglycogen/macroglycogen and α/β particles is not completely clear as these 
distinctions are discussed separately. However, since they are relevant to tissues 
generally lacking α particles, proglycogen and macroglycogen likely represent two 
states of β particle synthesis (226). When the TCA extraction method was first 
introduced for the purification of glycogen, it was observed that a portion of the 
glycogen was resistant to extraction by cold TCA (50). It could not be released 
unless the tissue was treated with heat, alkali, or protease, so it was concluded 
that this resistant fraction was attached to protein, and the two fractions were 
called lyo- ("free") and desmo- ("fixed") glycogen (50, 384). Such observations 
also gave rise to the terms acid-soluble, i.e. extractable, glycogen, and acid-
insoluble, i.e. residual, glycogen (385, 386). In a 1960 literature review, Stetten 
and Stetten noted that while the quantity of free glycogen was widely variable with 
nutritional state, the quantity of fixed glycogen remained constant. However, 
experiments suggested the latter was more metabolically active, since injected 
[14C]glucose was more readily incorporated into fixed glycogen (386). For 
decades, researchers continued to debate whether such observations were 
artefactual, merely reflecting the association of known metabolic enzymes with 
glycogen (387). Whelan revisited the subject in the late 20th century while 
investigating the origin of glycogen synthesis. Using cultured primary astrocytes, 
his group showed that fixed glycogen, which was re-named proglycogen, 
contained 10% protein by weight and was rapidly resynthesized upon refeeding 
after glucose starvation, reaching a size of 400,000 Da. The proglycogen was later 
converted to macroglycogen, as demonstrated by pulse-chase labeling (383). The 
group proposed that proglycogen was an intermediate between glycogenin and 
the mature glycogen granule (226, 383). Resynthesis of proglycogen prior to 
macroglycogen following exhaustive exercise was also confirmed in vivo in 
humans {Adamo, 1998 #1640}. 
It has been suggested that the upper limit of proglycogen size corresponds to 
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a diameter of ~30 nm, a molecule of approximately 8 tiers; anything larger would 
be considered macroglycogen (Figure 1.9a,d) (136, 339, 365). However, 
Whelan's group estimated that the upper limit of proglycogen was 400 kDa (226, 
383), which corresponds to a glycogen molecule with ~2500 glucose residues, i.e. 
approximately 5 tiers. Whelan's group also suggested that proglycogen and 
macroglycogen are synthesized by different enzymes, however it may be that the 
different activities associated with the pro- and macroglycogen fractions both 
correspond to glycogen synthase. Two independent groups have demonstrated 
that glycogen synthase in the proglycogen fraction has a higher affinity for UDP-
glucose than synthase in the macroglycogen fraction {Curtino, 2000 
#1461}{Tavridou, 2003 #1330}. Curtino and Lacoste proposed that the insolubility 
of proglycogen in TCA was due to its heavy association with glycogen synthase, 
not with glycogenin, as Whelan had proposed (388). Tavridou and Agnius showed 
that the hormone insulin increased the association of glycogen synthase with the 
proglycogen fraction, and glucagon had the opposite effect (219). Insulin is known 
to stimulate dephosphorylation (and activation) of glycogen synthase, and the 
effects of both hormones are well known to regulate glycogen synthesis through 
signaling cascades, so the difference in synthase activity may be due to its 
phosphorylation state. Indeed, phosphorylation-dependent stimulation of 
glycogen synthase and phosphorylase has been shown to induce translocation of 
these proteins to actin-rich structures proximal to sarcoplasmic reticulum in 
skeletal muscle (389, 390). In liver, newly synthesized glycogen has also been 
reported to be associated with a protein backbone (391) and smooth endoplasmic 
reticulum (343). Additionally, glycogenin has been shown to bind to actin (392). In 
vitro studies suggest that glycogen synthase is more active when it is bound to 
glycogenin (109, 393). When glycogen content decreases, glycogen synthase has 
been shown to translocate from a glycogen-enriched membrane fraction to the 
cytoskeleton, concurrent with a decrease in activity (394). In isolated hepatocytes, 
glucose stimulated the cytoskeleton-dependent translocation of synthase from the 
cytosol to the plasma membrane, and newly synthesized glycogen molecules 
always appeared first at the cell membrane, but moved inward as they were 
replaced by newer molecules (395-397).  
Proglycogen may represent a membrane-associated and/or actin-bound form 
of glycogen that is primed and ready for active anabolism/catabolism. When it 
grows to a certain size, it becomes macroglycogen, synthesis levels off, and it is 
released into the cytosol. A similar model has been proposed recently (137) and 
prompts further discussion of glycogen and its associated proteins as a dynamic 
subcellular entity rather than a static molecule (see Section 1.7) (382). It is still 
not clear whether synthesis and degradation can occur simultaneously on the 
same granule, but proximity of these activities is suggested (389). The 
spatiotemporal regulation of glycogen metabolism is an interesting area of 
research requiring further elucidation. 
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1.6.3 Nuclear glycogen 
Dozens of microscopy studies have reported intranuclear glycogen deposits, 
most often in pathological conditions of the liver (398-400). In a 1975 case report, 
Ferrans et al. beautifully reviewed 24 prior studies on intranuclear glycogen either 
in the context of diabetes, glycogen storage diseases, or as an incidental feature 
in healthy humans and animals (401). In these reports, nuclear glycogen was 
usually in the form of β particles, sometimes dispersed, other times clustered; 
occasionally a few α particles were reported. The findings of Ferrans et al. were 
unusual in that nuclear glycogen was observed in the diseased myocardium. 
Intranuclear glycogen was only found in 6 out of 90 patients with cardiac diseases, 
and only in a few nuclei per patient. Most of the glycogen was present as β 
particles, often aggregated and filling the entire nucleoplasm. The presence of 
nuclear glycogen was not associated with any cellular damage. The authors 
proposed three mechanisms for the formation of nuclear glycogen, but shrewdly 
concluded that only one was possible: (1) there was no ultrastructural evidence 
supporting phagocytosis or endocytosis of glycogen particles by the nuclear 
membrane; (2) glycogen particles were too large to pass through the nuclear pore 
complex; (3) the glycogen must be synthesized in situ, which had been previously 
demonstrated in normal Müller cells of the rat retina (402) and in Novikoff 
hepatoma cells (403). Ferrans et al. proposed that conditions favoring increased 
permeability of the nuclear membrane facilitated the entry of the metabolic 
enzymes into the nucleus, but that they became trapped when permeability 
returned to normal. This implies that atypical trapping of glycogenic enzymes into 
the nucleus may result in excessive levels of glycogen. Nuclear α and β particles 
have also been reported in the context of various cancers: human gastric 
adenocarcinoma (404), sublines of the Ehrlich-Lettré mouse ascites tumor (405), 
chicken sarcoma (406) and human and mouse hepatoma (407, 408). Nuclear 
glycogen synthase activity was also detected in the Ehrlich-Lettré subline (409, 
410). In the brain, intranuclear glycogen deposits have been observed in the 
abnormal astrocytes of Alzheimer's disease (411, 412) and in the pituicytes of 
aged rats (413). Nuclear polyglucosan was also reported in a neuronal cell culture 
model of GBE deficiency (262).  
In more recent years, Guinovart, Gentry and others have shown that nearly all 
the central glycogen metabolic enzymes can be found in the nucleus: glycogenin 
(392, 414), glycogen synthase (300, 415, 416) glycogen phosphorylase (Sun, 
Dukhande, and Gentry, unpublished results), and debranching enzyme (304). 
Guinovart's group published a series of studies demonstrating the translocation of 
the muscle isoform of glycogen synthase from the cytosol to the nucleus in 
conditions of glucose deprivation, which required glycogen binding (415-417). 
They also showed that neurons display primarily nuclear localization of glycogen 
synthase, characteristic of cells lacking glycogen, in contrast to glycogen-rich 
astrocytes with cytosolic synthase (300). Additionally, GDE and glucokinase, a key 
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glucose sensing enzyme, also shuttle to the nucleus upon glucose deprivation 
(304, 418). In contrast, glucose starvation has an opposite effect on the 
gluconeogenic enzyme fructose bisphosphatase, inducing its translocation to the 
cytosol (419). It has been suggested that the nuclear sequestration of these 
enzymes is yet another way to regulate their activity, preventing them from acting 
inappropriately in times of energy stress (420). Laforin and AMPK, which both 
contain CBMs and bind to glycogen in vitro and in cell culture, also translocate to 
the nucleus with glucose deprivation and glycogen depletion (304, 421) (Figure 
1.10a,b).  
Nuclear-cytoplasmic shuttling has also been observed for yeast glycogen 
synthase. In a review discussing these data, it was postulated that "the freeing of 
glycogen synthase from its cytoplasmic tether to the glycogen particle as these 
stores reduced would therefore be a signal that carbon and energy reserves were 
low. The uptake of glycogen synthase into the nucleus might therefore represent 
a form of molecular 'fuel gauge.' It is possible that glycogen synthase could 
regulate transcription in response to energy availability by some as yet 
undetermined means" (422). 'Moonlighting' of metabolic enzymes in the nucleus 
is not a new theme. Moonlighting proteins perform multiple unrelated functions, 
expanding the functional repertoire of the cell without expanding the number of 
genes, and the first to be described was the lens structural protein ε-crystallin, also 
known as lactate dehydrogenase (423). All essential glycolytic enzymes have 
been observed in the nucleus, as well as some mitochondrial proteins and 
enzymes involved in methylation and acetylation (424, 425). These energy-
sensing proteins have been shown to regulate transcription by diverse means in 
a "metabolism-epigenetic axis" that is critical for cellular homeostasis (425). 
Although the epigenetic role of glycolytic proteins is well described, it is still not 
clear whether glycolysis occurs in the nucleus, although its products ATP and 
NADH could certainly be useful. Glycogen-associated enzymes may also have 
both an epigenetic and energy producing role, and perhaps excessive glycogen 
deposits result from misregulated nuclear sequestration. AMP-activated protein 
kinase (AMPK), a master regulator of cellular energy known to bind to and sense 
glycogen levels (426) (see Section 1.7), also translocates to the nucleus and 
regulates transcription and the circadian clock through phosphorylation (427, 428). 
1.7 The glycogen granule and its associated proteins 
In 1968, Scott and Still recognized the dynamic nature of glycogen and 
introduced the term "glycosome" to refer to the molecule and its associated 
proteins, stating that the nature of glycogen as a cellular organelle had not been 
appreciated (348). Rybicka reintroduced the term in a detailed historical review of 
the evidence for such a classification (382). Unfortunately, the term "glycosome" 
has been used far more frequently to refer to the glycolytic enzyme-containing 
peroxisomes of trypanosomatids, a family of unicellular parasites (429), which 
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creates confusion. Also, in the strict definition, organelles are membrane-bound 
entities (430, 431), and glycogen is primarily cytosolic. Perhaps it is safest to 
simply recognize that a host of proteins are associated with the glycogen granule, 
its structure is complex and highly regulated, and it is a dynamic participant in 
cellular metabolism.  
The γ particle named by Drochmans was a description of the ramifying fine 
fibers (3 nm in diameter) comprising β particle structure, likely corresponding to 
glucan chains (74). Later authors came to identify protein-rich subdomains on the 
glycogen molecule as γ  particles, which may be a misinterpretation (137). Protein 
is more electron dense than carbohydrate, so with lead and uranyl acetate 
staining, protein-rich regions appear darkly stained clusters about 2-3 nm in 
diameter; alternatively, staining with the histochemical method of Thiéry using 
silver proteinate results in electron-dense clusters of the same size corresponding 
to vicinal glycols (137, 382, 432). Rybicka refers to the electrodense vicinal glycols 
as γ particles, which is likely consistent with the meaning originally intended by 
Drochmans. Due to their very small size, both γ particles and protein-rich 
subdomains are only visible by EM. It is not yet clear why they exist as discrete, 
regular entities and which proteins correspond to the protein subdomains. 
However, it is well established that all of the primary glycogen metabolic enzymes 
(glycogenin, synthase, phosphorylase, GDE and GBE) bind to and colocalize with 
glycogen granules in cell culture and in vivo (251, 300, 304, 433, 434) (Figure 
1.10c). In fact, due to its very tight association, glycogen synthase is frequently 
used as a marker for glycogen and polyglucosan bodies (179, 324). There are a 
few antibodies that directly bind to the polysaccharide chains of glycogen, but they 
are not yet commercially available and are still being characterized (120, 435). 
Other proteins known to closely associate with the glycogen molecule all contain 
a glycogen-binding CBM: laforin and Stbd1 (Section 1.5), the β-subunit of AMPK, 
and the glycogen-targeting subunits of protein phosphatase 1 (discussed below) 
(Figure 1.10b,c). Phosphorylase kinase also binds to glycogen (245, 436).  
Protein phosphatase 1 (PP1) catalyzes a vast array of dephosphorylation 
events in cells, regulation of which is achieved by diverse targeting subunits that 
bring the catalytic subunit (PP1c) into the vicinity of its target (437, 438). Seven 
glycogen-targeting subunits of PP1 have been identified (PPP1R3A-G), but four 
have been most extensively characterized as primary regulators of glycogen 
synthesis (114, 439). GM (also known as RGL, encoded by PPP1R3A) expression 
is restricted to heart and skeletal muscle; GL (encoded by PPP1R3B) is primarily 
expressed in liver; and Protein Targeting to Glycogen (PTG, also known as R5, 
encoded by PPP1R3C) and R6 (encoded by PPP1R3D) are more ubiquitously 
expressed, with enrichment in glycogen-rich tissues (www.proteinatlase.org) 
(114). All these subunits possess both a PP1-binding domain and a putative 
CBM21 and recruit PP1 to glycogen granules (www.cazy.com) (439, 440). 
Dephosphorylation by PP1 has opposing effects on synthase (activating) and 
phosphorylase (inhibitory), leading to net glycogen synthesis (300, 439, 441). 
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Overexpression of PTG, GM, GL, and R6 leads to glycogen accumulation in cell 
culture and mouse models (182, 301, 441-444).  
AMPK, a cellular energy sensor with multiple intracellular targets, is also 
considered an important glycogen sensor (445). AMPK is activated by elevated 
levels of AMP relative to ATP reflecting energy deficits. It is a heterotrimeric 
complex composed of a catalytic α subunit and regulatory β and γ subunits; the β 
subunit contains a CBM48 and targets AMPK to glycogen granules (252, 426, 
446). AMPK phosphorylates both isoforms of glycogen synthase, inhibiting its 
activity (447). It has been speculated that recruitment of activated AMPK to 
glycogen granules would lead to decreased glycogen synthesis. There is also 
significant evidence for regulation of AMPK activity by glycogen via the β subunit 
(448). AMPK is particularly inhibited by the presence of a single α-1,6 linked 
glucose unit or by a glycogen molecule that has been partially degraded by 
phosphorylase (426, 449). A single glucose unit at a branch point could be 
exposed during debranching, since GDE is likely to dissociate from glycogen 
between its transferase and glucosidase activities (251). Thus, glycogen, 
especially when being actively degraded, is a potent inhibitor of AMPK, and there 
is likely to be reciprocal regulation between glycogen and AMPK.  
Proteomic studies have been performed on glycogen isolated from mouse 
and rat liver and the mouse adipocyte cell line 3T3-L1 (381, 434). Synthase, 
phosphorylase, GBE, GDE, and glycogenin were all abundant, as well as PP1 
regulatory subunits. Stbd1, laforin, and proteins associated with endoplasmic 
reticulum were only found in the hepatic proteome; lysosomal α amylase was 
identified only in the 3T3-L1 proteome, indicative of cell-specific differences in 
glycogen metabolism. The lack of AMPK or PhK binding was consistent with 
earlier studies and attributed to the stringency of the isolation procedure and the 
nutritional state of the liver (450). A number of proteins associated with 
mitochondria, ribosomes and nuclei were also identified in lower abundance, 
suggestive of both a heterogeneous subcellular distribution and the link between 
glycogen and a variety of cellular processes, as has been discussed in previous 
sections.  
It should be noted that many structures of glycogen-associated enzymes 
have been determined, and they are quite large relative to the size of the glycogen 
granule (Figure 1.11). The dimeric structure of rabbit muscle glycogenin is ~80 
kDa in solution and the crystal structure of the monomer is 63 Å at its widest point 
(228). This corresponds to one fourth of the diameter of the average glycogen β 
particle (25 nm, i.e. 250 Å). Yeast glycogen synthase is tetrameric, measuring 115 
Å at its widest point, approximately half the diameter of a glycogen granule; each 
subunit is about 90 Å long (264). Monomeric human brain phosphorylase is 78 Å 
long, but it also is known to function as a dimer (246).  Yeast GDE and human 
GBE monomers are 137 Å and 94 Å long, respectively. (250, 251). The elongated 
human laforin dimer measures 119 Å in length both in crystals and in solution 
(190). PhK and AMPK are both very large multisubunit complexes (245, 445). 
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Although a complete structure of AMPK is not yet available, structures of the PhK 
holoenzyme and PhK in complex with phosphorylase determined by cryo-EM 
reveal that these complexes are 270 Å by 225 Å and 310 Å by 250 Å, respectively, 
roughly the same dimensions as glycogen β particles (451). With this scale in 
mind, one can begin to envision that the surface of glycogen molecules is likely to 
be very crowded, and enzymes may compete for access to glucan chains. 
Molecular crowding has been shown to influence the interaction of PhK with 
phosphorylase and with the glycogen molecule (436). Glycogen and its associated 
proteins may function as molecular scaffolds, binding to one another and recruiting 
a variety of enzymes that respond to glycogen levels and regulate energy 
homeostasis.   
1.8 The future of brain glycogen research 
The groundbreaking discoveries of the 20th century greatly expanded our 
understanding of glycogen metabolism and monumentally impacted the broader 
field of biochemistry. As a result, there is a widespread belief that glycogen 
metabolism is an antiquated area of research that requires no further investigation. 
However, there is a milieu of interesting questions that remain unresolved 
regarding glycogen, particularly on its complex yet elusive role in the mammalian 
brain. Defects in glycogen metabolism are a hallmark of many diseases, including 
neurodegenerative diseases. The advent of new technologies makes it possible 
to better study brain glycogen and will most certainly lead to a better 
understanding of its architecture and metabolism in a variety of contexts.  
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Figure 1.1 Timeline of landmark discoveries in the history of glycogen-
related research. 
Notable discoveries and papers are shown. Claude Bernard, the physiologist who 
discovered glycogen and its function in liver, and Nobel laureates are pictured. 
PubMed (https://www.ncbi.nlm.nih.gov/pubmed/) searches were performed using 
the keywords shown (glycogen, liver glycogen, muscle glycogen, or brain 
glycogen), and the number of publications per year for each set of keywords are 
shown. Key terms related to glycogen synthase kinase (GSK, GSK3, GSK3 beta) 
were excluded from search results since much of the GSK-related literature is not 
directly relevant to glycogen metabolism.  
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Figure 1.2 Glycogen in the CNS of invertebrates and vertebrates. 
Drawings illustrating glycogen in the CNS of multiple organisms detected via 
iodine staining (18). Copyright © 2005 John Wiley and Sons, Inc. Used with 
permission. 
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Figure 1.3 The Cori cycle and the tree-like structure of glycogen. 
 (a) The cycle of carbohydrates between liver and muscle proposed by Cori and 
Cori (1929) when they observed that ingestion or subcutaneous injection of sodium 
d-lactate led to glycogen deposition in the liver. Their subsequent work validated 
and elaborated this model, which became known as the Cori cycle. (b) A segment 
of the tree-like structure of glycogen based on Meyer's model and the results of 
the Cori group. Glucose residues are represented by circles; dotted, bisected, and 
half-filled circles correspond to glucose residues released by the first, second, and 
third rounds of degradation with phosphorylase, as indicated. Filled circles 
represent glucose residues released by α-1,6 glucosidase (i.e. debranching 
enzyme). Tiers are numbered. Modified from Larner et al. 1952. Copyright © 
American Society for Biochemistry and Molecular Biology. Used with permission. 
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Figure 1.4 Early studies of brain glycogen. 
(a) Rapid glycogen loss following extraction from brain of normal and convulsed 
mice; glycogen was measured using a modification of the method by Kerr (1938) 
(from (56)). Copyright © Company of Biologists, Ltd. Used with permission. (b) 
Staining of glycogen (dark stain) in the perfused rabbit brain using the lead-tetra-
acetate-Schiff method, a modification of PAS (65). The identity of stained regions 
as glycogen was confirmed by salivary digestion of comparable sections. Left: 
glycogen is abundant in the granular and molecular layers of the cerebellum, but 
Purkinje neurons lack glycogen. Upper right: ependymal cells of the hypothalamus 
lining the third ventricle show intense staining for glycogen, and granules are 
abundant in the neuropil, but nerve cells lack glycogen in this region. Lower right: 
some small nerve cells in the lateral hypothalamic nucleus appear to contain 
glycogen. Scale bars have been approximated based on magnification. Copyright 
© 2004 John Wiley and Sons, Inc. Used with permission. 
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Figure 1.5 Glycogen ultrastructure as demonstrated by electron 
microscopy. 
(a, b) Negative staining of natively purified rat liver glycogen from reveals the 
presence of α, β and γ particles (74). Copyright © 1962 Elsevier. Used with 
permission. (c) Typically, purified muscle glycogen exists only as β particles (75). 
Scale bars have been approximated based on magnification. Copyright © 
Rockerfeller University Press. Used with permission. (d,e) Glycogen in the rat 
cerebral cortex visualized by EM (76). (d) In sections of normal cortex, glycogen 
β particles (g) can be found in astrocyte processes (AP) and astrocytic end feet 
applied to the basement membrane (b). An astrocytic bundle of fibrils (f) is labeled. 
(e) One day after irradiation with ionizing particles, end feet (ef) are enlarged and 
contain numerous glycogen granules and mitochondria (m). An endothelial cell 
lining the capillary is also labeled (E). Copyright © Rockerfeller University Press. 
Used with permission.  
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Figure 1.6 Structure and synthesis of polyglucans. 
(a) Starch and glycogen contain linear chains of glucose joined by α-1,4 glycosidic 
linkages, and α-1,6 glycosidic linkages constitute the branch points. The reducing 
ends (containing an aldehyde group) are oriented near the interior of the 
polysaccharide molecule, while metabolic enzymes work on the nonreducing 
ends, which are oriented outward. (b) The α conformation of α-1,4 linked 
polyglucans gives them a propensity to twist, and long unbranched chains can 
form single or double helices; a model of a double helix is shown. (c) A model of 
the first five tiers of the glycogen particle according to the Whelan model. A 
tyrosine residue of glycogenin (GYG) is shown, which is covalently linked to the 
glucan chain making up the first tier. (d) A recent model for starch structure 
according to Bertoft {Bertoft, 2017 #1132}. In amylopectin, the branched 
component of starch, branching is clustered, and the long linear chains form 
double helices (grey cylinders) that make up the crystalline regions of starch. 
Amylose, the unbranched component of starch, is believed to occupy areas 
around the amylopectin molecules.  
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Figure 1.7 Chain length distribution (CLD) of glycogen and amylopectin 
demonstrated by HPAEC. 
(a) CLD of bovine liver and rabbit liver glycogen determined by HPAEC (156). 
Copyright © 1993 Japan Society for Bioscience and Agrochemistry, reprinted by 
permission of Taylor & Francis, Ltd. (b) HPAEC profile and CLD of potato 
amylopectin (157). Copyright © 1996 Elsevier. Used with permission. (c) CLD of 
skeletal muscle glycogen from rested mice (not run) and 1 hour following 
exhaustive exercise (160). (d) Iodine spectra of skeletal muscle glycogen from 
rested mice and 1 hour, 3 hour, 1 day, and 6 days post-exercise (160). Copyright 
© 2015 American Society for Biochemistry and Molecular Biology. Used with 
permission.  
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Figure 1.8 Insights from Lafora disease, a non-classical glycogen storage 
disease. 
A typical LB visualized by electron microscopy in the human retina (452). Scale 
bar has been approximated based on magnification. Copyright © 1980 Springer 
Nature. Used with permission. (b) Neuronal (arrows) and astrocytic (arrowheads) 
polyglucosan accumulations visualized by immunostaining in the dentate gyrus 
(DG) and CA1 of the hippocampus in malin knockout (KO) mice (180). Scale bars 
= 10 μm. (c) Normal and abnormal CLD of purified polysaccharides from WT and 
LD (Epm2a-/-) mice determined by HPAEC (159).  
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Figure 1.9 Size and structure of glycogen α and β particles, proglycogen 
and macroglycogen. 
(a) Distribution of β glycogen particle size in muscle (365) compared to the 
estimated number of glucosyl residues per glycogen molecule (339). The 
theoretical threshold between proglycogen and macroglycogen is after tier 8. (b) 
Estimated diameter of the tiers of glycogen particles. (c) Schematic diagrams of 
an 8-tiered glycogen molecule based on the studies of Whelan and mathematical 
modeling of (134). (d) A possible relationship between proglycogen and 
macroglycogen and α and β particles and approximated sizes. Grey circles 
represent glycogenin molecules. Diagram of α particle was adapted from (379). 
  
Proglycogen Macro-
glycogen
1 2 3 4 5 6 7 8 9 10 11 12
0
1000
2000
3000
4000
0
10,000
20,000
30,000
40,000
50,000
60,000
Tier
F
re
q
u
e
n
c
y
T
o
ta
l g
lu
c
o
s
y
l re
s
id
u
e
s
Proglycogen
Macroglycogen
1 2 3 4 5 6 7 8
Tier Diameter (nm)
1
2
3
4
5
6
7
8
9
10
11
12
0.2
4
7.8
11.6
15.4
19.2
23
26.8
30.6
34.4
38.2
42
< 42 nm
~25 nm
α
 p
a
rt
ic
le
~127 nm
synthase
phosphorylase
glycogenin
c
a db
β
 p
a
rt
ic
le
47 
 
 
 
Figure 1.10 Nuclear-cytoplasmic shuttling and colocalization of glycogen 
associated enzymes. 
(a) In media containing glucose and metformin, laforin colocalizes with glycogen 
in Neuro2A cells (421). (b) When expressed in COS-7 cells, laforin and AMPK 
colocalize (with glycogen) in the cytosol in the presence of glucose, and 
translocate to the nucleus upon glucose starvation (421). For (a,b), scale bars = 
10 μm. Copyright © 2012 American Society for Microbiology. Used with 
permission. (c) Immunolabeling of glycogen synthase, phosphorylase, and 
glycogen itself in tilapia gill sections (433). Scale bars = 20 μm. Copyright © 
Company of Biologists. Used with permission. 
  
c
b Laforin AMPK DAPI Merged
G
lc
 (
+
)
G
lc
 (
-)
Laforin Glycogen DAPI Merged
G
lc
 +
 M
F
Glycogen
Synthase
Glycogen
Phosphorylase
Merged
Glycogen Mergeda Glycogen
Synthase
48 
 
 
Figure 1.11 Crystal structures and relative sizes of glycogen-associated 
proteins. 
Crystal structures of yeast glycogen synthase (PDB: 3NAZ), yeast glycogen 
debranching enzyme (PDB:5D06), human branching enzyme (PDB: 4BZY), 
human brain glycogen phosphorylase (PDB: 5IKO), rabbit muscle glycogenin 
(PDB: 1LL2), and human laforin (PDB: 4RKK). Structures were superimposed 
manually in PyMol and are shown at equivalent zoom. The size of an average 
glycogen β particle (diameter = 250 Å) is shown for scale to illustrate the relative 
sizes of the proteins and glycogen particle. Crystal structure dimensions were 
calculated based on an inertia axis aligned bounding box in PyMol. In multimeric 
structures, individual subunits are colored separately. 
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  MATERIALS AND METHODS 
2.1 Structure-guided in vitro studies of laforin and laforin mutants 
2.1.1 Cloning, protein expression, and protein purification 
Laforin tends to aggregate when expressed in E. coli, but removal of 3 amino 
acids at the C-terminus reduces aggregation (453). We refer to this construct as 
laforin C329X. The crystal structure of laforin C329X containing a mutation of the 
catalytic cysteine (C266S) has been described (190). For the studies herein, wild-
type and mutant laforin on the C329X background were expressed as His6-tagged 
fusions in pET28b (Novagen) as previously described (190, 453). Laforin is a 
bimodular protein with a carbohydrate-binding module (CBM) spanning amino 
acid residues 1-137 and a dual specificity phosphatase (DSP) domain spanning 
residues 138-331. A crystal structure of the laforin DSP domain (residues 150-
331) has been previously crystallized (454). An analogous DSP construct was 
generated by subcloning the DNA sequence for residues 150-331 from pET28b 
laforin (full length) into ppSUMO, a gift from the Dixon laboratory encoding a small 
ubiquitin-like modifier (SUMO), to generate the N-terminally His6-tagged SUMO-
DSP fusion. The laforin CBM construct (amino acids 1-137) was generated with 
an N-terminal His6-tag in pET28b using the Gibson Assembly® Cloning Kit (New 
England Biolabs).  
All proteins were expressed in BL21-Codon Plus E. coli cells and purified using 
immobilized metal affinity chromatography and a Profinia Purification System 
(BioRad) and size exclusion chromatography via an ÄKTA fast protein liquid 
chromatography system (GE Healthcare). Purity of proteins was determined by 
SDS-polyacrylamide gel electrophoresis (PAGE) with Coomiassie staining. For 
yeast two-hybrid assays, pEG202 laforin encoding a LexA-laforin fusion protein 
and pACT2, pACT2-malin and pACT2-PTG encoding Gal4 activation domain 
(GAD) and GAD fusions have been previously described (313, 455-457). pWS-
malin and pWS-PTG encoding HA-tagged proteins were generated by the Sanz 
Laboratory. All pET28b and pEG202 laforin mutants were generated by site-
directed mutagenesis (QuickChange Lightning, Agilent; Q5 Site-Directed 
Mutagenesis, New England BioLabs; GENEWIZ Site-Directed Mutagenesis).  
 
2.1.2 Glycogen phosphate determination and dephosphorylation assays 
Glycogen purification from rabbit muscle and phosphate content determination 
were performed as previously described (174, 210). Glycogen was also 
dephosphorylated with purified laforin, amyloglucosidase (Sigma), -amylase 
(Sigma), and/or Antarctic phosphatase (New England Biolabs). Phosphate 
release was quantified using the Pi ColorLock Gold Phosphate Detection system 
(Innova Biosciences), a commercial reagent based on the malachite green assay 
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for detecting inorganic phosphate (174, 458). Kinetics of dephosphorylation were 
defined as previously (174). Assays were performed in 100 L reactions 
containing 2.5 g enzyme, 2 mM DTT, and phosphatase buffer (100 mM sodium 
acetate, 50 mM bis-Tris, 50 mM Tris-HCl, pH 6.5) at 25C, and time and glycogen 
concentration were varied as indicated for kinetic experiments. Mutants were 
assayed in the linear range with respect to time, enzyme amount, and substrate 
concentration. For specific activity determinations, reactions were performed for 
30 minutes with 10mg/ml glycogen. Reactions were terminated with the addition 
of 25 L of the highly acidic Pi ColorLock Gold mix, and 10 L stabilizer was added 
after 5 minutes. After an additional 5 minutes, absorbance was measured at 635 
nm. Phosphate release was quantified based on the Pi ColorLock standard curve.  
 
2.1.3 Site-specific dephosphorylation assays 
Radiolabeled starch was prepared as previously described (184, 206, 207). 
Briefly, phosphate-free Arabidopsis (sex1-3) starch was phosphorylated with 
purified glucan water dikinase (GWD) and phospho-glucan water dikinase (PWD). 
The C6-labeled starch was prepared by including [β 33P]-ATP during the GWD 
incubation and unlabeled ATP during the PWD incubation. The C3-labeld starch 
was prepared by including unlabeled ATP during the GWD incubation and [β 33P]-
ATP during the PWD incubation. Labeled starch was washed thoroughly after 
each phosphorylation step to remove unbound phosphate. [β 33P]-ATP was 
obtained from Hartman Analytic. 
 Dephosphorylation reactions were performed in a volume of 150 L with 50 ng 
of enzyme in dephosphorylation buffer (100 mM sodium acetate, 50 mM bis-Tris, 
50 mM Tris-HCl, pH 6.5, 0.05% [v/v] Triton X-100, 1 g/L [w/v] BSA, and 2 mM 
DTT) and 3 mg/ml of either C6- or C3-labeled starch. After 2.5 minutes on a 
rotating wheel at 25C, reactions were quenched by adding 50 L of 10% SDS, 
and then centrifuged for 5 minutes at 13,000 rpm to pellet the starch. 150 L of 
the supernatant was added to 3 mL scintillation liquid, and 33P release was 
quantified using a 1900 TR liquid scintillation counter (Packard). For kinetic 
experiments, time and substrate concentration were varied as indicated. Kinetic 
parameters were determined using the Prism Software (Graphpad). 
 
2.1.4 Differential scanning fluorimetry (DSF) 
Experiments were performed using a CFX96 Real-Time PCR system (BioRad). 
Individual reactions contained 2 μM protein and 5X SYPRO Orange Protein Gel 
Stain (Invitrogen). DP7/maltoheptaose (Elicityl), DP24 maltodextrins (Elicityl), 
rabbit liver glycogen (Sigma), or -cyclodextrin (Sigma) were used as substrates 
in DSF reactions. Melting was monitored from 20 to 90°C at a ramp rate of 
1°C/50sec. Melting temperature (Tm) was calculated from a Gaussian fit of the first 
derivative of the melting curve. Data analyses and binding fits were determined 
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using the Prism software (Graphpad).  
For DSF experiments in Chapter 4, buffers, water, and substrates were 
preincubated with PiBind resin to remove contaminating phosphate. Phosphate 
was added to DSF experiments from a 0.05 M K2HPO4/KH2PO4 stock for the 
indicated concentration. 
 
2.1.5 Yeast two-hybrid assays 
Saccharomyces cerevisiae were transformed with the indicated plasmids, and 
transformants were grown in selective SC medium. Extracts were prepared as 
described previously (313); samples were separated by SDS-PAGE and analyzed 
by Western blotting using the corresponding anti-LexA (Santa Cruz 
Biotechnology), anti-HA (haemagglutinin; Sigma) antibodies. Yeast two-hybrid 
assays were performed as previously described (456). Briefly, transformants were 
screened for β-galactosidase activity using a filter lift assay. The strength of the 
interaction was determined by measuring β-galactosidase activity in 
permeabilized yeast cells and expressed in Miller units.  
 
2.1.6 Protein phosphate content determination 
Pi ColorLock Gold (Innova Biosciences) was added to at least 100 g of 
protein, and then centrifuged at 13,000 rpm for 1 minute to pellet insoluble protein. 
The supernatant was removed and added to a 96-well plate for absorbance 
measurement at 635nm. Samples were boiled prior to phosphate measurement 
unless otherwise indicated. PiBind resin (Novus Biologicals) was used to remove 
contaminating phosphate from buffers, substrates and incubations, as indicated. 
 
2.1.7 Dialysis with phosphate binders 
Aliquots of 50 g of laforin C266S was added to Pur-A-Lyzer mini dialysis tubes 
(Sigma) and dialyzed into 100 mL of purification buffer (100 mM NaCl 20 mM Tris 
pH 7.5, 10% glycerol) with either 50-100 L PiBind or 1 mM phosphate binder. 
Samples were incubated at room temperature for 24 hours on a mixing plate with 
a slowly rotating stir bar. Exchanges of fresh buffer with PiBind or phosphate 
binder were performed approximately every four hours (4 exchanges total). 
Aluminum hydroxide [Al(OH)3], calcium carbonate [CaCO3], calcium acetate 
[CaAc2], lanthanum carbonate [La2(CO3)3], magnesium carbonate [MgCO3] were 
obtained from Sigma. Sevelamer HCl and CO3 were purchased from ApexBio. 
 
2.1.8 Hydrogen deuterium exchange mass spectrometry (DXMS) 
Deuteration experiments on laforin WT and C266S were performed as 
previously described (459, 460). Deuterated laforin samples were prepared by 
incubation of 10 g protein with D2O buffer (300 mM NaCl, 50 mM Tris-HCl, 3 mM 
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TCEP, pD (read) 7.1) at 0°C for 10, 30, 100, 300, 1000, 3000, and 10000 s, and 
then quenched (5.3% v/v/ formic acid, 15% v/v glycerol, 2.5M GuHCl, 39 mM 
TCEP, pH 2.4). Quenched samples were digested with pepsin and peptides were 
separated by chromatography. Mass spectrometric analysis of peptides was 
performed using an LCQ Classic (Thermo Fisher) electrospray ion trap-type mass 
spectrometer and an electrospray Q-TOF mass spectrometer (Waters Corp, 
Milford, MA). Data from all sample sets were acquired from a single automated 
run of 8 hours. Deuteration experiments were also performed with 5 mg/ml rabbit 
liver glycogen (Sigma). Maximum changes in deuteration for peptides were used 
to determine the difference between WT and C266S laforin and differences with 
each protein binding to glycogen.   
 
2.1.9 Analytical ultracentrifugation (AUC) 
Sedimentation velocity experiments were conducted using a Beckman XL-I 
analytical ultracentrifuge (Beckman-Coulter, Fullerton, CA) as previously 
described (190). Samples were analyzed at 40,000 and 4 °C and absorption 
measurements taken at 280 nm. Measurements of sedimentation coefficient 
distributions between 0.1 and 8 s were analyzed using numerical solutions of the 
Lamm equation implemented in Sedfit (461).  
 
2.1.10 Structural analysis 
PyMol 2.0 was used for structural analysis, measurements and generating 
molecular graphics (462). Solvent accessible surface area was calculated for 
4RKK using the GetArea program (Supplemental File 1) 
(http://curie.utmb.edu/getarea.html) (463). DSP-DSP and CBM-DSP interface 
surface area and residue contributions were determined using PDBePISA 
(http://www.ebi.ac.uk/msd-srv/prot_int/cgi-bin/piserver) (464). Homology models 
for malin and PTG were generated using Phyre2 
(http://www.sbg.bio.ic.ac.uk/phyre2/html/page.cgi?id=index) (465).  2D ligand-
protein interaction diagrams were generated using the Ligplot+ software 
(https://www.ebi.ac.uk/thornton-srv/software/LigPlus/) (466). Structural 
comparisons were performed using the DALI server 
(http://ekhidna2.biocenter.helsinki.fi/dali/) (467). Electrostatic potential was 
mapped onto the laforin structure and malin homology model using the Adaptive 
Poisson-Boltzmann Solver (APBS) plugin in Pymol 2.0 (468).  
2.2 LB purification, characterization, and VAL-0417 studies  
2.2.1 Mouse lines 
Epm2a-/- (177, 469) and Epm2b-/- (178) mice have been previously 
described. C56Bl/6 WT, Epm2a-/- and Epm2b-/- animals were maintained in a 
53 
 
12:12 hr light-dark cycle and were given ad libitum access to food and water. All 
procedures were approved by the UK Institutional Animal Care and Use 
Committee (IACUC) as specified by the 1985 revision of the Animal Welfare Act.  
 
2.2.2 Generation of the antibody-enzyme fusion VAL-0417  
VAL-0417 was designed and produced by Valerion Therapeutics (Concord, 
MA). The cDNA encoding the human IgG1 Fab-linker-AMY2A heavy chain and 
light chain were synthetically produced with codon optimization for mammalian 
cell expression and cloned into pTT5. HEK293 cells expressing a truncated variant 
of the Epstein Barr Virus nuclear antigen 1 (HEK293-6E) increase the volumetric 
yield of monoclonal antibodies and fragments and were used for VAL-0417 
expression (470).  2 1L cultures of HEK293-6E cells in 2L shake flasks were 
transfected with 1 mg of total plasmid DNA/L (1:1 ratio heavy chain:light chain) 
culture using PolyPlus linear Q-PEI at a 1:1.5 (w/v) DNA:PEI ratio. Culture 
parameters were monitored using a ViCell XR (Beckman Coulter) for density and 
viability. Culture was harvested 5 days post transfection via centrifugation for 5 
minutes at 1000×g. The conditioned culture supernatant was clarified by 
centrifugation for 30 minutes at 9300×g.  
Pre-packed CaptureSelect IgG-CH1 affinity columns (Fisher) were 
equilibrated in PBS (pH 7.2). VAL-0417 from 2 L of exhausted supernatant was 
top-loaded onto affinity columns (2 x 1 mL columns in tandem) at 4°C overnight. 
The column was washed with approximately 15 column volumes (CV) of PBS, 15 
CV of buffer B (1×PBS with 500 mM NaCl, pH 7.2) and 15 CV of PBS. The resin-
bound fusion protein was eluted with 10 CV of Buffer C (30 mM NaOAc, pH 3.5-
3.6), collecting the protein in 1 mL fractions diluted in 1/10th volume Buffer D (3 M 
NaAcetate pH~9.0) to neutralize. To minimize the elution volume, elution was 
paused for several minutes between each fraction collected. Fractions were 
analyzed by A280 prior to pooling fractions and pools were analyzed by SDS-
PAGE. VAL-0417 remained in the non-bound pool from the first affinity 
chromatography pass. The above procedure was repeated to capture remaining 
fusion protein. The affinity pools were combined prior to dialysis. The combined 
CaptureSelect IgG-CH1 affinity pool (18 mL) was dialyzed against 3 x 1 L of 
dialysis buffer (20 mM Histidine, 150 mM NaCl, pH 6.5) at 4°C. The dialyzed pool 
was concentrated to 1 mg/mL using a VivaSpin 20 (10K MWCO, PES membrane) 
centrifugal device prior to final analysis and storage at -80°C. Purified Fab-AMY 
was analyzed by size exclusion chromatography (Agilent HP1100) showing a 
single peak before and after a freeze-thaw cycle, indicative of a single, stable 
species.  
Activity of the purified protein was quantified by an amylase activity 
colorimetric kit (BioVision) utilizing the amylase-specific E-G7-pNP substrate (51).   
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2.2.3 Purification of native LBs from Epm2a-/- and Epm2b-/- mice 
19-24 month old Epm2a-/- mice were euthanized by CO2 and decapitation, 
and brain, heart and hindlimb skeletal muscle were immediately harvested, flash 
frozen and stored at -80°C. 12 month old Epm2b-/- mice were euthanized by 
cervical dislocation, and muscle tissues were similarly collected and stored. 
Tissues were pulverized over liquid N2 using a Freezer/Mill Cryogenic Grinder 
(SPEX SamplePrep). Powdered tissue was weighed and homogenized on ice in 
4 vol. lysis buffer (100 mM Tris-HCl pH 8.0, 200 mM NaCl, 1mM CaCl2, 0.5% 
sodium azide) using a Dounce tissue grinder. For larger volumes, the grinding 
pestle was attached to a motorized drill. The homogenate was centrifuged for 10 
min at 10,000×g at 4°C in a Ti-70 rotor and Optima XPN-90 ultracentrifuge 
(Beckman Coulter) and the supernatant was removed. The pellet was 
resuspended in an equivalent volume of lysis buffer, and 20% SDS was added for 
a final concentration of 0.2%, and 20 mg/ml Proteinase K (Invitrogen) was added 
for a final concentration of 0.4 mg/ml. Proteolytic digestion was performed in a 
37°C water bath overnight. The digested samples were then syringe-filtered 
through 140 μm and 60 μm nylon net filters installed in Swinnex filter holders 
(Millipore), centrifuged at 16,000×g for 5 min, and the supernatant was removed. 
The LBs were resuspended in 10% SDS and then washed 5 times in LB buffer (10 
mM HEPES-KOH pH 8.0, 0.1% sodium azide) each time with centrifugation at 
16,000×g for 5 min. Final LB pellets were gently and thoroughly dispersed in LB 
buffer with a pipet. Polysaccharide yield at various steps of the purification were 
determined using the Pflüger method (see below). 2 μL of LB preparations were 
stained with 5 μL 20× Lugol's iodine, mounted on glass slides with a glass 
coverslip, and visualized at 100x using a Zeiss Axioimager Z1 equipped with an 
AxioCam 1Cc5 color camera. Individual LBs in 3-5 micrographs were measured 
manually using ImageJ and a frequency distribution was calculated for LBs from 
each tissue type using Prism 6.0 software (GraphPad) and a bin width of 1 μm. 
Only clearly delineated LBs were measured; clumps and dust-like particles were 
excluded. Purified LBs were stored at -20°C.  
 
2.2.4 Pflüger method for polysaccharide isolation  
Glycogen and polyglucosan from Epm2a-/- and Epm2b-/- mice have been 
purified and characterized by multiple groups using the Pflüger method, but a 
chaotropic salt must be added to enhance the efficiency of polyglucosan 
precipitation (209). We wanted to clarify that under native conditions, and prior to 
the Pflüger treatment, LBs in Epm2a-/- and Epm2b-/- tissues are intact, micron-
sized structures. Pflüger treatment converts the LBs to much smaller 
polysaccharide molecules that are on the same nanometer scale as glycogen 
molecules, but they contain elevated phosphate and an altered chain length 
distribution (158, 209). Thus, the term "LB" refers to the native, micron-sized 
55 
 
polysaccharide-containing structures found in LD tissues, and "polyglucosan" 
refers to the abnormal polysaccharide comprising LBs, which is released with 
Pflüger treatment.  
 The Pflüger method is direct and very sensitive and was used to track 
polysaccharide yield throughout the native LB purifications or to detect 
polysaccharide content of mouse tissues for in vivo studies. Aliquots from native 
LB purifications or tissue homogenates were added to 10 vol. 30% KOH, boiled 
for 2 hours, and allowed to cool. 2 vol. cold ethanol and 10 μL LiCl (1 M or 20 mM) 
were added, and samples were precipitated overnight at -20°C. Precipitated 
samples were centrifuged for 10 min at 16,000×g at 4°C, the supernatant was 
removed, and the polysaccharide pellet was resuspended in water. Two additional 
precipitations with cold ethanol and LiCl were carried out, each for 1-2 hours at -
20°C. The final pellet was washed in cold ethanol and resuspended with vortexing 
in 200 μL water. Polysaccharide was quantified by overnight hydrolysis with 
amyloglucosidase from Aspergillus niger (Sigma) and glucose determination was 
carried out using the R Biopharm Inc. D-glucose kit (Fisher). Fluorescence 
(ex340/em445) rather than absorbance of the NADPH product (stoichiometric to 
glucose) was measured for higher sensitivity.  
 
2.2.5 Separation of glycogen and LBs in native LB purification  
After the initial centrifugation step in the LB purification, a fraction of the heart 
and muscle glycogen was consistently present in the supernatant. In our 
preliminary purifications, we found that the homogenate and pellet fractions 
stained brown with Lugol's iodine after boiling, as did the final LBs and 
amylopectin, but the supernatants stained yellow like glycogen. We also stained 
the Pflüger-purified polysaccharide fractions from our large-scale preparations 
with Lugol's iodine, measured absorbance at 550 nm, and compared the values 
to the polysaccharide concentrations determined by hydrolysis and glucose 
measurement. While the polysaccharide from the supernatant did not absorb at 
550 nm, polysaccharide from the pellet, filtrate and final fractions produced a high 
absorbance relative to concentration. Polysaccharide in the homogenate fraction 
was less absorbent relative to concentration. These data indicate that the 
polysaccharide in the heart and muscle tissue homogenates included both 
glycogen and polyglucosan (in the form of LBs), that were separated into 
supernatant and pellet fractions after low-speed centrifugation. No polysaccharide 
was detected in the supernatant fractions from brain. This result is consistent with 
the observation that in normal mice, glycogen levels are lower in brain than in 
other tissues in part due to its rapid catabolism after euthanasia (471). 
 
2.2.6 Iodine-based measurements 
Lugol's iodine was prepared as a 20× stock (1.5 M KI and 100 mM I2). To detect 
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LBs in preliminary purifications, 50 μL samples from purification fractions were 
boiled for 15 minutes on a 95°C heat block, clarified by centrifugation (16,000×g 
for 1 min), and 35 μL of the supernatant was added to 50 μL 1×Lugol's iodine and 
15 μL water for 100 μL total. To analyze iodine absorbance of polysaccharide from 
LB purifications, Pflüger-isolated polyglucosan fractions were added to 50 μL 
1×Lugol's iodine for 100 μL total and absorbance was measured at 550 nm. 
Absorbance was graphed alongside glucose-based concentrations to illustrate the 
fractionation of polyglucosan and glycogen into supernatant and pellet fractions, 
respectively. For spectral scans, 50 μg LBs, rabbit liver glycogen (Sigma), and 
potato amylopectin (Sigma) were solubilized by boiling for 30 min, and added to 
50 μL 1×Lugol's iodine for 100 μL total. Absorbance scans were performed at 400-
800 nm in 10 nm steps. 
 
2.2.7 Determination of LB phosphate content 
Muscle glycogen and LBs contain covalent phosphate linked to the C2, C3, and 
C6 hydroxyls of glucose moieties, and the relative ratios of these modifications are 
equivalent (158, 210, 212). Boiling in mild HCl hydrolyzes glycosidic bonds and 
releases the acid-labile C2- and C3-linked phosphate leaving C6 phosphoesters 
intact in the form of glucose-6-phosphate (158). Thus, inorganic phosphate after 
mild acid hydrolysis represents only C2- and C3-linked phosphate, i.e. two-thirds 
of total phosphate. To determine phosphate content, skeletal muscle LBs were 
boiled for 2 hours at 95°C in 1 M HCl. Reactions were neutralized with NaOH and 
inorganic phosphate in the sample was determined using the Pi ColorLock Gold 
Phosphate Detection System (Innova Biosciences). Glycogen purified from rabbit 
skeletal muscle as previously described was used as a positive control, and the 
levels of phosphate detected using our method are consistent with two-thirds of 
published total phosphate levels (210).  
 
2.2.8 In vitro degradation assays 
Corn starch used for degradation assays and microscopy was purchased from 
Sigma. Starch and LB degradation experiments were performed in degradation 
buffer (30 mM HEPES-KOH pH 7.5, 5 mM MgCl2, 5 mM CaCl2) and a total volume 
of 100 μL. Reactions were performed in triplicate using PCR strip tubes and 
moderate agitation on a vortex to keep substrates in suspension, and we found 
that this level of agitation did not affect enzyme activity. Degradation reactions 
were allowed to proceed overnight (13-18 hours) unless otherwise indicated, after 
which tubes were centrifuged to pellet undigested substrate. 50 μL of the 
supernatant (containing the soluble degradation product) was transferred to a new 
tube with 50 μL 2 M HCl and boiled for 2 hours at 95°C in a C1000 thermocycler 
(Bio-Rad) to hydrolyze all glucans to glucose. Samples were neutralized with 50 
μL 2 M NaOH, and glucose was determined using the Boehringer-Manheim D-
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glucose kit (R-BioPharm). For visualization of LB degradation product, 
degradation reactions were allowed to proceed as above, and the reactions were 
centrifuged to pellet undigested substrate. After 75 μL of the supernatant was 
removed, the remaining 25 μL was resuspended, and 5 μL was stained with 5 μL 
20× Lugol's iodine, mounted on glass slides with a glass coverslip, and visualized 
using a Nikon Eclipse E600 using DIC/Nomarski contrast and an AxioCam MRm 
camera at 100x. In addition to the R Biopharm D-glucose kit, the absorbance-
based PGO assay (Sigma) was also used to quantify glucose in starch 
degradation assays.  
In vitro degradation of LBs in muscle homogenates was performed as follows: 
300 mg of skeletal muscle from WT or laforin KO mice was pulverized over liquid 
N2 and homogenized in 4 vol. degradation buffer. Homogenate was split into 2 × 
500 μL aliquots, and 25 μg VAL-0417 was spiked into one aliquot for a final 
concentration of 0.05 mg/ml. Samples were incubated on a rotator overnight at 
room temperature and the next morning centrifuged for 5 min at 16,000×g. The 
supernatant was removed, and the pelleted material containing LBs was 
resuspended in degradation buffer and boiled for 30 min on a 95°C heat block to 
solubilize LBs. The boiled samples were clarified by centrifugation (16,000×g for 
5 min) and 25 μL of supernatant was added to a microplate. 50 μL of 1×Lugol's 
iodine and 25 μL of water were added to samples, and absorbance was measured 
at 550 nm.  
 
2.2.9 Scanning electron microscopy 
Starch granules were incubated with enzymes in degradation buffer overnight 
while agitating, washed in 1mL 100% ethanol, dried in a vacuum centrifuge, and 
applied to carbon tape on a pin mount. Samples were coated with gold and 
platinum to improve sample conductivity, and visualized under high vacuum at 2 
kV using an FEI Quanta 250 field emission scanning electron microscope. 
Washing in ethanol, drying, and manual application to carbon tape did not yield 
satisfactory results for LB visualization, so alternatively, diluted LBs were applied 
to a mounted silicon wafer, lyophilized, coated in gold and platinum, and visualized 
at 2 kV with the FEI Quanta 250.  
 
2.2.10 Profiling of VAL-0417 degradation product by HPAEC-PAD 
80 μg of LBs were treated with 2.67 μg of VAL-0417 in degradation buffer to a 
final concentration of LBs at 1 μg/μL. The enzymatic reactions were done at 37°C 
in triplicates. 20 μL samples were removed at 24, 48, 72 hour intervals followed 
by addition of 2.67 μg of VAL-0417. The aliquots were stored at -20°C until they 
were run. The final reactions were continued at 37°C for total of 168 hours. All 
samples were profiled using CarboPac PA-100 column (Thermo-Dionex, 4 x 250 
mm) and detected with PAD detector. 5 μL of samples from each time point 
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(corresponding to 5 μg LBs total) were injected on the column. Blank LBs and 
degradation buffer were injected as controls. Glucose and maltose in the 
degradation reactions were quantified by comparing with standards of known 
amount. 5 μg Maltrin100 was also included as a standard for oligosaccharide 
profiling.  
 
2.2.11 Generation of HEK293-PTG/PP1Cα cells and polysaccharide quantitation 
Protein Phosphatase 1 (PP1) stimulates glycogen synthesis by both 
dephosphorylating and activating glycogen synthase and inhibiting glycogen 
phosphorylase, the primary enzymes catalyzing glycogen synthesis and 
degradation, respectively (439). Protein targeting to glycogen (PTG) is a 
regulatory, glycogen-targeting subunit of PP1 that stimulates glycogen synthesis 
when overexpressed in cell lines (301, 442). Constitutive overexpression of PTG 
in WT mice has been shown to lead to cerebral polyglucosan accumulation that is 
similar to LBs in Epm2b-/- mice (182). We sought to design a cell line that 
accumulates polyglucosan like that which makes up LBs. 
  HEK293 cells (472) were co-transfected with plasmids pCDH-FLAG-PTG and 
pCDH-(HA)3-PP1Cα-GFP harboring mouse PTG and the human PP1Cα (catalytic 
alpha-subunit of PP1) cDNAs, respectively.  Mixed clones were selected for ~10 
days in the presence of 1 μg/ml hygromycin and 0.2 mg/ml puromycin, expanded 
and stored in liquid N2. Analyses of protein expression and glycogen synthase 
activity ratio in the absence and presence of glucose-6-phosphate indicated that 
both proteins were expressed and the glycogen synthase activity ratio was 
increased 3-fold, from 0.02 in control cells to 0.06 in transfected cells.  Quantitation 
of the expression of PTG and PP1Cα is difficult because the basal levels are very 
low, undetectable under our conditions.    
 For quantitation of polysaccharide levels HEK293, HEK293-PTG/PP1Cα and 
Rat1fibroblasts were plated in 96-well plates at a density of 40,000 cells/well. After 
48 hr, media was changed and the next day, the cells were washed 3 times with 
PBS followed by overnight incubation at 40°C in 50 μL of 0.2 M sodium acetate 
pH 4.8 containing 0.2% Triton and 0.3 mg/ml amyloglucosidase (Aspergillus niger; 
Sigma).  Identical cell cultures were lysed in 50 μL of in 0.2 M sodium acetate pH 
4.8 containing 0.2% Triton for protein determination by the Bradford procedure.  
 After overnight digestion, polysaccharide was measured by transferring 40 μL 
samples to a new 96-well plate. A 160 μL reaction mixture consisting of 0.375 M 
ethanolamine pH7.6, 5 mM MgCl2, 1.12 mM NADP, 2.5 mM ATP and 0.2 Units of 
G6PDH (Roche Biochemicals 10127655001) was added and OD340 nm was 
recorded.  Subsequently, 0.75 units of hexokinase (Roche 11426362001) were 
added, the reaction incubated at room temperature for 30 min and OD340 
recorded again. Background absorbance was subtracted from sample absorbance 
and glucose equivalents were determined based a digested glycogen standard 
curve. The engineered HEK293 line accumulated >30-fold more polysaccharide 
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than the native HEK293 cells, and twice the level of normal glycogen found in Rat1 
cells.  
 
2.2.12 Cell culture studies of VAL-0417 uptake  
PTG and the catalytic alpha-subunit of protein phosphatase 1 (PP1Cα) were 
stably expressed in HEK293 cells to generate a stable cell line that accumulates 
polyglucosan. To determine the effect of VAL-0417 on polysaccharide 
degradation, cells were plated in 96-well plates at a density of 40,000 cells/well, 
and after 4 days various concentrations of VAL-0417 were added for 20 hr to fresh 
growth media. Cells were then washed 3 times with PBS, fixed for 7 min with 3.7% 
formaldehyde in 90% ethanol, washed again 3 times with PBS and polysaccharide 
content was determined by hydrolysis and glucose determination.  Statistical 
significance was assessed by using an unpaired Student t-test. 
For Western analyses, 20 μg of total cell lysates were separated on SDS-PAGE 
and protein transferred to nitrocellulose membranes that were probed with 
antibodies against human pancreatic α-amylase (Abcam #ab21156) and ENT2 
(Alomone Labs #ANT-052) followed by appropriate HRP-conjugated secondary 
antibodies and chemiluminescence.  
 
2.2.13 In vivo mouse studies with VAL-0417 
For each IM injection, 20 μL VAL-0417 (30 mg/ml; 0.6 mg per injection) or 20 
μL PBS was injected into one gastrocnemius. For the IV injections, mice were 
pretreated intraperitoneally with diphenhydramine (15mg/kg) before each IV 
injection to prevent anaphylaxis. After the diphenhydramine, the mice where kept 
under a heat lamp for twenty minutes. A  Mouse Tail Illuminator (BrainTree 
Scientific, Inc.) was used to restrain the mouse and an insulin syringe/needle was 
used to inject PBS or VAL-0417 into the dorsal tail vein. 100 μL of PBS was 
injected into IV control mice on days 1, 5, 8, and 13. For the IV treatment group, 
100 μL of 30 mg/ml VAL-0417 (3 mg total) was administered on days 1 and 5, 200 
μL of 20 mg/ml VAL-0417 (2 mg total) on day 8, and 130 uL of 23 mg/ml VAL-
0417 (3 mg total) on day 13. At the indicated time points post-injection(s), mice 
were euthanized by cervical dislocation and decapitation. Tissues were harvested, 
flash frozen, powdered over liquid N2 using Freezer/Mill Cryogenic Grinder (SPEX 
SamplePrep), and stored at -80°C. Powdered tissues were weighed, 
homogenized in assay buffer from the BioVision amylase assay kit and protein 
concentration was determined using the Pierce BCA Protein Assay Kit 
(ThermoScientific). For the ELISA assay, tissue homogenates were diluted in PBS 
for a final concentration of 0.1 μg protein/μL in 100 μL. Diluted homogenates were 
added to 96-well plates for the ELISA. Polysaccharide content was determined 
using the Pflüger method.  
 IT and ICV studies were performed by Northern Biomedical Research, Inc. 
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(Spring Lake, MI). Animals were anesthetized with a mixture of oxygen 0.5 to 1 
L/min and isoflurane 1 to 5% prior to and during the catheter implantation 
procedure. The IT catheter attached to an osmotic pump was inserted at the 
cisterna magna and advanced caudally 2.5 cm to the lumbar region. The ICV 
cannula attached to an osmotic pump was inserted into the cerebral lateral 
ventricle and anchored. VAL-0417 (30 mg/ml) or PBS was continuously 
administered via the IT catheter or ICV cannula for 3 or 28 days (0.11 μL/hr). On 
the following day, mice were euthanized by isofluorane/oxygen sedation and 
perfusion via the left cardiac ventricle with 0.001% sodium nitrite in heparinized 
saline. Brains were harvested, weighed, sectioned using a Rodent Brain Matrix 
(RBM-2000C, ASI Instruments) with 2.0 mm coronal section slice intervals, flash 
frozen and stored at -80°C. Slices were directly homogenized in BioVision assay 
buffer using polypropylene pellet pestles in microcentrifuge tubes. VAL-0417 
levels and amylase activity were determined by ELISA and the BioVision assay 
and normalized to protein content. Protein and polysaccharide content were 
determined by BCA assay and the Pflüger method, respectively.  
 
2.2.14 Statistical analyses 
Statistical analysis of correlation plots was performed using the Prism 6.0 
software (GraphPad). Statistical significance of polysaccharide reduction was 
determined by one-way or two-way analysis of variation (ANOVA) using Prism. 
 
2.2.15 Enzyme-linked immunosorbent assay (ELISA) 
The capture antibody raised against the 3E10 Fab fragment was generated by 
Valerion Therapeutics (Concord, MA). Wells of a 96-well plate were incubated with 
100 μL of capture antibody overnight (~16 hours) at a final concentration of 2 μg/ml 
in PBS. All incubations were done in a humidified chamber. Wells were then rinsed 
3 times with 200 μL PBS followed by incubation for 1 hour with 200 μL of blocking 
solution (5% non-fat milk in PBS). Wells were then rinsed 3 times with 200 μL 
PBS. 100 μL of diluted tissue homogenates were added and incubated for 1 hour. 
Wells were then rinsed 3 times with 200 μL of Tris-buffered saline (TBS) and 100 
μL of primary antibody (anti-AMY2A, Abcam #ab21156) in 5% non-fat milk and 
TBS was added and incubated for 1 hour. The wells were then washed (solution 
added and incubated for 5 minutes before being removed) 3 times with TBS. 100 
μL of secondary antibody (anti-rabbit IgG, HRP-linked, Cell Signaling Technology 
7074) in 5% non-fat milk in TBS was added and incubated for 1 hour. Wells were 
then washed 5 times with TBS. 100 μL of TMB substrate (ThermoFisher N301) 
was added and a timer started. After the highest concentration of standard curve 
saturated or a pre-set time was met, the reaction was stopped by adding 100 μL 
of stopping solution (0.18% H2SO4). The plate was then read for absorbance at 
450 nm. 
61 
 
 
2.2.16 Confocal microscopy  
For confocal microscopy, LBs or corn starch (Sigma) were stained with 20× 
Lugol's iodine, embedded in Mowiol 4-88 (Sigma cat #81381) on glass slides, and 
visualized using the TRITC channel (561nm excitation laser) and differential 
interference contrast (DIC) using a Nikon AR+ Scope. Z-stack images of LBs were 
captured in 0.1 μm steps, starch granules in 0.25 μm steps, and 3D deconvolution 
was performed using the Nikon Elements Advanced Research Software. The 
Richardson-Lucy deconvolution algorithm was utilized with 10 iterations per stack.  
 
2.2.17 Fluorescence-associated capillary electrophoresis (FACE) 
Chain length distribtuion was determined using FACE as previously described 
(473, 474). Samples were debranched with 20U isoamylase (Sigma) and 1U of 
pullulanase (Sigma) for 5h at 42°C. Enzymes were then precipitated at 100°C 
during 10 min, and samples centrifugated 5 min at full speed. Samples were 
desalted using Carbograph column with 5 mL of water. After desalting, 
debranched samples were eluted with 2 mL of Acetonitrile (ACN) 25% and dried 
using a speedvac overnight.  Then, the debranched samples were labeled by 
adding 2 μL of 1M sodium cyanoborohydride (Sigma-Aldrich, France)/THF 
(tetrahydrofurane) and 2 μL of 200 mM APTS (Sigma-Aldrich, France)/15% acetic 
acid, with incubation overnight at 42°C. A Beckman Coulter PA800 plus instrument 
(Sciex Separations, Les Ulis, France) equipped with a laser induced fluorescence 
(LIF) detector and a 488 nm wavelength laser module was used to perform 
electrophoresis on reverse polarity. Separation was performed in a 50 μm I.D., 
375 μm O.D. bare fused silica capillary of 60.2 cm in length (Sciex Separations, 
Les Ulis, France). Samples were injected for 10s at 0.5psi and separation was 
achieved at 30 kV in carbohydrate separation gel buffer (Sciex Separations, Les 
Ulis, France), diluted 1/3 in ultrapure water. 
 
2.2.18 Wide angle and small angle X-ray scattering (WAXS and SAXS) 
For WAXS studies, purified SmLBs, BrLBs and potato amylopectin starch were 
centrifuged and part of the wet pellet was poured into a 1 mm (outer diameter) 
glass capillary. The capillary was flamed-sealed and X-rayed in vacuum by a Ni-
filtered CuKα radiation (λ = 0.1542 nm) using a Philips PW3830 generator 
operating at 30 kV and 20 mA. Two-dimensional diffraction diagrams were 
recorded on Fujifilm imaging plates read offline with a Fujifilm BAS 1800-II 
bioanalyzer. SAXS studies were performed at the European Synchrotron 
Radiation Facility (Grenoble, France) as previously described (475). 1D scattering 
profiles were calculated by rotationally averaging the 2D diffraction patterns. 
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2.2.19 LB treatments and light microscopy 
Lugol's iodine was prepared by adding elemental iodine (for a final 
concentration of 100 mM) to a 1.5M potassium iodide solution to produce the 
triiodide anion (I3-). SmLBs and BrLBs were aliquoted (100 μg per tube) and 
washed in water by centrifugation at 16,000xg for 1 min. LB pellets were 
resuspending in 100 μL water or 100 μL 30% KOH for a final concentration of 
1mg/ml. For sonication treatment, five pulses of 5 seconds each at 25% amplitude, 
with one minute on ice between each pulse to prevent sample heating. Samples 
were heated for 30 minutes or 2 hours as indicated. 5 μL of samples were stained 
with 2 μL 20× Lugol's iodine, mounted on glass slides with a glass coverslip, and 
visualized using a Nikon Eclipse E600 using DIC/Nomarski contrast and an 
AxioCam MRm or Zeiss 512 camera at 100x. LBs had a tendency to clump, after 
staining, samples were carefully titruated with a pipet, added to glass slides, and 
the coverslip was laid on top. The coverslip was very gently prodded and pressed 
to disperse the LB clumps and reduce the number of focal planes. Image 
thresholding was performed using ImageJ software (National Institutes of Health, 
USA).   
 
2.2.20 Transmission electron microscopy (TEM) and lintnerization  
 Droplets of the dilute polysaccharide suspension were deposited onto PELCO 
Carbon support film with removable formvar baking (Ted Pella, Inc.). The excess 
liquid was blotted and samples were negatively stained with 2% uranyl acetate 
and allowed to dry. The grids were imaged with a JEOL 2010F field emission 
transmission electron microscope operating at 100kV using a CCD camera via 
Gatan DigitalMicrograph software.  
Lintnerization was performed by solubilizing LBs with 2.2 N HCl and 
incubation at 36°C. After 5 days, 15 μL aliquots were removed, neutralized with 
0.1M aqueous NaOAc (2×) and washed with water. Samples were lyophilized, 
resuspended in water, and deposited onto glow-discharged carbon-coated TEM 
grids. After blotting of the excess liquid, the preparations have been negatively 
stained with 2 wt% uranyl acetate and allowed to dry. They were observed with a 
Philips (FEI) CM200 microscope operating at 200 kV. Images were recorded using 
a TVIPS TemCam F216 camera. 
 
 
 PERSONALIZED BIOCHEMISTRY OF LAFORA DISEASE 
PATIENT MUTATIONS 
3.1 Introduction  
Nearly all LD patients carry mutations in either the Epilepsy progressive 
myoclonus 2A (EPM2A) gene encoding laforin or EPM2B gene encoding malin. 
Laforin, mutated in approximately 50% of LD cases, is a bimodular protein 
comprised of a carbohydrate-binding module (CBM) from the CBM20 family and 
a dual-specificity phosphatase (DSP) domain. Laforin is the founding member of 
a class of enzymes known as the glucan phosphatases and has been shown to 
dephosphorylate glycogen, a soluble carbohydrate storage molecule synthesized 
by eukaryotic cells (173, 174, 183). In cell culture, laforin interacts with and is 
ubiquitinated by malin, an E3 ubiquitin ligase with a RING domain followed by six 
NHL repeats that comprise a substrate-interacting domain (175, 176). Malin has 
also been shown to ubiquitinate multiple enzymes involved in glycogen 
metabolism, and many of these interactions require laforin (300-304). It has been 
suggested that laforin may serve as an adaptor protein (310) and that the primary 
cause of LD is the lack of a functional laforin-malin complex (188). 
 Over 171 distinct mutations affecting the EPM2A and EPM2B genes have been 
described in the LD population, including missense, nonsense, insertion, and 
deletion mutations (http://projects.tcag.ca/lafora/) (476, 477). Many patients are 
complex heterozygotes, meaning they have different mutations in the two loci of 
the same gene. LD is an orphan disease with an estimated prevalence fewer than 
one per million, though it is likely to be underdiagnosed (478). The number of 
reported mutations grows yearly, and many mutations have been found in only a 
single patient (479, 480). The genotypic variability and small number of patients 
make genotype-phenotype correlations very difficult, and descriptive clinical data 
for LD patients is not readily available. Although most LD patients degenerate 
rapidly, mild or late-onset cases of LD have been recently described (481, 482). A 
particularly mild clinical course has frequently been associated with the D146N 
mutation in EPM2B affecting the malin protein (483-487). This mutation decreases 
the laforin-malin interaction in vitro while not disrupting the ability of malin to 
ubiquitinate proteins (300). Other mild or late-onset cases have been linked to 
EPM2A mutations affecting laforin (456, 488). These patients were either 
homozygous for a missense mutation, carried two different missense mutations, 
or carried a missense and a nonsense mutation in EPM2A. A particularly striking 
case is a patient who lived to the age of 56, with a history of seizures that were 
relatively controlled with sodium valproate (489). This patient was homozygous for 
a novel laforin mutation, F321C.  
 A vast amount of disease-related genetic information has emerged with the 
advancement of DNA technologies. Whole exome sequencing is frequently used 
to diagnose suspected genetic disorders or identify single nucleotide 
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polymorphisms (SNPs) predisposing patients to certain diseases or cancers (490). 
As a result, much effort has been directed at understanding the effects of the 
identified missense mutations or SNPs on protein stability, function, and dynamics 
and their contribution to disease (reviewed in (491). A popular approach is to use 
computational algorithms to predict pathogenicity of a variant based on sequence 
homology, protein structure, or both (492, 493). However, these algorithms range 
in performance from poor to moderately good, and results from different programs 
do not correlate well (494-496). Personalized medicine, the use of genetic 
information to diagnose and treat disease, is becoming more common in the clinic 
especially for the treatment of certain cancers (497). Therefore, the effects of 
nucleotide variants need to be determined with the greatest possible accuracy 
since they may be used to guide diagnostic and therapeutic decisions for patients.  
 Cystic fibrosis (CF) is a genetic disease with variable clinical manifestations 
and a large number and variety of mutations that initially hindered genotype-
phenotype studies (498-500). Effects of disease variants were difficult to predict 
using in silico tools, and were instead carefully defined through many basic 
biological studies (501, 502). Now, CF mutations are classified based on their 
functional effect(s), and mutation-specific therapies are used to treat patients 
(500). Although seemingly tedious and time-intensive, experimental studies 
defining the biological, biochemical, and biophysical defects of missense 
mutations are highly informative and have also been described for other diseases 
(491).  
Our lab previously determined the crystal structure of laforin, defined the 
structural basis for glycogen binding and dephosphorylation, and characterized its 
quaternary structure and dynamics (190). In this study, we analyze 27 missense 
mutations, some of which are associated with mild LD. These mutations reveal 
allosteric interactions between the CBM and DSP domain and clarify the role of 
structural dynamics in protein-protein interactions. The missense mutations are 
grouped into 5 classes based on the severity of their biochemical effects, and the 
data provide an explanation for mild or late-onset forms of LD. Moving forward, 
novel mutations can be rapidly profiled using the described biochemical pipeline. 
These data can be used to influence clinical decisions regarding personalized 
diagnoses and emerging LD therapies.  
3.2 Results 
3.2.1 Pathogenicity predictions of EPM2A missense mutations  
As of 2017, 356 cases of LD associated with EPM2A or EPM2B mutations had 
been reported in the Lafora Progressive Myoclonus Epilepsy Mutation and 
Polymorphism Database (http://projects.tcag.ca/lafora/) (Figure 3.1a). These 
consist of missense mutations, premature termination codons (PTCs), and 
insertions and deletions (indels) in either EPM2A or EPM2B. Of the 94 different 
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mutations reported in EPM2A, 51 unique missense mutations were identified 
(Figure 3.1b). These 51 missense mutations accounted for 43% of LD cases 
caused by EPM2A mutations and 22% of all LD cases (Figure 3.1a). In 2009, 21 
of these mutations were reviewed in a meta-analysis of LD mutations (477). The 
effects of some of these mutants on laforin function had been previously tested 
and were discussed, but many had not been tested. Some had no detectable 
defect in generic phosphatase activity.  
The present study was initiated with the prediction of mutation pathogenicity 
using three different computational tools. We selected 27 EPM2A mutations, some 
of which had been previously studied by our group or others (190, 477). Clinical 
data on many of these mutations are limited, but for most mutations their allelic 
context and the age of seizure onset for the patient(s) were known (Table 3.1). 
We also selected additional mutants identified more recently in patients with mild 
or late-onset LD (Table 3.1). PolyPhen-2 is a popular pathogenicity prediction 
programs that estimates the deleterious effects of mutations based on sequence 
homology, site conservation and structural features (503). The only query is amino 
acid sequence. PolyPhen-2 predicted that the majority of the mutations queried 
were "probably damaging," i.e. determined to be damaging with high confidence 
(Table 3.2). Many of the mutations were "possibly damaging," that is, predicted to 
be damaging with low confidence. The mutations F5S, V7A, F84L, N148Y, and 
E210K were all predicted with high confidence to be benign variants. However, 
most of these mutations have been identified in LD patients in the homozygous 
state, indicating that they are indeed pathogenic (Table 3.1).  
SDM and CUPSAT are commonly used to estimate changes in free energy 
(ΔΔG) induced by a missense mutation using the crystal structure as input (504, 
505). Loss-of-function induced by destabilizing mutations is considered the most 
common cause of genetic disease, so stability predictions are often used to 
evaluate pathogenicity (491). Both programs estimated that most mutations would 
induce a negative ΔΔG, indicating they were moderately or severely destabilizing 
(Table 3.2). However, the algorithms employed by SDM and CUPSAT for 
calculating ΔΔG are distinct, and there was no correlation between the predicted 
values nor with the PolyPhen-2 pathogenicity scores (Figure 3.1c). Furthermore, 
we previously showed that W32G, Y294N, P301L, and F321S were significantly 
destabilized by a thermal melt assay, and Y294N was significantly more dynamic 
than wild-type (WT) laforin via hydrogen deuterium exchange (190). However, 
these mutations were predicted by either SDM or CUPSAT to produce a positive 
ΔΔG, leading to increased stability (Table 3.1).  
The results of prediction programs are inconsistent with patient data and our 
previous biochemical studies. Therefore, we initiated an experimental analysis of 
a panel of laforin missense mutations using the crystal structure as a roadmap for 
understanding their effects on laforin structure and function.  
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3.2.2 Stability and activity of laforin missense mutations 
The 27 missense mutations selected for analysis are scattered throughout the 
primary structure of laforin (Figure 3.2a). When mapped onto on subunit of the 
dimeric laforin crystal structure (Figure 3.2b), they affect many regions with many 
clustered within the carbohydrate binding module (CBM) (Figure 3.2c). All 
mutations were generated by site-directed mutagenesis in a laforin construct 
lacking 3 amino acids at the C-terminus shown to reduce in vitro oligomerization 
(190, 453). The proteins were purified from E. coli via a two-step purification 
scheme using both affinity and size exclusion chromatography to very high purity 
(Figure 3.3). Structure-guided mutants were also generated and purified (Figure 
3.3). Multiple attempts were made to purify F5S, Y86D, and R108C, affecting core 
residues of the CBM, and T187A affecting the DSP domain (Figure 3.3). However, 
these mutations consistently underwent significant proteolysis during the 
expression and/or purification process and were not further analyzed (Figure 3.3).  
We previously defined four regions of the laforin quaternary structure that 
possess different functional roles: the CBM, the CBM-DSP interface, the DSP 
domain, and the dimer interface (190). The LD mutants for this study were first 
divided into these four groups based on their location in the laforin structure for an 
initial assessment. We first studied the mutants by a thermal melt assay, i.e. 
differential scanning fluorimetry (DSF). In this assay melting temperature (Tm) is 
used to quantify protein stability. Additionally, since binding to ligands typically 
stabilizes a protein, the change in melting temperature (ΔTm) in the presence of a 
ligand can be used to quantify binding (506, 507). Wild-type (WT) laforin has a Tm 
of 49.6°C and incubation of laforin with short or long oligosaccharides (7 or 24 
degrees of polymerization, i.e. DP7 or DP24) produced a ΔTm of 5°C or more 
(Figure 3.4a,b) (190). Incubation of WT laforin with saturating levels of DP7 and 
DP24 (10 mM) produced a ΔTm of 4.5 and 7.8°C, respectively (Figure 3.4b,c). 
The patient mutations W32G and K87T were somewhat destabilized with a Tm 
of 44-45°C (Figure 3.4a,b). These mutants produced minimal shifts of 1°C or less 
in the presence of glucans (Figure 3.4a,b). CBM20 domains utilize aromatic and 
hydrophilic residues to coordinate glucan binding (440). In the maltohexaose-
bound crystal structure, laforin interacts with glucans via W32, K87, W99, and 
D107 (190). We and others have shown that W32G and K87A abolish or reduce 
the co-sedimentation of laforin with glycogen (190, 285, 508, 509). Additionally, it 
is well established that W32 and K87 are conserved residues of the CBM20 family 
and are directly involved in carbohydrate binding (190, 440). These results validate 
the use of DSF to assess binding to glucans. 
Mutations in core of the CBM (V7A, E28K, F84L, R91P) and at the CBM-DSP 
interface (E56K, I126T, Y294N, P301L) were highly destabilized, with a Tm of 40°C 
or less (Figure 3.4a,b). It must be noted that the melting profile of these mutants 
is quite different from WT laforin in that they possess two transitions, while other 
mutants had a WT-like transition. This is discussed in the next section (Section 
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3.2.3). The Tm values shown in Figure 3.4 correspond to the first transition. 
However, these mutations also produced a much greater ΔTm with DP7 and DP24, 
suggesting they actually bind more tightly to oligosaccharides than WT laforin 
(Figure 3.4b,c). Indeed, previous studies using affinity gel electrophoresis 
demonstrated that P301L and Y294N migrate more slowly than WT laforin through 
glycogen-rich polyacrylamide gels, indicative of a higher affinity for glycogen 
(460). The only CBM mutant with a similar stability and binding profile to WT was 
S25P (Figure 3.4a,b,c). This mutation is unique among the mutations in the CBM 
that we studied in that it does not have major effects on stability or glucan binding. 
Rather, it impacts a surface-exposed residue in the CBM that has been shown to 
be a phosphorylation site for AMPK (313). These data suggest a distinct disease 
mechanism for this mutation.  
Mutations in the DSP domain produced varying results. G279C, G279S, 
L310W, F321C and F321S, all affecting buried residues within the DSP, were all 
very destabilizing with a Tm of 36-41°C (Figure 3.4a,b). In contrast, other DSP 
mutations (A188G, K140N, N148Y, G240S, E210K, P211L, E224I, P246A) 
produced little to no destabilization with a Tm of 45-49°C. All of these mutations 
produced a binding shift with DP7 and DP24 that was similar to WT laforin with 
the exception of F321S and F321C (Figure 3.4b,c). Therefore, unlike the CBM, 
the DSP is less susceptible to destabilizing mutations, and with the exception of 
mutations at the dimer interface, mutations in the DSP domain do not affect 
carbohydrate binding. 
F321 is buried at the hydrophobic core of the DSP-DSP dimer interface (Figure 
3.2c). We previously studied this mutant by analytical ultracentrifugation (AUC), 
and the data indicated that F321S is a monomer (190). Similarly, SEC coupled 
with multi-angle light scattering analysis of F321C also suggested that it is 
monomeric. (510). The lack of laforin dimerization results in impaired cooperative 
binding to long oligosaccharides such as DP24. We also determined the 
dimensions of laforin-F321S by small angle X-ray scattering  and found that the 
size and shape parameters also correspond to a monomer (data not shown). 
Cysteine and serine mutations are likely to produce similar effects, and the DSF 
profiles of F321S and F321C are indeed nearly identical (Figure 4a,b,c). Both 
proteins are similarly destabilized and bind equally well to DP7 and DP24, 
reflecting their inability to cooperatively bind to long-chain glucans.  
To determine whether the melting temperature of the mutants correlated with 
the solvent exposure of the affected residues, we calculated solvent accessible 
surface area (SASA) using the GetArea program (Supplemental File 1) 
(http://curie.utmb.edu/getarea.html) (463). The ratio of side chain surface area to 
a value "random coil" determines whether the residue is solvent exposed (ratio > 
50%) or buried (ratio < 20%). A significant positive correlation between Tm and 
SASA ratio was found (r = 0.4139), indicating mutations affecting buried residues 
produced a lower Tm (Figure 3.4d). However, no correlation was found between 
the experimentally determined Tm and the PolyPhen-2 score or ΔΔG values 
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predicted by CUPSAT and SDM (Figure 3.4e,f,g). 
We next tested the activity of the mutants using the biological substrate of 
laforin, glycogen, in a malachite green assay to measure phosphate release. 
Glycogen was purified from rabbit muscle as previously described (174). 
Covalently bound phosphate levels in the glycogen were determined by digesting 
the glycogen with perchloric and sulfuric acid, diluting in water, and then 
measuring phosphate using the malachite green assay. The levels of glycogen-
bound phosphate were similar but slightly lower than reported in a precious 
preparation (Figure 3.5a) (174). However, these values were still in the linear 
range of detection by the malachite green assay. All of the phosphate could be 
released by treating glycogen with amyloglucosidase and Antarctic phosphatase 
(Figure 3.5a,b). Additionally, up to 96% of the phosphate could be released by 
treating glycogen with a combination of laforin, amylase and amyloglucosidase 
(Figure 3.5a,c). These results are in agreement with previous work (174). 
Glycogen dephosphorylation assays were performed in the linear range with 
respect to time, enzyme amount, and substrate concentration (Figure 3.5d). 
Given the low Tm of some laforin mutants, we tested the stability of the W32G, 
Y294N, P301L, and F321S mutants at both 25°C and 37°C. Laforin mutants with 
a low Tm, i.e. Y294N, P301L, and F321S, displayed precipitation after 30 minutes 
at 37°C, while these mutants were stable at 25°C (Figure 3.5e). Glycogen 
dephosphorylation assays were performed at 25˚ C to assess the phosphatase 
activity of these mutants. Consistent with previous studies of W32G and K87A, 
W32G and K87T had significantly impaired glycogen phosphatase activity due to 
a reduced affinity for glycogen (Figure 3.5f). Mutations in the CBM-DSP interface 
had variable effects on activity as seen for E56K, Y294N and P301L (Figure 3.5f). 
Surprisingly, the remaining 20 mutants produced a reduction in phosphatase 
activity of 50% or less. E28K, F84L, and K140N displayed no decrease in glycogen 
phosphatase activity. Additionally, no correlation between stability and 
phosphatase activity was observed (Figure 3.5g).  
Glycogen possesses phosphate bound to both C3- and C6-hydroxyls of 
glucose moieties, and increased phosphorylation at these sites is linked with 
aberrant polyglucan formation (210). Site-specific dephosphorylation assays were 
performed to define the ability of each mutant to dephosphorylate the C3- and C6-
position. Arabidopsis starch free of phosphate was labeled with 33P at the C3- and 
C6-positions with starch dikinases, and the phosphorylated product was utilized 
as substrate in dephosphorylation assays. Laforin has previously been shown to 
exhibit a slight preference for C3 dephosphorylation when similar in vitro assays 
were performed (184). First, the kinetic parameters were defined for laforin WT 
and mutant proteins to determine the linear range of specific activity. Time course 
and substrate titration experiments were performed with both WT protein and the 
catalytically inactive mutant C/S to determine the appropriate assay parameters 
(Figure 3.6a,b).  
Kinetic studies were performed on both WT laforin and a subset of LD mutants. 
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W32G and F321S possessed a reduced Michaelis constant (Km) in assays with 
C3- and C6-labeled starch compared to WT laforin (Figure 3.6c,d,e). These data 
highlight how decreased affinity for the substrate results in reduced activity for 
W32G (Figure 3.5g). Conversely, the decreased activity for F321S is likely due to 
the lack of cooperative binding by F321S to substrates with long glucan chains 
(190). In contrast, P301L had a similar Km to WT but a reduced maximum reaction 
velocity (Vmax) (Figure 3.6c,d,e). This result indicates that the reduced activity of 
P301L is due to impaired catalytic turnover rather than reduced affinity for 
substrate. Other mutants were also analyzed for C3- and C6-specific 
dephosphorylation at a single substrate concentration (Figure 3.7a). P301L and 
the mutants with impaired affinity (W32G, K87T, and F321S) were the only 
mutants that produced a change in the C3 vs. C6 dephosphorylation ratio (Figure 
3.7a). The change in activity for each mutant compared to WT laforin mirrored the 
change in glycogen dephosphorylation, with the exception of F321S due to its lack 
of cooperativity (Figure 3.7b). Therefore, most mutants do not change the 
preference of laforin for C3- vs. C6-phosphate. Glycogen contains C3 and C6 
phosphate in approximately equal proportion (158, 210, 212). It is therefore 
unlikely that LD would result from a change in the ratio between C3 and C6 
phosphate.  
 
3.2.3 Mutation-induced decoupling of the CBM and DSP domains 
 In addition to defining the Tm, the melting profile from DSF experiments 
provides information regarding the structure and dynamics of multidomain proteins 
(511). Tightly integrated domains lead to cooperative thermal denaturation; in 
contrast, intermediate states during melting suggest discreetly folded domains. In 
other words, for a bimodular protein such as laforin, a single melt transition reflects 
tight integration between the domains, while the appearance of two peaks 
indicates the domains are decoupled and melt independently (512). WT laforin 
melts with a single sharp peak, reflecting tight coupling between the CBM and 
DSP (Figure 3.8). The shape of this peak shifts to the right but does not change 
with binding to DP7 and DP24 (Figure 3.8 and 5.9a,c). This result is consistent 
with the extensive hydrophobic CBM-DSP interface observed in the crystal 
structure (~1200 Å2) and the minimal solvent accessibility of residues in this 
interface observed in hydrogen deuterium exchange experiments (190, 205). Most 
laforin mutants also produced a melting profile with a single sharp transition, and 
the shape of the peak did not change with the shift induced by carbohydrate 
binding (Figure 3.8). Interestingly, mutations affecting the CBM core or CBM-DSP 
interface produced melting profiles that were either broader than WT (e.g. V7A, 
E56K, F84L) or had two distinct peaks (e.g. E28K, R91P, Y294N, P301L) (Figure 
3.8). These data indicate that mutations in the core of the CBM and CBM-DSP 
interface induce domain decoupling. We previously observed increased 
deuteration of peptides at the CBM-DSP interface in Y294N compared to WT 
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laforin (190). The DSF results are perfectly consistent with those observations. 
However, no differences in the size and shape parameters of Y294N compared to 
WT laforin via small angle X-ray scattering were observed, indicating this is not a 
global effect (data not shown). These data indicate that the CBM and CBM-DSP 
is sensitive to stability perturbations and many LD mutations induce local domain 
decoupling.  
E210K also had an unusual melting profile, but this pattern was unique among 
the mutations that we studied. The decoupling mutations led to a broadening or 
separation of peaks during the denaturation phase (i.e. when fluorescence was 
increasing). In contrast, for E210K, a delay in the quenching phase (when 
fluorescence was decreasing) was observed. Quenching occurs at high 
temperatures when the denatured protein aggregates, which reduces the surface 
area interacting with dye and quenching its fluorescence. These data indicate that 
E210K affects the aggregation of laforin post-denaturation, which may or may not 
have biological relevance.  
Strikingly, these mutants melted with a single transition like WT laforin in the 
presence of 10 mM DP7 or DP24 (Figure 3.8 and 3.9a). The only exception was 
P301L, which even in the presence of DP7 still showed a profile suggesting two 
peaks (Figure 3.8). The data also suggest that decoupling is reversed by binding 
to a carbohydrate. When a lower concentration of DP24 was used, Y294N 
displayed an intermediate profile with a broad peak, and two peaks were still 
observed for P301L (Figure 3.9a). Interestingly, the peaks of the P301L profile 
were so distinct that each Tm could be determined: 31.8 and 52.5°C, likely 
corresponding to the decoupled domains (Figure 3.9b). The Tm of P301L in the 
presence of DP24 is between these two values, reflecting a distinct conformation 
that is substrate-bound. These data strongly suggest that binding to a sugar tightly 
integrates the two domains, rather than stabilizing one of the domains (such as 
the CBM) so much that it is masked by the peak of the other.  
The Y294N mutation produces an unambiguous two-state melting profile 
(Figure 3.8). We found that a Y294N yields from E. coli were generally similar to 
those of WT laforin. In contrast, more highly decoupled mutations (e.g. E28K, 
R91P and P301L) underwent significant proteolysis during expression and 
purification and yielded much less soluble protein. Since a higher quantity of this 
protein could be produced, which is necessary for DSF titration experiments, 
Y294N was selected for further study. To define how the DSF profile shifted with 
increasing concentrations of glycogen, a glycogen titration was performed with WT 
laforin and Y294N. While WT laforin exhibited a rightward shift with no change in 
peak shape, Y294N exhibited a gradual transition from two-state melting with low 
concentrations of glycogen to one-state melting with higher concentrations 
(Figure 3.9c). The ΔTm values from this experiment were used to graph a binding 
curve for WT and Y294N. Interestingly, a two-site binding equation provided a 
better fit for both WT and Y294N binding curves better than a one-site equation 
(Figure 3.9d). These data suggest that both WT and Y294N have two binding 
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sites with different affinities. We previously observed that the laforin dimer binds 
cooperatively to DP24, which implies two binding sites with interdependent 
affinities (190). Since cooperativity requires dimerization, the two binding sites 
likely correspond to the two CBM domains. Two-site binding to glycogen, a 
substrate with shorter linear chains than DP24, reflects two binding sites with 
different affinities that are independent rather than cooperative, It is also 
interesting to note that for Y294N, the second binding event occurs after the 
melting curves have shifted full to a single peak (Figure 3.8d, enlarged circle). 
This further suggests a binding at one CBM initiates allosteric conformational 
changes that propagate through the CBM-DSP and dimer interfaces to the other 
subunit. Binding to the second CBM is not achieved until the CBM and DSP are 
fully integrated and produce a single melt peak. 
In the crystal structure of laforin, the ends of the maltohexaose (DP6) molecules 
bound to the CBM and DSP domains are ~24 Å apart. This distance could be 
bridged by 4-5 additional glucose moieties (each unit is about ~5.5 Å long). There 
is continuous directionality the two sites so a glucan of least 16-17 units could 
potentially tether the two domains.  A DP7 molecule would only be long enough to 
bind to one site, and it could not physically tether the two domains.  Given these 
distances, an allosteric conformational change must be induced by DP7 binding 
that unites the domains in the decoupled mutants. Indeed, an alanine mutant of 
W32 surprisingly produced two-state melting, but unlike all other mutants with this 
type of profile, it did not shift to one state in the presence of sugars (Figure 3.10a). 
These results suggest that W32 is facilitating that conformational change via its 
interaction of substrate at the CBM glucan binding site.  
Y294 and P301 contribute 159 and 100 Å2, respectively, to the CBM-DSP 
interface and together comprise nearly 20% of the total interface surface area. It 
is not surprising then that mutation of these well-conserved and integral residues 
to very different amino acids would be detrimental to domain coupling (Figure 
3.10b). Alanine mutants of P301 and Y294 also produced broad melting profiles, 
but they were not as exacerbated as the LD patient mutations (Figure 3.10c). In 
contrast, E56 contributes only 43 Å2 to the interface. E56K exhibits a slightly 
broadened peak indicative of mild decoupling, while E56A did not display a 
broadened peak. Although alanine mutants of these CBM-DSP interfacing 
residues still mildly destabilized laforin (Supplemental File 2), it is likely that these 
mutations would be less pathogenic since they are less structurally disruptive than 
replacing an acidic residue with a basic one (E56K), exchanging an aromatic with 
a hydrophilic residue (Y294N), or a substituting proline with a bulkier hydrophobic 
(P301L).  
Y294 makes multiple hydrogen bonds to surrounding residues, particularly with 
backbone hydroxyls of R4 and L124. These bonds are immediately adjacent to 
the hydrophobic CBM core and LD mutation "hotspot" containing LD-associated 
residues F5, V7, Y86, and F84 (Figure 3.10b). Hydrophilic residues affected by 
LD mutations, E28, R91 and R108, are also in this region. This hotspot appears 
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to bridge Y294 and the DSP domain with W32 of the CBM. Y294 mutated to a 
phenylalanine produced very mild decoupling and destabilization (Figure 3.10c). 
These data indicate that both the hydrophobic nature and hydrogen bonding 
capacity of Y294 are important for tethering between the DSP domain and CBM. 
Y294F abolishes this bond but still contains the aromatic benzene ring, therefore 
producing the mildest effect. Y294A lacks both aromatic and hydrogen bonding 
capacity and is partially decoupled. The LD mutation Y294N introduces a 
hydrophilic residue, inducing further structural perturbation and producing the 
most severe domain decoupling effect. 
In the laforin crystal structure, oligosaccharides are bound to both the CBM and 
DSP domain. However, data thus far suggests that only CBM residues associating 
with glucan contribute significantly to binding: W32, K87 and W99 (Figure 3.10c) 
(190). The individual laforin CBM and DSP domains were purified by affinity 
chromatography and size exclusion chromatography (Figure 3.11a,b). The DSP 
domain was expressed as a SUMO fusion protein to enhance stability. We were 
unable to express the DSP domain in the absence of the SUMO tag, and attempts 
to cleave the tag caused the DSP to become sticky and prone to aggregation. 
Neither domain had phosphatase activity, consistent with previous reports (data 
not shown) (454). The CBM Tm was 38.2˚ C, a lower Tm than full-length laforin. 
CBMs are flexible domains so they can coordinate ligand binding and presentation 
to an active site, and we have shown that CBM of laforin is more dynamic than the 
DSP domain (190, 440). These characteristics may explain the reduced stability 
of the laforin CBM. The SUMO-DSP fusion protein yielded a Tm of 51.7°C. While 
the CBM bound to both DP7 and DP24, SUMO-DSP exhibited no shift in Tm 
(Figure 3.11c). When these proteins were incubated with increasing 
concentrations of DP7, the CBM exhibited a similar binding curve to full-length 
laforin, while the DSP domain did not shift even at high concentrations of DP7 
(Figure 3.11d). Interestingly, full-length laforin with the W32G mutation produced 
a right-shifted binding profile (Figure 3.11e). These data indicate that laforin 
binding to carbohydrates does rely on the CBM. Although W32 seems to be the 
primary residue involved in binding, even at high concentrations of substrate, other 
residues of the CBM can compensate.  
 
3.2.4 Effects of LD mutations on protein-protein interactions  
Thus far, the assays that we have utilized have revealed defects in some, but 
not all, of the LD-causing mutations. Mutations reducing or abolishing 
carbohydrate binding (W32G and K87T) have severe effects on glycogen 
phosphatase activity. Highly destabilizing mutations, i.e. having a Tm < 37°C, are 
likely too unstable in vivo to function, prone to unfolding and aggregation, and are 
likely degraded. Indeed, expression of Y294N in HeLa cells, which are cultured at 
37°C, led to the formation of ubiquitin-positive aggregates, suggesting it was 
unfolded and targeting for degradation (513). Most of the mutations affecting the 
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CBM core or the CBM-DSP interface would fall into this category. However, 
mutations with a Tm > 37°C could still be functional in vivo.  For example, the 
F321S and F321C mutations both have a Tm at or just above 37°C, and LD patient 
data strongly suggest that F321C is at least partially functional since a 
homozygous patient with F321C displayed a very mild LD phenotype (489). In 
contrast, W32G and K87T are only mildly destabilized, but these mutations 
severely impair carbohydrate binding (Figure 3.4b,c) and are found in patients 
with a typical LD progression, suggesting they are highly pathogenic (Table 3.1). 
Therefore, pathogenicity probably does not necessarily correlate with stability, 
unless the Tm of the mutant is below 37°C. Furthermore, the majority of the 
mutants analyzed yielded only mild defects in protein stability or phosphatase 
activity. Since laforin is known to interact with multiple proteins involved in 
glycogen metabolism, we next assessed the impact of the mutants on the 
association of laforin with its binding partners.  
Malin and Protein Targeting to Glycogen (PTG) are perhaps the best 
characterized laforin binding partners (175, 176, 301, 307, 313, 514). PTG is a 
regulatory subunit of protein phosphatase 1 (PP1) and contains a CBM21 that 
targets PP1 to glycogen. PTG indirectly promotes glycogen synthesis through 
PP1-mediated dephosphorylation of glycogen synthase (which is activating) and 
phosphorylase (which is inhibitory) (300, 439, 441). Malin and PTG are both 
difficult proteins to work with in vitro because they are largely insoluble when 
expressed as recombinant proteins (175, 301). To circumvent this issue, we 
employed a directed yeast two-hybrid analysis that has been used extensively to 
define the interaction of laforin with malin, PTG, and other proteins (175, 176, 313, 
455, 515). Laforin mutations were generated in the bait yeast expression vector 
pEG202 and expressed as laforin fusion proteins with the DNA-binding protein 
LexA. Wildtype malin and PTG were expressed as prey fused with the Gal4 
activation domain (GAD). The interaction of bait and prey proteins results in 
transcription of β-galactosidase (i.e. β-gal), so β-gal activity is used to quantify 
interactions. We also tested laforin mutations that we were unable to express in 
E. coli: F5S, Y86D, T187A and R108C. These proteins were all expressed at 
similar levels in yeast (Figure 3.12).  
The majority of laforin mutations reduced or abolished both PTG and malin 
interaction with laforin (Figure 3.13a). When co-expressed with GAD alone, only 
K87T, which ablates glycogen binding, yielded a significant interaction (Figure 
3.13a). The other fusion proteins did not interact with this negative control protein 
(Figure 3.13a). The K87T result could be due to the finding that mutations 
affecting glycogen binding can localize to the nucleus in cell culture (421). In yeast, 
K87T may translocate to the nucleus and interact with GAD, promoting some auto-
activation. However, this was not observed for any other mutants.  Interestingly, 
mutations at the CBM glucan binding site, W32G, and K87T, reduced PTG 
interaction, while not affecting the interaction with malin (Figure 3.13a). In 
contrast, mutations at the dimer interface, F321S and F321C, specifically 
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abolished the malin interaction, and the PTG interaction was either unchanged or 
slightly increased (Figure 3.13a). Mutations that destabilize laforin (i.e. decrease 
its Tm) reduced the interaction of laforin with both binding partners despite normal 
expression levels of the mutants (Figure 3.12). Surprisingly, E210K, P211L, 
E224I, K140N, G240S, and P246A showed no defect in PTG or malin binding. 
Conversely, S25P did not interact with either binding partner. The effects of these 
mutations on multiple aspects of laforin have now been defined: stability, activity, 
and interaction with established binding partners. Based on these results and the 
location of the mutants in the crystal structure, the mutants were further subdivided 
into 5 groups. W32G and K87T affect residues at the glucan binding site and are 
the only mutations that lead to a complete loss of carbohydrate binding. F5S, V7A, 
E28K, F84L, Y86D, R91P and R018C clustered in the core of the CBM, and lead 
to domain decoupling and a reduction in the laforin-malin and laforin-PTG 
interactions. E56K, Y294N, and P301L affect the CBM-DSP interface and have 
similar effects as mutations at the CBM core. N148Y, T187A, A188G, G279S/C, 
and L310W affecting different regions of the DSP domain. These mutations do not 
affect phosphatase activity but are somewhat destabilizing and reduce the laforin-
malin and laforin-PTG interaction. E210K, P211L and E224I clustering in a 
surface-exposed region of the DSP. They are very mildly destabilized and have 
little effect on the laforin-malin and laforin PTG interaction.  F321S/C affects the 
dimer interface, destabilizing the protein and abolishing dimerization, and leading 
to a loss of malin binding only. We were not able to detect a defect in K140N, 
P246A and G240S using our assays. S25P displayed no interaction with malin or 
PTG, but the reason for this is not clear since this mutation is only very mildly 
destabilized.  
We performed pairwise correlation analyses between Tm, PTG interaction and 
malin interaction to determine whether these aspects of laforin function were 
interdependent. Importantly, the mutations clustered by group in these correlation 
graphs. A weak correlation between PTG interaction and Tm was observed, but it 
was not statistically significant (Figure 3.13c). A positive correlation was found 
between the malin interaction and Tm (Figure 3.13b). A very strong correlation 
was found between PTG and malin interaction (Figure 3.13d). These data indicate 
the primary defect of most LD mutations is a decreased interaction with malin 
and/or PTG. Binding to malin and PTG is tightly dependent on laforin stability, 
which is altered by many LD mutations. Furthermore, the effects of each group of 
mutations has a certain pattern of functional effects, leading to defined clusters in 
these graphs. The strong correlations between these functional parameters 
among LD mutations suggest they are the most relevant to LD pathogenesis. 
 
3.2.5 Laforin binding sites for malin and PTG are disparate 
It was striking that mutations at the CBM specifically affected the PTG 
interaction while mutations at the dimer interface specifically affected the 
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interaction of laforin with malin. More centrally located mutations affected both 
interactions. These data suggest that the binding sites for PTG and malin are 
spatially distinct. This arrangement seems plausible since PTG has been shown 
to be a substrate for malin in a laforin-dependent fashion, and therefore both PTG 
and malin are likely form a complex with laforin (188, 301). We tested this 
hypothesis by performing yeast triple hybrid experiments in which laforin was 
expressed in the presence of both binding partners. One partner was expressed 
as prey, and fused to GAD, while the other was expressed with only an HA tag. If 
the two binding partners had overlapping binding sites, the HA-tagged partner 
would displace the first and result in reduced β-gal activity. No change in β-gal 
activity was observed when HA-tagged PTG was expressed in addition to LexA-
laforin and GAD-malin (Figure 3.14a). To account for the possibility that the 
laforin-malin interaction was too strong for malin to be displaced by PTG, we also 
performed the reverse experiment in which HA-tagged malin was expressed in 
addition to LexA-laforin and GAD-PTG. Again, no change was observed in β-gal 
activity. These data strongly suggest that PTG and malin have independent 
binding sites on laforin, and these binding sites are differentially affected by LD 
missense mutations. 
Mapping of electrostatic potential on the surface of the laforin crystal structure 
illustrates that the DSP active site is a highly positively charged pocket, ideal for 
binding to a negatively charged phospho-glucan (Figure 3.14b). The remaining 
surface of the molecule is fairly neutral. When rotated 180˚ along the longest axis, 
there are three discrete patches possessing charge: a positively charged region 
at each CBM-DSP interface and a patch of negatively charged residues comprised 
of the dimer interface. Each positively charged pocket corresponds to a CBM-DSP 
interface, particularly the region containing E56, Y294, and P301 (Figure 3.14c). 
F321 residues are located beneath either edge of the negatively charged patch 
(Figure 3.14c). The negatively charged patch is circular, approximately 30 Å in 
diameter.  
Malin possesses six NHL repeats that form a putative β-propeller fold (306). 
This type of fold is approximately 50 Å at its widest point (516). These β-propeller 
domains form a substrate-interacting domain, and we have shown that the NHL 
repeats are essential for the interaction of malin with laforin (175). A homology 
model of malin using Phyre2 shows the β-propeller fold of the NHL repeats and 
the location of D146, a known residue involved in the laforin-malin interaction, on 
the surface of this substrate-interacting domain (Figure 3.14d). Electrostatic 
mapping onto this homology model shows that the interior of the NHL β-propeller 
is highly negatively charged (Figure 3.14e). This negative charge may be suited 
to interact with the target lysine intended for ubiquitination. At the edges of the 
domain are regions of positive charge. It is possible that these may be involved in 
laforin binding. E3 ligases have been shown to dimerize (517, 518).  Also, yeast 
two-hybrid assays and co-immunoprecipitation experiments in mammalian cells 
have shown that malin interacts with itself (519). Malin may also dimerize, and like 
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laforin, an interaction surface may form from the interaction between two malin 
subunits.  
PTG is a 36 kDa protein containing a PP1-binding motif at its N-terminus and 
a CBM21 spanning amino acids 149-257. An earlier study showed that a region 
encompassing the CBM21 (amino acids 141-263) is necessary for the interaction 
of PTG with laforin (514). Therefore, it is likely that laforin and PTG interact via 
their CBMs. Binding of both CBMs to a carbohydrate substrate would likely 
enhance their interaction by proximity effects. A homology model of PTG was also 
generated using Phyre2 (Figure 3.14f). Based on this information and our data, it 
is likely laforin acts as a glycogen-associated scaffold for PTG, malin, and other 
binding partners involved in glycogen metabolism (Figure 3.14g). These data 
suggest that a crucial detrimental effect of LD mutations is negatively impacting 
the interaction of laforin with malin and PTG and perhaps other proteins involved 
in glycogen metabolism.  
3.3 Discussion 
 In the present study, we defined the molecular defects of LD-associated 
EPM2A missense mutations using biochemical tools. Genotype-phenotype 
correlations in the LD population are extremely difficult due to a small number of 
patients, large number of mutations, under diagnosis, and limited clinical data. 
Furthermore, computer algorithms do not yield satisfactory or consistent 
predictions regarding the pathogenicity of missense mutations. Therefore, we 
employed a reductionist biochemical approach to circumvent these limitations and 
identify molecular-level defects to provide a framework for evaluating the 
pathogenicity of LD mutations and predict their clinical course. These data provide 
a biochemical explanation for mild LD cases and provides insights into the 
physiological and etiological roles of laforin. 
 
3.3.1 Functional classes of EPM2A missense mutations 
 Over the past three decades, the cystic fibrosis (CF) community has uncovered 
the molecular basis of CF and defined multiple classes of CFTR mutations through 
detailed basic biological and mechanistic studies (500, 502). These extensive 
investigations have led to mutation-specific therapeutics. The LD patient and 
research community are significantly smaller than the CF community and the 
reduced sample size poses additional challenges. Furthermore, the genetic basis 
of LD was only defined in 1998 with the identification of the laforin gene and 2003 
with the identification of the malin gene (170-172, 328). This biochemical analysis 
of LD missense mutations was largely facilitated by the laforin crystal structure 
that was only determined in 2015 (190). Using the biochemical and biophysical 
pipeline that we developed, we identified five distinct classes of laforin mutations 
and propose a structure-guided, molecular explanation for why mutations in each 
class cause disease.  
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 Class I mutations affect carbohydrate binding of the CBM (Table 3.3). We have 
shown that the CBM is essential for carbohydrate binding and that W32 and K87 
each contribute significantly to binding (Figure 3.4 and 3.11) (190). These 
mutations are only slightly destabilizing to the laforin structure, but their 
phosphatase activity is greatly reduced (Figure 3.4, 3.5f, 3.7). Furthermore, these 
mutations abolished the laforin interaction with PTG (Figure 3.13). This defect 
may be partly due to their impaired association with the glycogen molecule, with 
which PTG is also associated. Although both mutant proteins are still able to bind 
to malin, they are likely not able to properly target malin to its glycogen-associated 
substrates. A patient homozygous for the W32G mutation was 13 years old at 
disease onset, typical of classic LD (Table 3.1); no other information about this 
patient was provided in the case report (520). A compound heterozygous patient 
carrying K87T and E56K mutations was 11 years old at seizure onset and 15 years 
old when cognitive decline began. These clinical features are characteristic of 
what is considered a classic LD course (479). Based on our biochemical results 
and these clinical data, it is reasonable to conclude that these mutations are highly 
detrimental to laforin function and lead to a very severe phenotype with rapid 
progression (Table 3.3).  
 Class IIa mutations affect the CBM core and class IIb mutations affect the CBM-
DSP interface (Table 3.3, Figure 3.2c). Although structurally distinct, the 
mutations produce similar biochemical defects: they dramatically destabilize 
laforin and impair or abolish interactions with both PTG and malin (Figure 3.4, 3.8, 
3.9, 3.13). Class II mutations also appear to associate more tightly with 
carbohydrates than WT laforin (Figure 3.4) (460). Most of the mutations also have 
little or no effect on phosphatase activity, with the exception of P301L (Figure 3.5f, 
3.7). Patients either homozygous or heterozygous for class II mutations also 
appear to have a classic clinical course based on available clinical data. Seizure 
onset is typically between the ages of 11 and 14 years old (Table 3.1). One 
exception is a family of 3 children all homozygous for R108C that experienced 
seizure onset at ages 5, 8 and 10 years old (513). These patients also had early 
onset learning disability that manifested at the age of 4 years old. Another patient 
homozygous for Y86D displayed early onset learning problems, although his 
brother did not (488). Both Y86D and R108C completely abolish interactions with 
PTG and malin. We were unable to purify these recombinant mutants, likely due 
to their severe instability. The major destabilization and impaired interactions of 
class II mutations likely lead to a very rapid disease progression, possibly even 
more rapid than class I mutations. 
 Class III mutations affect the DSP domain (Table 3.3) and have variable effects 
on laforin stability and PTG/malin interaction (Figure 3.4, 4.13). All class IIII 
mutations have mild or moderate effects on phosphatase activity and they do not 
affect carbohydrate binding (Figure 3.4, 3.5f, 3.7). Patients carrying T187A, 
N148Y, and L310W mutations experienced seizure onset between the ages of 10 
and 13 years old. These mutations also significantly impair the interaction with 
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PTG and malin (Figure 3.13). The clinical features of patients carrying the A188G 
mutation were not reported (477). Interestingly, G279C and G279S mutations 
have both been associated with a slower clinical course (488) (Jose Serratosa, 
personal communication). A compound heterozygous patient, carrying the G279C 
mutation and a common PTC (R241X) did not present with seizures until the age 
of 21 years old, and cognitive impairment did not develop until the patient was 24 
years old. Since these mutations retain some interaction with malin and PTG, they 
may delay LD onset. Therefore, class III mutations are associated with variable 
phenotypes. We recently published a study on a compound heterozygous patient 
carrying the missense mutation N163D and a PTC (Y112X) (456). This patient 
had her first seizure at 16 but was still able to walk, still very cognitively engaged 
at the age of 28. We showed that N163D had no effect on laforin stability, 
carbohydrate binding, or activity, but impaired the interaction of laforin with its 
binding partners. N163 is in the DSP domain and the biochemical profile of the 
N163D mutation is consistent with other mutations and cases in class III (Table 
3.3). Therefore, mutations in class III can produce both moderate and severe 
phenotypes, depending on how severely the malin and PTG interactions are 
affected. 
 Class IV mutations affect a surface-exposed region of the DSP domain 
adjacent to the dimer interface (Table 3.3, Figure 3.2c). These mutations display 
no major defects in laforin stability, carbohydrate binding, phosphatase activity, or 
interaction with PTG or malin (Figure 3.4, 3.5f, 3.7, 3.13). This surface may be 
important for binding to another laforin substrate, such as AMP-activated protein 
kinase (AMPK), glycogen synthase, or other regulatory subunits of PP1 such as 
R6 (208, 300, 302, 303). A compound heterozygous patient carrying the E210K 
displayed seizure onset at the age of 17, which is later than classic LD. Another 
patient heterozygous for P211L experienced seizure onset at the age of 11 and 
lived to the age of 28, longer than the typical disease course (unpublished case). 
Therefore, it is likely that class IV mutations yield a more moderate effect on laforin 
function with a more moderate disease progression. 
 Class V mutations affect laforin dimerization. Thus far we have only identified 
one residue affected by class V mutations, F321 (Figure 5.2c). F321 mutations 
reduce laforin stability, render laforin monomeric, and abolish the preference of 
laforin for binding long oligosaccharides (Figure 5.4) (190). They do not affect the 
interaction of laforin with PTG but significantly reduce the malin interaction (Figure 
3.13). The origin of the F321S mutation is unknown; however, the F321C mutation 
is associated with a homozygous case of extremely mild LD (489). This case is 
comparable in clinical course only with LD patients homozygous for the malin 
D146N mutation. Disease onset for these patients is variable, reported between 
the ages of 13 and 29 years old, and the patients can live 10-20 years or more 
after onset, often into their 30s and 40s (483, 484, 486, 487, 521). One patient 
homozygous for D146N had his first seizures at 30 and lived beyond the age of 
48 (522). Both laforin F321C and D146N have been shown to affect the laforin-
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malin interaction while not affecting the other functions (Table 3.3) (300). F321C 
and F321S may also be mildly pathogenic due to their impaired ability to 
specifically target LB-like structures. 
 We were unable to classify the mutants S25P, K140N, P246A and G240S 
because they did not affect the biochemical or biophysical properties of laforin that 
we measured (Table 3.3). All of these mutants had little to no effect on laforin 
stability, phosphatase activity, and carbohydrate binding (Figure 3.4, 3.5f, 3.7). Of 
these mutants, only S25P had impaired interaction with malin and PTG, but the 
reason for this is not clear. Laforin has been shown to be phosphorylated at S25 
by AMPK, and phosphorylation has been shown to enhance the laforin-malin 
interaction via yeast two-hybrid (313, 455). It is possible that laforin must be 
phosphorylated in yeast in order to interact with malin in vivo (and perhaps also 
PTG). All of the mutants except S25P may be phosphorylated by Snf1 (the yeast 
homolog of AMPK) when expressed in yeast, facilitating an interaction with PTG 
and malin. Therefore, S25P may be pathogenic by preventing the phosphorylation 
of laforin by AMPK. K140N may also affect a post-translational modification site. 
Laforin has been shown by many groups to be ubiquitinated by malin (175, 176, 
307). Although the specific lysine(s) that are ubiquitinated have not been identified, 
only 3 of the 11 lysine residues in laforin are surface exposed, according to SASA 
analysis of the crystal structure: K140, K219, and K323 (Supplemental File 1). It 
is possible that K140 is a primary ubiquitination site and that mutation of this 
residue leads to LD by impairing laforin ubiquitination. Our assays did not detect 
a defect in P246A and G240S. Both are buried in the core of the DSP between 
the active site and dimer interface (Figure 3.2c). Further study will be required to 
determine why these mutations lead to disease.  
 
3.3.2 Laforin stability and interaction, not activity, are the primary defects of 
EPM2A missense mutations 
 It has been hypothesized that most genetic diseases are caused by loss-of-
function resulting from destabilizing mutations (491). Herein we show that many 
LD-causing missense mutations are indeed destabilizing. The core of the laforin 
CBM and the CBM-DSP interface are the regions most susceptible to destabilizing 
mutations. At physiological temperatures, these mutations would likely lead to 
unfolding, aggregation, and entire ablation of protein function. Indeed, Y294N has 
been shown to form ubiquitin-positive aggregates when overexpressed in cell 
culture, although other mutants did not (R108C, E28L) (513). Like Y294N, L310W 
also forms aggregates in cell culture (523). However, pathogenicity of a mutation 
cannot be determined simply by its stability. Many LD-causing mutations have 
normal or nearly normal melting temperatures, such as S25P, K140N, N148Y, 
A188G, E210K, P211L, E224I, G240S, and P246A. Furthermore, some 
destabilizing mutations are associated with a milder phenotype, such as G279C 
and F321C.  
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It is very striking that most missense mutations have intact phosphatase 
activity at the permissible temperature (Figure 3.5f, 3.7). The only mutations we 
found with reduced glycogen phosphatase activity were W32G and K87T, which 
clearly have impaired binding to carbohydrate substrates. Furthermore, few LD 
mutations are found near the laforin active site, and none affect catalytic residues 
or are found in the active site loop (The Lafora Progressive Myoclonus Epilepsy 
Mutation and Polymorphism Database, http://projects.tcag.ca/lafora/). Recently, 
the relevance of laforin phosphatase activity has been questioned due to the 
observation that overexpression of the catalytically inactive laforin mutant C266S 
rescues the LD phenotype in mouse models (159, 189). Strikingly, C266S has 
possesses enhanced interaction with laforin binding partners compared to WT 
laforin in yeast two-hybrid studies (455, 514, 524). This result is consistent with 
our observation that most LD mutations do not affect laforin phosphatase activity 
but do negatively affect protein-protein interactions.  
 
3.3.3 A slower progression in LD and genetic effects 
LD was previously believed to produce a severe disease course irrespective of 
the mutation of the patient (477, 520). Before the genetic loci were identified, if 
patients presented with progressive myoclonic epilepsy and lived beyond the age 
of 30, a diagnosis of LD was ruled out (326). However, differences in clinical 
presentation have always been observed (322, 326). Even at present, adult 
patients with mild progressive myoclonus epilepsy typically do not undergo LD 
screening (484). With the increasing use of genetic testing to confirm LD 
diagnosis, only recently has the neurology community begun to accept that LD is 
a heterogeneous disease (328, 484).  
Modifier effects are certain to play a role in clinical manifestation. These effects 
could be either genetic or environmental. Patients carrying the same mutations do 
show phenotypic variability (525). Siblings carrying identical mutations sometimes 
display differences in disease progression, suggesting a role for genetic factors 
(481, 488, 513, 526). Furthermore, a PTG variant has been reported to contribute 
to a milder disease course (457). Differences in medical care can also influence 
clinical progression (520). However, a clinically homogeneous patient progression 
is often reported in families and among genetic isolates (487, 527).  
Another complicating factor for predicting disease progression is that many 
patients are compound heterozygotes, i.e. carrying two different chromosomal 
aberrations that affect the same gene. LD is a recessive disorder, meaning 
patients carrying only one mutated allele do not display any symptoms. It is likely 
that a disease threshold exists regarding decreased laforin function (Figure 3.15). 
Our data suggests that laforin function is defined as its ability to function as a 
protein scaffold on the glycogen molecule. When laforin function is above a 
specific threshold then individuals are completely healthy. Below this threshold, 
there is a gradation of how rapidly patients progress down a clinical path. Both the 
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type of mutation and whether the mutation is in the homozygous or heterozygous 
state may influence disease progression. For example, the mildest form of LD 
associated with an EPM2A mutation is a patient homozygous for F321C, a Class 
V mutation (489). Based on our analyses, this patient would have laforin function 
just below the disease threshold (Figure 3.15). In contrast, compound 
heterozygous patients carrying a class III or IV mutation in addition to a deleterious 
mutation such as a PTC or indel would experience a clinical course that is milder 
than classic LD and yet still more rapid than patients with class V mutations (456, 
488). The most severe and rapidly progressing LD cases are homozygous or 
compound heterozygous patients with class I or II mutations leading to 
nonfunctional protein (Figure 3.15). Patients with these mutations are likely 
indistinguishable from patients with PTCs and/or indels. 
 
3.3.4 A biochemical pipeline for personalized medicine 
Genetic testing is being used with increasing frequency to detect or confirm a 
LD diagnosis. It is likely that in the near future, LD will be detected earlier, and that 
even more cases of mild or late-onset cases will be identified. A biochemical 
analysis of novel mutations using our biochemical and biophysical methods could 
be performed in a matter of weeks and would provide the most accurate prediction 
of mutation pathogenicity. New mutations would be classified based on the 
similarity of their biochemical profile with known mutations (Figure 3.16). 
Additionally, preclinical studies of LD therapeutics are currently underway (328). 
With the large number of novel mutations arising in new patients, such a 
biochemical pipeline could become extremely useful for providing patients with a 
personalized diagnosis and treatment strategy once therapies become available. 
Furthermore, genetic screening during pregnancy or at birth is already widely 
employed to identify genetic diseases and chromosomal abnormalities (528). Life-
threatening disorders, even those as rare as LD, may soon be added to these 
early genetic screens. Pre-symptomatic detection of LD would be extremely 
valuable since early treatment could better ameliorate or even prevent LD onset. 
However, benign SNPs would also need to be correctly differentiated from mild, 
moderate or severely pathogenic mutations to prevent a false diagnosis and/or 
unnecessary treatment, which could be needlessly devastating, expensive, or 
even harmful for individuals.  
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Table 3.1  Clinical data for patients carrying EPM2A missense mutations 
analyzed in this study.  
Each line refers to a single patient unless noted below. Some patients have been 
cited multiple times. Asterisk(s) indicates this mutation has been explicitly 
associated with a milder phenotype, either in the compound heterozygous (*) or 
homozygous (**) state.  
a 2 cases in same family. b 3 cases in different families. 
Mutation Allelic context 
Age of seizure 
onset 
Reference 
F5S Unknown Unknown Unpublished case. 
V7A Hom. 17 (522) 
S25P Hom. 13 (513) 
E28K Comp. het. (R171H / E28K) 14 (520) 
W32G Hom. 13 (520) 
E56K Comp.  het. (E56K/K87T) 11 (479) 
F84L Hom. Unknown (529) 
Y86D Hom.a 10,14 (488) 
K87T Comp.  het. (E56K/K87T) 11 (479) 
R91P Unknown Unknown (530) 
R108C 
Hom. 
Hom. 
11 
5, 8,10 
(520) 
(513) 
K140N Comp. het. (L310W / K140N)a 13 (523) 
N148Y Hom. 11 (523) 
T187A Comp. het. (T187A / G75fs) 10 (531) 
A188G Unknown Unknown (477) 
E210K Comp. het. (E210K / unknown) 17 (523) 
P211L* Comp. het (P211L / unknown) 11 Unpublished case. 
E224I Unknown Unknown (513) 
G240S Comp. het. (G240S/H253fs) Unknown (529) 
P246A Unknown Unknown (477) 
G279C* Comp. het (G279C / R241X) 21-28 (488) 
G279S 
comp. het. (G279S/R241X)b 
comp. het. (G279S/Ex2-del2) 
Unknown 
14 
(172, 520, 529) 
(529) 
Y294N 
Comp. het. 
(Y294N / Ex1-32bpdel 2) 
Unknown (172, 529) 
P301L Comp. het. (P301L / unknown) Unknown (529) 
L310W Comp. het. (L310W / K140N)a 13 (523) 
F321C** Hom. Early 20s (489) 
F321S Unknown Unknown Unknown 
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Table 3.2 Predicted pathogenicity of selected EPM2A missense mutations. 
Asterisk(s) indicates this mutation has been explicitly associated with a milder 
phenotype, either in the compound heterozygous (*) or homozygous (**) state. 
CUPSAT and SDM cutoff scores: stabilizing/neutral >=0 (green); destabilizing, 
between -2 and 0 (orange); destabilizing <-2 (red). For CUPSAT results, ΔΔG was 
predicted for residues in both subunits (chain A and C) and the values in the table 
represent an average. 
 
 PolyPhen-2 CUPSAT SDM 
 
Prob. 
Score 
prediction 
ΔΔG 
(kcal/mol) 
Predicted 
Stability 
ΔΔG 
(kcal/mol) 
Outcome 
F5S 0.198 benign -4.045 Destabilizing -2.96 Reduced stability 
V7A 0.092 Benign -6.71 Destabilizing -2.71 Reduced stability 
S25P 1 probably damaging 0.56 Stabilizing -0.78 Reduced stability 
E28K 1 probably damaging -0.76 Destabilizing -1.09 Reduced stability 
W32G 1 probably damaging -0.595 Destabilizing 2.76 Increased stability 
E56K 1 probably damaging 2.605 Stabilizing -0.87 Reduced stability 
F84L 0.003 Benign -2.705 Destabilizing -1.89 Reduced stability 
Y86D 0.863 possibly damaging -1.68 Destabilizing -2.77 Reduced stability 
K87T 1 probably damaging -0.26 Destabilizing -0.63 Reduced stability 
R91P 0.988 probably damaging -0.145 Destabilizing -1.26 Reduced stability 
R108C 1 probably damaging 1.31 Stabilizing -0.28 Reduced stability 
K140N 0.915 possibly damaging -1.975 Destabilizing -0.86 Reduced stability 
N148Y 0.085 Benign 0 No effect 1.21 Increased stability 
T187A 0.999 probably damaging -1.06 Destabilizing 0.06 Increased stability 
A188G 1 probably damaging -5.965 Destabilizing -0.92 Reduced stability 
E210K 0.381 Benign 0.28 Stabilizing -0.04 Reduced stability 
P211L* 0.867 possibly damaging -1.74 Destabilizing -0.58 Reduced stability 
E224I 0.812 possibly damaging 0.585 Stabilizing -0.57 Reduced stability 
G240S 0.815 possibly damaging 1.11 Stabilizing -0.01 Reduced stability 
P246A 0.985 probably damaging -2.71 Destabilizing 2.19 Increased stability 
G279C* 1 probably damaging -1.76 Destabilizing -0.01 Reduced stability 
G279S 1 probably damaging -1.73 Destabilizing -2.32 Reduced stability 
Y294N 0.999 probably damaging 1.44 Stabilizing -2.3 Reduced stability 
P301L 1 probably damaging -4.335 Destabilizing 1.26 Increased stability 
L310W 1 probably damaging -2.275 Destabilizing -1.24 Reduced stability 
F321C** 1 probably damaging -2.5 Destabilizing -0.19 Reduced stability 
F321S 1 probably damaging -3.885 Destabilizing 0.38 Increased stability 
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Table 3.3  Classification of LD-causing EPM2A missense mutations based 
on biochemical and clinical data. 
Asterisk(s) indicates this mutation has been associated with a milder phenotype, 
either in the compound heterozygous (*) or homozygous (**) state. Mutants in 
parentheses are likely classifications but were not fully characterized due to 
extensive proteolysis.   
 
 
Region 
affected 
Mutations General Effects 
Predicted 
Pathogenicity 
Class I 
CBM 
carbohydrate-
binding site 
W32G 
K87T 
Severely impaired 
carbohydrate binding and 
phosphatase activity; 
decreased PTG interaction 
Severe  
Class IIa CBM core  
(F5S) 
V7A 
E28K 
F84L 
(Y86D) 
F88L 
R91P 
(R108C) 
Destabilization and 
decoupled CBM and DSP; 
mild or moderate effects on 
phosphatase activity; 
severely impaired PTG and 
malin interaction.  
Severe 
Class IIb 
CBM-DSP 
interface 
E56K 
Y294N 
P301L 
Class III DSP 
N148Y 
(T187A) 
A188G 
L310W 
G279S 
G279C* 
Destabilized; variable effects 
on phosphatase activity; 
impaired malin and PTG 
interaction. 
Variable  
Class IV 
Surface-
exposed regions 
E210K 
P211L* 
E224I 
Slightly destabilized; slight 
decrease in activity; slight 
decrease in malin/PTG 
interaction. 
Moderate 
Class V Dimer interface 
F321S 
F321C** 
 
Destabilized; mild effects on 
phosphatase activity; 
impaired malin interaction; 
loss of dimerization and 
preferential binding to long 
oligosaccharides 
Mild 
Unknown 
Possible 
PTM/regulatory 
site 
S25P 
K140N 
G240S 
P246A 
Mild or no effect on stability 
or activity. 
S25P displays no interaction 
with malin or PTG. 
Unknown 
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Figure 3.1 Distribution of LD cases and predicted pathogenicity of EPM2A 
missense mutations.  
(a) Distribution of 356 LD cases by mutation type. (b) Distribution of 94 reported 
EPM2A mutations by mutation type. (c) Correlation analysis between PolyPhen-2 
pathogenicity score and ΔΔG (kcal/mol) predictions by CUPSAT and SDM for 27 
mutations selected for analysis (see Table 3.2). 
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Figure 3.2 Distribution of LD missense mutations in the laforin structure.  
(a) Laforin is a bimodular protein with a CBM and DSP domain. LD missense 
mutations selected for study are shown throughout the primary sequence of laforin. 
(b) The X-ray crystal structure of laforin bound to maltohexaose (PDB:4RKK) 
(190). Laforin forms an antiparallel homodimer with a DSP-DSP interface. The 
CBM and DSP domain of one subunit are shown in light and dark shades of blue, 
respectively. Bound maltohexaose molecules are shown in green. (c) Residues 
affected by missense mutations are shown in red. Phosphate at the active site is 
shown in orange. The CBM and DSP domain are shaded as in (a) and (b).   
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Figure 3.3 Recombinant laforin mutants purified from E. coli.  
LD-associated and structure-guided mutants were expressed in E. coli, purified by 
ion exchange and size exclusion chromatography, and then assessed for purity 
by SDS-polyacrylamide gel electrophoresis (PAGE). Approximately 5-20 g of 
purified protein was loaded per lane, and gels were stained with Coomassie blue 
to visualize protein content. Lanes containing molecular weight markers (MWM) 
are indicated.  
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Figure 3.4 Stability and carbohydrate binding of LD mutants.  
(a) Stability measured by Tm. (b) Absolute Tm for mutants without substrate, and 
in the presence of 10 mM DP7 or 10 mM DP24. (c) ΔTm for mutants with incubation 
with DP7 or DP24. In (a-c), assays were performed in triplicate, and graphs 
represent the average ± SD. (d-g) Correlation of Tm with SASA ratio (a), PolyPhen-
2 score (b), CUPSAT (c) and SDM (d) predictions for ΔΔG (kcal/mol). Correlation 
coefficients (r) are shown. Statistical significance is indicated: ns p > 0.05, * p ≤ 
0.05. 
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Figure 3.5 Glycogen phosphate levels, kinetics, and phosphatase activity of 
LD mutants.  
(a) Comparison of glycogen phosphate determined by different methods in the 
present study and the previous one (174). (b) Phosphate release after treatment 
of glycogen with antarctic phosphatase (AP) and/or amyloglucosidase (AG) 
overnight at 37°C. nt = no treatment. Averages of triplicate reactions are shown 
±SD. (c) 0.5 mg glycogen was treated with 2.5 μg laforin for 1-2 hours to 
saturation, then α-amylase (AA), AG, or AA + AG was added for a final 
concentration of each enzyme of 0.3 mg/ml. Reactions were performed in 
duplicate; averages ± SD are shown. (d) Time course of phosphate release from 
glycogen at two different substrate concentrations. 10 mg/ml glycogen was treated 
for 30 minutes in subsequent assays. (e) Stability of laforin mutants over time at 
37°C or room temperature. WT laforin and the catalytic mutant C/S were used as 
positive controls. (f) Specific activity of LD mutants; average and SD of triplicate 
reactions are shown. (g) Correlation between Tm and specific activity.    
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Figure 3.6 Kinetics of C3- and C6-labeled starch dephosphorylation.  
(a) Time course of C3- and C6-phosphate release from labeled starch by WT and 
C266S (C/S) laforin. (b) Phosphate release by WT laforin with increasing 
concentration of labeled starch. (c) C6- and (d) C3-labeled starch 
dephosphorylation kinetic studies on laforin mutants. The catalytically inactive C/S 
laforin mutant (C266S) was used as a negative control. (e) Kinetic constants for 
starch dephosphorylation. Units for Vmax and Km are pmol min-1 μg-1 and mg/mL, 
respectively. For (a-d), average of triplicates ± SD are shown. 
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Figure 3.7 Effects of LD mutants on C3- and C6 dephosphorylation.  
(a) Specific activity of laforin mutants. C3 versus C6 percent phosphate release 
are shown in the top panels as a percent of total dephosphorylation. (b) Specific 
activity comparison of laforin mutants with C3-labeled starch (yellow), C6-labeled 
starch (blue), and glycogen (grey; data from Figure 3.4c). Activity of each mutant 
was normalized to WT activity for each substrate. All assays were performed in 
triplicate; averages ± SD are shown. 
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Figure 3.8 Melting profiles of laforin mutants determined by differential 
scanning fluorimetry.  
Melting profiles of proteins in the absence of substrate are shown in black. Melting 
profiles in the presence of 10 mM DP7 are shown in blue. Data are representative 
of 3 replicates. Only DP7 profiles are shown for clarity. 
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Figure 3.9 Effects of carbohydrate binding on domain decoupling in Y294N 
and P301L.  
(a) Raw melt curves for WT, Y294N, and P301L binding to different concentrations 
of DP24. (b) First derivative of melt curves in (a). Tm values (calculated from the 
peak maxima) are shown. Only curves for 0 and 10 mM DP24 are shown for clarity. 
(c) Melt curves of WT and Y294N binding to increasing concentrations of glycogen. 
Data in (a-c) are representative of 3 replicates. (d) Tm values from the experiment 
in (c) were graphed to generate a binding curve for WT and Y294N; averages of 
triplicates ± SD are shown. One-site and two-site fits were determined using the 
Prism Software (Graphpad). 
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Figure 3.10 LD mutation "hotspot" along the allosteric path between the 
CBM and DSP domain.  
(a) DSF melting profile of W32A in the absence of glucan (black) and in the 
presence of 10 mM DP7 (blue). Graphs are representative of 3 replicates. (b) The 
CBM core and CBM-DSP interface is a “hotspot” for LD mutations. Affected 
residues are shown in orange. Glucan is shown in green. Y294 makes hydrogen 
bonds (in yellow) with main chain hydroxyls of R4 and L124 (in blue). (c) Melting 
profiles of structure-guided mutants compared to LD mutants.  
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Figure 3.11 Purification and characterization of laforin CBM and DSP 
domain.  
(a) The laforin CBM (amino acids 1-137) was expressed as a His6-tagged 
recombinant protein in E. coli and purified by affinity and size exclusion 
chromatography. (b) The laforin DSP domain (amino acids 150-331) was 
expressed as a fusion protein with a His6-tagged SUMO protein for stability. The 
fusion was purified by affinity and size exclusion chromatography. (c) Stability of 
CBM and DSP constructs compared to full-length laforin (FL). (d) Binding of FL, 
CBM and DSP constructs to increasing concentration of DP7 determined by DSF. 
(e) Binding of W32G laforin to DP7 compared to WT (FL) laforin data from (d). 
DSF assays in (c-e) were performed in triplicate; averages ± SD are shown. 
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Figure 3.12 Expression levels of LD mutants fused to LexA.  
LD mutations were expressed as LexA fusion proteins and coexpressed with 
either HA-tagged GAD (Ø), GAD-malin (M), or GAD-PTG fusion proteins. 
Antibodies for LexA and HA were used to detect the levels of each fusion protein. 
The expected molecular weights for GAD-malin and GAD-PTG are 55 kDa and 49 
kDa, respectively.  
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Figure 3.13 Effects of LD mutants on the interaction of laforin with malin 
and PTG.  
(a) Interaction of WT laforin and mutants with GAD, GAD-PTG and GAD-malin 
fusion proteins. Mutants are color coded by class. Average of triplicate reactions 
± SD are shown. (b, c, d) Correlation between Tm and GAD-malin interaction (b), 
Tm and GAD-PTG interaction (c), and GAD-malin and GAD-PTG interactions (d). 
Correlation coefficients (r) and p-values are shown. Significance is indicated:  ns 
= not significant, * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001. In (d), box corresponds to 
inset.  
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Figure 3.14 Laforin as a scaffolding protein.  
(a) Triple hybrid experiment demonstrating noncompetitive binding of malin and 
PTG to laforin. LexA-laforin was expressed with either GAD-malin and pWS-PTG 
or GAD-PTG and pWS-malin. A reduction in β-gal activity with expression of the 
second binding partner would indicate malin and PTG have overlapping binding 
sites. Average of triplicate reactions ± SD are shown. (b) Electrostatics mapped 
onto the laforin crystal structure. (c) LD-affected residues relative to charged 
patches on the laforin dimer. (d) Phyre2-generated homology model of malin. 
Zoom of D197 in the NHL domains is shown. (e) Electrostatics mapped onto the 
malin model. (f) Phyre2-generated homology model of PTG. CBM21 is shown in 
teal. (g) Proposed model of the assembly of laforin, malin and PTG on the 
glycogen molecule.  
  
99 
 
 
Figure 3.15 A threshold of laforin function in LD.  
LD progression is proposed to be dependent on the type of mutation(s) carried by 
LD patients and the overall threshold of laforin activity for patients carrying EPM2A 
mutations. In individuals who are homozygous or heterozygous for the wild-type 
allele, i.e. carriers and noncarriers, laforin function is above the disease threshold 
and are therefore healthy. LD patients carrying Class I or Class II mutations have 
a classic LD progression. This is likely to be the case whether the patients are 
homozygous for these missense mutations or complex heterozygotes, i.e. carrying 
a missense mutation and a nonsense mutation (or other mutation leading to 
complete loss-of-function). LD patients carrying Class III or Class I mutations have 
a slower progression; particularly if they are homozygous for one of these 
mutations. LD patients carrying Class V mutations will have the slowest 
progression, e.g. the patient who was homozygous for F321C (489). 
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Figure 3.16 A personalized biochemistry pipeline for LD patients.  
A suspected LD diagnosis will be confirmed by genetic testing. Skin biopsies will 
also be performed to facilitate comparisons of LB load between patients with 
different genotypes. Nonsense, frameshift, or indel mutations in either EPM2A or 
EPM2B leading to nonfunctional protein (i.e. total loss-of-function mutations) are 
highly pathogenic. If known loss-of-function or EPM2A missense mutation(s) are 
identified, patient progression could be predicted immediately. If novel EPM2A 
missense mutations are identified, mutant expression constructs could be 
generated, characterized, and classified within a matter of weeks. This 
classification would give rise to an estimated clinical progression for that patient.  
 
 
 
 THE CATALYTIC ACTIVITY AND DYNAMICS OF THE HUMAN 
GLYCOGEN PHOSPHATASE LAFORIN PROVIDE INSIGHTS INTO 
LAFORA DISEASE  
4.1 Introduction  
In the late 1990s, mutations in the gene encoding the novel phosphatase laforin 
were identified as the cause of Lafora disease (LD) (170, 172). Lafora bodies 
(LBs), the hallmark inclusions of LD, were assumed to form as a result of aberrant 
glycogen metabolism, but the molecular basis for LB formation and LD 
pathophysiology were unknown. Laforin contains a dual specificity phosphatase 
(DSP) domain and carbohydrate binding module (CBM) from the CBM20 family 
(285). It was assumed that laforin localized to glycogen via its CBM where it would 
dephosphorylate a protein substrate. However, a robust protein substrate for 
laforin was never identified.  
 Subsequently, the Dixon and Roach groups independently discovered that 
laforin's substrate was not a protein but glycogen itself, the only carbohydrate 
storage molecule found in mammals (173, 174). Laforin was the first member of 
the glucan phosphatase family, a subgroup of atypical DSPs that dephosphorylate 
complex carbohydrates. The other known members of this family are the plant 
enzymes Starch Excess 4 (SEX4) and Like Sex Four 2 (LSF2). SEX4 also 
contains a CBM and a DSP but in the reverse orientation, and the SEX4 CBM is 
from the CBM48 family (183). LSF2 only contains a DSP domain and utilizes 
starch surface binding sites to engage its substrate (187, 205). All of glucan 
phosphatases directly dephosphorylate carbohydrates, and their X-ray crystal 
structures have been determined (186, 187, 190, 207, 454). A common active site 
motif has been defined among them, but each member possesses a unique 
architecture and binding platform (139, 184, 205).  
 DSPs are part of the protein tyrosine phosphatase (PTP) superfamily that 
utilizes a catalytic triad of cysteine, arginine and aspartate residues (532, 533). 
The PTP-loop contains the Cx5R-motif in which the arginine side chain and main 
chain nitrogen moieties stabilize the phosphate moiety of the substrate (534). A 
flexible loop containing the catalytic aspartic acid, often called the WPD-loop or 
simply the D-loop, closes over the active site once the phospho-substrate is 
bound. The first step of catalysis is nucleophilic attack of the substrate by the 
thiolate of the active site cysteine (535). The aspartate acts as a general acid, 
donating its proton to the substrate leaving group. A cysteinyl-phosphate 
intermediate is formed, which in the second step is hydrolyzed by an attacking 
water molecule. The same aspartate acts as a general base during this step, and 
inorganic phosphate is released. Studies of the prototypical PTPs YopH and 
PTP1B show that during catalysis, closing of the D-loop involves a ~10 Å swinging 
motion that initiates catalysis (536). DSPs are aptly named for their ability to 
dephosphorylate both phospho-tyrosine and phospho-serine/threonine residues 
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using the same catalytic triad. However, in contrast to PTPs, which have a deep 
and narrow active site cleft, DSPs have a wide and shallow active site that can 
accommodate phospho-tyrosine (537). Glucan and lipid phosphatases are all 
considered atypical DSPs and have slightly different active site topologies suited 
to their specific substrates (139, 208, 537).  
One of the most common ways to produce a catalytically incompetent PTP or 
DSP is to mutate the active site cysteine to serine (538). Alternatively, the catalytic 
aspartate can be mutated, although the D/A mutation can harbor some residual 
activity (538, 539). Surprisingly, in 2014, it was reported that transgenic 
overexpression of a catalytic mutant of mouse laforin, C265S, could reverse LB 
formation and autophagy defects in a laforin-deficient mouse model (189). This 
result was confirmed by another group in 2017: overexpression of human laforin 
C266S rescued LD in laforin-deficient mouse models (159). Glycogen in the 
laforin-deficient mice expressing the laforin C266S transgene did not over 
accumulate nor was it abnormally branched, both hallmarks of LBs, but the 
glycogen was still hyperphosphorylated. These results suggested that either the 
C/S mutants possess residual phosphatase activity, or that laforin prevents LB 
formation independent of its catalytic activity. The latter was more likely since the 
glycogen was still hyperphosphorylated. 
X-ray crystal structures of the laforin DSP domain and full-length protein were 
both recently published (190, 454). The crystal structure of the DSP domain with 
the C266S mutation revealed a prototypical PTP-loop bound to a sulfate ion (454). 
The authors proposed that a second "triad" involving C169, R171, and D197 exists 
in laforin that is in close proximity to the original triad. It was suggested that laforin 
C266S might possess residual activity via this “second” triad, which could explain 
how C266S could rescue the LD phenotype. Furthermore, this group proposed 
that laforin forms a CBM-CBM dimer interface reminiscent of VH1, a prototypical 
DSP that dimerizes via its N-terminal helices (Koksal 2009). The laforin model was 
based on the crystal structure of the DSP domain, a homology model of the CBM, 
and manual fitting of the domains to small angle X-ray scattering data.  
We determined the crystal structure of laforin C266S lacking three C-terminal 
amino acids in complex with maltohexaose and phosphate (190). The two 
molecules in the asymmetric unit formed an antiparallel homodimer with an 
extensive 880 Å2 interface mediated exclusively by the two DSP domains. Multiple 
glucans were bound both to the CBMs and the DSP domains. We discovered that 
laforin C266S binds cooperatively to long oligosaccharides with an average length 
of 24 glucose units. The LD-associated mutant laforin F321S affecting the core of 
the hydrophobic DSP-DSP interface rendered laforin monomeric and abolished 
high-affinity cooperative binding. These data suggested that laforin dimerization 
mediates its specific binding to substrates with long glucan chains, such as those 
found in LBs.  
In the present study, we employ both crystal structures and an array of 
mutations coupled with biochemical analysis to characterize the laforin active site 
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and dimer interface. We show that a second catalytic triad is mechanistically 
impractical and incongruent with biochemical data. We define the architecture of 
the laforin active site in the context of the glucan phosphatase family and 
characterize the unique laforin dimer interface. Finally, we discover that the laforin 
C266S mutant scavenges phosphate and exhibits unique binding properties 
compared to WT laforin. The laforin C266S mutation confers rigidity to the protein, 
leading to increased interactions with laforin binding partners. These data support 
an important role for laforin as a protein scaffold and may explain why laforin 
C266S overexpression rescues the LD phenotype in mouse models.   
4.2 Results  
4.2.1 The laforin active site 
 The laforin DSP domain structure bound to sulfate was determined at 2.3 Å 
(PDB: 4R30) and the laforin CBM and DSP structure bound to phosphate and 
maltohexaose was determined at 2.4 Å  (PDB: 4RKK) (190, 454). The isolated 
DSP domain is comprised of residues 153-331, and there are four molecules in 
the asymmetric unit (Figure 4.1a). There is very little conformational difference 
between each DSP domain with root mean square deviation (RMSD) values 
between the chains of 0.1-0.2 Å (Table 4.1). The CBM-DSP protein includes 
residues 1-329 and there are two molecules in the asymmetric unit, also with an 
RMSD of 0.1 Å within the DSP (Figure 4.1b, Table 4.1). The interface between 
chains B and D in 4R30 is the same interface as the one observed in 4RKK 
(Figure 4.1c); however, due to conformational differences, which are discussed 
later, the interface in 4R30 has slightly more surface area than in 4RKK (Table 
4.1). The RMSD between the DSP domains in 4R30 and 4RKK is 1.7-1.8 Å (Table 
4.1). 
DSPs share four common motifs that frame the PTP-loop at the catalytic core. 
The D-loop contains the catalytic aspartic acid; the recognition domain contributes 
to active site depth; the variable insert or V-loop, which is shorter in DSPs than 
PTPs; and the R-motif named for a highly conserved arginine that is surface-
exposed in the DSPs (540). The DSP domains in 4R30 and 4RKK only deviate 
moderately in the PTP-loop, D-loop, R-motif, and helix α10 that immediately 
precedes the R-motif (Figure 4.1d). In 4R30, the majority of the recognition 
domain is missing (residues 137-153) and this absence results in an open D-loop; 
while the D-loop is closed over the glucan substrate in 4RKK (Figure 4.1d,e,f). 
D235 is the catalytic aspartate for laforin, and there is a 7 Å difference in its 
position between the open and closed conformations (Figure 4.1f). In both 
structures, the oxyanion interacts with the PTP-loop, but in the glucan-bound 
structure (4RKK) the phosphate is 2.0 Å deeper into the catalytic cleft than the 
sulfate in the glucan-free structure (4R30) (Figure 4.1f). Also, the alanine, glycine, 
and valine residues at position 2, 3, and 4 within the Cx5R-motif are inverted 
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inward in 4RKK in contrast to 4R30. Alanine and a long-chain aliphatic residue at 
positions 2 and 4 are hallmarks of the active site motif in glucan phosphatases, 
and they interact with glucans in all glucan phosphatase structures (184, 187, 190, 
205, 207). The conformational difference in the PTP-loop of 4R30 is likely due to 
the absence of bound glucan but may also be due to the deleted recognition 
domain in this construct, which also makes contact with the PTP-loop (Figure 
4.1d).  
 In the glucan-bound structure (4RKK), the side chains of C266S, R272, and 
D235 are all within 7 Å of each other (Figure 4.1f). In the glucan-free structure 
(4R30), D235 is 12 Å away from C266S and 8 Å away from R272, but C266S and 
R272 are only ~5 Å apart. This positioning is ideal for coordinating a ~ 4 Å 
phosphate moiety. Mapping of surface electrostatic potential also reveals the 
strong positive charge of this pocket, suitable for accommodating phosphate 
(Figure 3.14b).  
Cingolani and colleagues predicted that C169, R171 and D197 form a second 
catalytic triad. In contrast, these residues are all at least 7 Å apart in both 
structures (Figure 4.1f) and are present in a region with no pocket or charge 
(Figure 3.14b). Furthermore, rather than being part of a flexible loop that is 
required for dephosphorylation, D197 is within an α-helical region of a highly 
conserved DSP structural motif and has very little solvent exposure 
(Supplemental File 1) (190). Therefore, it is structurally unlikely to rotate between 
an open and closed conformation upon binding to a substrate. Although C169, 
R171, and D197 are all highly conserved, upon close inspection of the laforin 
structures, the location and orientation of these residues indicates that they are 
unlikely to form a second catalytic triad and instead likely to be key structural 
elements of the protein.  
 To test the contribution of each triad residue to stability and catalysis, individual 
alanine mutants in the context of the full-length protein were generated. These 
mutants were expressed and purified via nickel affinity and size exclusion 
chromatography to very high purity, similar to C266S (Figure 4.2a). Multiple 
attempts to purify D197A were necessary, since this protein had a tendency to 
undergo proteolysis during expression and purification. The mutants were first 
analyzed by differential scanning fluorimetry (DSF) to quantify stability and 
carbohydrate binding. D235A, C266S, and R272A all possess similar melting 
temperatures (Tm) compared to WT laforin, indicating these mutations did not 
affect laforin stability (Figure 4.2b). C266A was significantly destabilizing, 
reducing the Tm of laforin from 50.0 to 41.8°C. C169A, R171A, and D197A all 
reduced stability to a similar extent with a Tm of 44.3-45.6°C. WT laforin exhibits 
an increased Tm when it binds to maltoheptaose (i.e. DP7). None of the mutations 
negatively affected laforin binding to maltoheptaose with all exhibiting a ΔTm of 4-
5°C except for laforin C266A. Laforin C266A yielded an increase of 11.3°C in the 
presence of DP7. This result is consistent with our previous observation that 
destabilizing mutations exhibit a greater ΔTm in the presence of carbohydrates 
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(Figure 3.4).  
 With the exception of C266A, the glucan phosphatase activity of these mutants 
has already been determined via malachite green assay utilizing amylopectin as 
the substrate (454). Amylopectin is the major component of plant starch and 
contains covalently bound phosphate (196, 197). C266S, D235A, R272A and 
D197A were all catalytically inactive, while C169A and R171A were nearly as 
active as wild-type. It was suggested that the malachite green assay is not very 
sensitive and that C266S might harbor some residual activity below the limit of 
detection, which could explain why a laforin C266S mutant could rescue laforin-
deficient mice (454).  
Glycogen and starch can both be phosphorylated on C3- and C6-hydroxyls 
(139, 158, 200, 210). We have previously employed a highly sensitive 
radiolabeling assays to quantify specific phosphate release from C3- and C6-
positions (184, 187, 207). We found that C266S, C266A, D235A, and R272A were 
entirely inactive and D197A activity was dramatically decreased, while C169A and 
R171A possessed slightly reduced activity compared to WT laforin (Figure 4.2c). 
No change in C3- versus C6-phosphate release was observed for those with high 
activity and D197A possessed only minimal activity toward C3-phosphate. These 
data indicate that residues of the first triad contribute primarily to activity rather 
than structural integrity. Conversely, residues in the proposed second triad 
contribute primarily to structural integrity rather than catalysis.  
 The glucan phosphatase family members share at least 19% identity and 36% 
similarity in the DSP domain (Figure 4.3a) (183). Within this family, each DSP 
motif has at least one highly conserved residue, typically an aromatic, that 
contributes to glucan binding and substrate presentation to the active site. All three 
glucan phosphatases share a conserved tyrosine in the recognition domain that is 
a major contributor to overall glucan phosphatase activity in both SEX4 and LSF2 
(Figure 4.3a,b) (187, 207). In the V-loop, SEX4 and LSF2 each have two adjacent 
aromatic residues that contribute to activity (Figure 4.3a,b) (187, 207). Laforin 
lacks an aromatic at this position, likely due to the fact that the glucan in laforin is 
positioned more deeply in the active site where it interacts instead with D197 
(Figure 4.4a). Additionally, a nearby tryptophan, W196, interacts with the second 
glucan at the laforin active site, and this aromatic residue is unique to laforin 
(Figure 4.3a, 4,4a). In the D-loop, SEX4 and LSF2 possess a phenylalanine 
immediately adjacent to the catalytic aspartate, which facilitates closing of the D-
loop over the bound phospho-substrate (Figure 4.3a). In LSF2, mutation of this 
residue (F162) reduces catalytic activity by over 50% (187). In contrast, the D-loop 
residue of laforin is M236, and actually forms a bridge-like interaction with M139 
over the maltoheptaose molecule in the glucan-bound structure (Figure 4.4a) 
(190). In SEX4 and LSF2, residues of the R-motif contribute to C3- vs. C6-specific 
activity and the specificity was engineered by mutating these residues (187, 207). 
In SEX4, F235 promotes glucan binding so that phosphate at the C6 position is 
oriented toward the catalytic cysteine. In contrast, LSF2 possesses a glycine at 
this position that promotes the accommodating of glucan with C3-phosphate 
oriented toward the catalytic cysteine (139, 190). Laforin possesses a tryptophan 
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at this position in the R-motif (Y304), and a nearby aspartate (D306) also interacts 
with glucan at the active site (Figure 4.4a). However, the C2 and C3 hydroxyls of 
maltohexaose are oriented towards catalytic cysteine in the glucan-bound laforin 
structure (Figure 4.3b) (139, 190).  
We generated alanine mutations of these residues and other residues 
interacting with the glucan at the laforin active site and purified the recombinant 
proteins (Figure 4.4a,b). We then characterized each mutant using DSF, 
malachite green assays using glycogen as the substrate, and the radiolabeling 
assay. With the exception of D304A and M236A, all of these mutations had a Tm 
between 48 and 50°C, indicating normal stability (Figure 4.4c). Additionally, all 
mutations exhibited a normal binding profile to DP7 with the expected 3-5˚C 
increase. These data are consistent with the observation of multiple groups that 
only CBM residues dramatically contribute to glucan binding (Chapter 3) (190) 
(285). Interestingly, M139A, a residue of the recognition domain directly 
interacting with glucan, did not affect glycogen phosphatase activity (Figure 4.4d). 
However, other mutations affecting the recognition domain, T142A and Y146A, 
abolished activity (Figure 4.4d). These data support the importance of the 
recognition domain for catalysis, and may help explain why the purified DSP 
domain, which lacks most of the residues of the recognition domain, has no 
phosphatase activity even when small molecule substrates are used (Chapter 3) 
(454). Intriguingly, W196A slightly enhanced glycogen phosphatase activity 
(Figure 4.4d). The location of this residue relative to the two glucans at the laforin 
active site suggests it may promote accommodation of a branch point (Figure 
4.4a). Mutations of the D-loop residue, M236A/F/N, partially reduced phosphatase 
activity (Figure 4.4d). M236F was the most detrimental mutation, suggesting a 
bulky aromatic like that of SEX4 and LSF2 prevents glucan access to the active 
site. In contrast, M236N was the least detrimental, indicating that a long and linear 
residue, even if hydrophilic, can accommodate a glucan better than a small 
residue like alanine. T238 and R241, proximal to the D-loop, and Y304 and D306 
of the R-motif, were also important residues for activity (Figure 4.4d). Similar 
changes in activity were observed when radiolabeled starch was used as a 
substrate, and we did not see any major changes in C3 versus C6 
dephosphorylation by these mutants (Figure 4.4e). These data further confirm 
that the C266 active site of the original PTP-loop is the laforin active site, and the 
second proposed triad lacks catalytic function in vitro or in vivo. Mutation of 
residues within the second triad instead affect the stability of laforin. These 
residues are likely to be highly conserved due to their importance in structural 
maintenance. D197 appears to interact with glucan at the active site, but it would 
not be able to perform a catalytic role due to its location within an  -helix. 
 
4.2.2 The DSP-DSP dimer interface 
Although Sankhala et al. proposed a CBM-CBM dimerization interface, three 
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unique interfaces were found in the asymmetrical unit of the crystallized DSP 
domain (Figure 4.1a). First, the A:C and B:D interfaces were the most extensive 
interfaces in the structure each with encompassing over 1000 Å2 of surface area 
(Table 4.1). The B:D interface matches that of the DSP-DSP interface in the full-
length crystal structure (Figure 4.1c). We previously demonstrated that the 
theoretical profile calculated for the dimeric crystal structure was consistent with 
small angle X-ray scattering data (190). Furthermore, the LD-associated mutation 
F321S falls within the DSP-DSP interface and this mutation renders laforin 
monomeric and abolishes laforin cooperativity towards long glucan substrates. To 
test if the CBM had a propensity for dimerization, we purified the laforin CBM 
(residues 1-137) and determined its oligomeric state by analytical 
ultracentrifugation (AUC). A single species of 21 kDa predominated, with a very 
small proportion of a 41 kDa species (Figure 4.5a,b). The molecular weight of the 
predominant species was in agreement with the predicted molecular weight of the 
monomeric CBM (15 kDa). These data indicate that the laforin CBM is 
predominantly monomeric and along with previously published data by 
Raththagala et al. that the DSP-DSP interface corresponding to the B:D interface 
in 4R30 is the physiologically relevant dimer interface.  
When the D-loop is in the open conformation (as in 4R30), it interacts with the 
D-loop of the other DSP subunit and extends the surface area of the dimer (Figure 
4.6a, Table 4.1). M236 rotates outward and becomes buried at the interface 
(Figure 4.6a). When the D-loop closes (as in 4RKK), M236 rotates away from the 
dimer interface to associate with glucan, and the interface surface area decreases 
by over 100 Å (Figure 4.6a, Table 4.1). F321, I229, C250, and L251 are all 
residues with a high percentage of buried surface area at the interface in both 
conformations (Figure 4.6a, Supplemental File 1). To define the contribution of 
these residues to dimerization and cooperativity, we generated, purified and 
characterized their corresponding alanine mutants (Figure 4.6b). While I229A and 
C250A were mildly destabilizing, having a Tm of 45.8 and 47.8°C, L251A and 
F321A were severely destabilized with a Tm of 41.5 and 36.6°C (Figure 4.6c). All 
mutants exhibited a similar ΔTm with DP7 as WT, demonstrating that they can bind 
short glucans (Figure 4.6c). We also performed glycogen dephosphorylation and 
radiolabeling assays to determine C3 versus C6 dephosphorylation and substrate 
differences. All three activities of I229A were reduced by over 50%, while C250A 
did not reduce any of the activities (Figure 4.6d). In contrast, L251A and F321A 
showed substrate-specific effects: each exhibited a moderate decrease in 
glycogen dephosphorylation while starch dephosphorylation was significantly 
reduced (Figure 4.6d). The data for L251A and F321A are similar to what we have 
observed for LD mutations F321S and F321C (Chapter 3), and strongly suggest 
that L251A and F321A also impair cooperative binding to long glucan substrates.  
Cooperativity refers to a binding event that allosterically induces change in the 
affinity for subsequent binding events. Cooperativity is often facilitated by 
dimerization and can be quantified by the Hill equation (541, 542). A Hill coefficient 
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greater than one represents positive cooperativity; that is, the first binding event 
increases the affinity of the second binding event. A classic example of positive 
cooperativity is binding of oxygen to hemoglobin: the affinity of hemoglobin for 
oxygen increases as more oxygen binds (543). In contrast, a Hill coefficient less 
than one indicates negative cooperativity, where the first binding event reduces 
the affinity for the second event. A Hill coefficient equal to one represents no 
cooperativity, that is, no change in substrate affinity. Laforin C266S binds to long 
oligosaccharides with a Hill coefficient greater than one, reflecting positive 
cooperativity (190). Conversely, monomeric F321S has a Hill coefficient of 
approximately one, meaning it lacks cooperativity (190). Therefore, cooperative 
binding is impacted by laforin dimerization. 
In order to test the contribution of residues I229 and L251 to cooperative 
binding, we performed binding assays with a titration of long oligosaccharides 
(with an average length of 24 glucose units, i.e. DP24). We included the LD-
associated mutation F321C, which has been shown to be monomeric like F321S 
and has a similar activity and binding profile (Chapter 3) (510), as well as F321A. 
Surprisingly, we found that none of the proteins exhibited the high affinity binding 
observed for C266S, including WT laforin (Figure 4.6e,f). The Hill coefficients for 
WT, L251A, F321A, and F321C were less than 1, indicative of negative 
cooperativity (Table 4.2). As previously reported, the Hill coefficient of C266S was 
greater than 1, indicative of positive cooperativity. I229A exhibited a Hill coefficient 
of approximately 1, reflecting a lack of cooperativity. Also, I229A possessed a 
lower maximum ΔTm (i.e. apparent Bmax). I229 is within a β-sheet adjacent to the 
D-loop (Figure 4.6a). Since this mutation abolishes cooperative binding, this β- 
sheet may assist in mediating interchain allosteric interaction. To further define the 
impact of I229A and L251A mutations on laforin structure, we also defined their 
oligomeric state using native polyacrylamide gel electrophoresis (PAGE) and 
AUC. Although the theoretical weight of the WT laforin dimer is 72 kDa, it migrated 
with the 66 kDa marker when analyzed by native PAGE, likely due to its elongated 
shape.  I229A and L251A both yielded similar migration patterns as WT laforin 
(Figure 4.6g). Furthermore, both mutations had a sedimentation coefficient similar 
to WT laforin by AUC (Figure 4.6h). Collectively, the substrate-specific effects of 
L251A and F321A and the change in binding dynamics induced by I229A suggests 
all of these residues are involved in the cooperative binding event.  
 
4.2.3 Distinct binding properties of WT and C266S laforin 
The difference between WT and C266S binding to DP24 were unexpected and 
striking. Interestingly, no difference in binding was observed when DP7 was used 
as substrate (Figure 4.7a). A smaller but less pronounced difference was 
observed when glycogen was used with laforin C266S again demonstrating a 
higher binding affinity compared to WT laforin (Figure 4.7b). Strikingly, phosphate 
was found at the active site in the crystal structure of laforin C266S even though 
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there was no phosphate in any of the purification or crystallization buffers, 
suggesting it was scavenged during the purification procedure (190). Scavenged 
phosphate may alter laforin binding to long carbohydrates. To test this hypothesis, 
we added malachite green reagent to 100 μg of native and boiled WT, C266S and 
D236A proteins. Malachite green is a highly acidic reagent, so it denatures 
proteins and causes them to precipitate. Boiling the proteins prior to adding 
malachite green reagent would release any bound phosphate prior to precipitation. 
After malachite green was added, the samples were centrifuged, and the soluble 
fraction was added to a 96-well plate for spectrophotometric quantification. While 
WT and D235A contained no phosphate, phosphate was readily detected in both 
native and boiled C266S samples (Figure 4.8a,b). Malachite green reagent was 
also added to the remaining precipitated protein pellets. The pellets from the 
C266S samples that were not boiled stained more intensely, while the boiled 
C266S samples stained weakly (Figure 4.8a). These data suggest the phosphate 
is tightly bound in a pocket of the protein, and the rapid denaturation caused by 
the acidic reagent causes the bound phosphate to precipitate with the collapsed 
protein. In contrast, boiling the protein released the bound phosphate into the 
supernatant before acid was added. This experiment was performed on three 
different days, and consistently, WT laforin had no phosphate, while C266S had 
0.5 nmol phosphate per nmol protein (Figure 4.8b). Since the protein 
concentration of laforin is determined based on the amino acid sequence, i.e. the 
theoretical molecular weight of the monomer, 0.5 nmol phosphate per nmol protein 
is equivalent to 1 phosphate per dimer.  
We then sought to identify the source of the scavenged phosphate. We 
performed a phosphate-strip experiment based on the method of Neznansky et al. 
used to remove phosphate from the well-known bacterial phosphate-scavenger 
PstS (544). PstS proteins were stripped of phosphate by washing with 70 column 
volumes of buffer during the metal-chelate chromatography step. We performed a 
similar procedure to strip phosphate from laforin C266S. To remove possible 
sources of phosphate contamination, all buffers were pre-incubated with  PiBind 
resin, a commercial resin designed to remove contaminating phosphate from 
buffers and prevent high background in phosphate-sensitive enzymatic reactions. 
After expression of laforin C266S was induced, E. coli cells were harvested by 
centrifugation, resuspended in phosphate-free buffer, and lysed. Insoluble protein 
in the lysate was pelleted by centrifugation. The clarified lysate was then divided 
into two aliquots, which were separately loaded onto a nickel column for affinity 
chromatography, and the flow-through was collected for each (Figure 4.8b). After 
loading, the control sample was washed with 12 column volumes and then eluted 
with 300 mM imidazole according to our standard protocol. The stripped sample 
was washed with 70 column volumes, and then eluted (Figure 4.8c). Samples 
taken from each step of the purification show that the lysate and column flow-
through fractions are phosphate-rich, and that the eluted proteins from both strip 
and control samples contained equal amounts of phosphate. When normalized to 
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protein content, the ratio of phosphate to protein was consistently 0.5. This 
experiment clearly demonstrates that all of the phosphate scavenged by laforin 
C266S comes from its bacterial host.  
The observation that C266S scavenges phosphate from the initial expression 
system suggested that this interaction is very tight, because the phosphate is 
carried all the way throughout the purification. We tested whether the addition of 
carbohydrates would cause C266S to release phosphate by incubating 100 μg of 
C266S with various carbohydrates in the presence of PiBind resin. Blank samples 
were included for the detection of phosphate contamination. After rotating for 1 
hour at room temperature, the PiBind was allowed to settle, the supernatants were 
boiled and centrifuged, and then the soluble fraction was assayed for phosphate. 
Phosphate levels were unchanged in all of the samples with one exception: the 
sample in which C266S was incubated with 10 mM DP24 had much higher 
phosphate levels (Figure 4.9a). Although the DP24 was pre-incubated with PiBind 
resin, there was some residual phosphate in the samples prior to the addition of 
C266S, which accounts for the higher signal observed in this sample. We 
attempted to remove the phosphate by dialyzing C266S with PiBind and various 
phosphate binders used to treat hyperphosphatemia (545). 50 μg of C266S in 33 
μL was dialyzed into 100 mL of buffer containing mixing PiBind resin or 1 mM of a 
phosphate binder. The buffers were exchanged four times over the course of 24 
hours, and then phosphate was measured after boiling the dialyzed samples. 
While PiBind did remove a small fraction of the bound phosphate, the phosphate 
binders had no effect (Figure 4.9b). These data indicate the off-rate for phosphate 
binding of C266S is very low.  
We next tested binding of WT and C266S to phosphate or sugars in the 
presence of phosphate. While C266S exhibited an increasing ΔTm with increasing 
phosphate concentration, WT did not (Figure 4.10a). The Hill coefficient (h) of this 
binding curve was less than 1 (Table 4.2). In the presence of 50 mM γ-cyclodextrin 
(γCD), a circular glucan with seven glucose units, the Tm of WT and C266S 
increased by 7-8°C. The addition of phosphate to the reaction did not change the 
ΔTm of WT laforin with γCD, but the ΔTm of C266S with γCD increased with 
phosphate (Figure 4.10b). The phosphate-dependent increase in ΔTm was similar 
to the increase in ΔTm when phosphate was added in the absence of sugar 
(Figure 4.10b, black dots).  
To determine how phosphate changed the binding dynamics of WT and C266S 
laforin, titrations of DP7, glycogen and DP24 were performed with different 
phosphate concentrations. Phosphate had no effect on the binding curves of WT 
laforin with the various sugars (Figure 4.11a,b, Table 4.2). Although phosphate 
shifted the binding curves of C266S upward (Figure 4.11c), a minimal effect was 
observed on the shape of the C266S curves or binding coefficients with DP7 
(Figure 4.11d, Table 4.2). For binding to DP7, both WT and C266S had Hill 
coefficients less than 1 regardless of phosphate concentration, indicative of 
negative cooperativity (Table 4.2). Higher concentrations of phosphate reduced 
111 
 
the steepness of the C266S binding curves with glycogen and DP24 (Figure 
4.11d). Binding to DP24 went from positively cooperative in the absence of 
phosphate (h > 1) to negatively cooperative in the presence of 1 mM phosphate 
(h < 1) (Table 4.2). In contrast, binding to glycogen went from negatively 
cooperative in the absence of phosphate (h < 1) to positively cooperative in the 
presence of 1 mM phosphate, but the apparent Bmax was lowered (Table 4.2). It is 
important to note that although the steepness of the glycogen and DP24 binding 
curves for C266S changed with phosphate, the absolute maximum Tm reached at 
the highest glucan concentrations was the same for each substrate regardless of 
phosphate concentration (Figure 4.11c).  
The molar ratio of phosphate to C266S protein suggests that one C266S dimer 
scavenges only one phosphate molecule, i.e. one molecule in the dimer binds a 
phosphate (Figure 4.8b). The laforin C266S dimer could clearly bind to an 
additional phosphate, but the bound phosphate at one subunit appears to reduce 
the affinity of the other active site for phosphate (Figure 4.10a, Table 4.2). The 
data in Figure 4.11 indicate that both WT and C266S exhibit negatively 
cooperative binding to DP7 regardless of phosphate. This finding supports the 
preferential binding of laforin to long glucan substrates that many groups have 
observed in vitro and in vivo (181, 190, 314, 508). It is well established that glucan 
binding is mediated by the CBM. Therefore, it is likely that laforin is frequently 
"sampling" glucans for phosphorylation via both CBMs of the dimer. Binding of one 
site to short glucans such as DP7 reduces the affinity of the other site, so laforin 
is less likely to bind to other short glucans (Figure 4.12a). WT laforin also exhibits 
negative cooperativity in the presence of glycogen or DP24. The glycogen used in 
these assays is from rabbit liver. Liver glycogen contains little to no phosphate 
compared to muscle glycogen (163, 174, 211). DP24 also does not contain 
covalent phosphate. Therefore, binding of the laforin CBM to any non-
phosphorylated carbohydrate, short or long, reduces the affinity of the other 
subunit for that glucan (Figure 4.12b). 
In contrast, laforin C266S, which binds at least one phosphate at the active 
site, shows positive cooperativity toward long glucans. This result means that 
when the CBM of one phosphate-associated dimer associates with DP24, the 
affinity of the adjacent CBM for DP24 is enhanced (Figure 4.12c). However, if 
both of the active sites are occupied with phosphate, then binding of one CBM to 
DP24 prevents the association of the second CBM with glucan (Figure 4.12d). 
The binding of a phosphate-bound C266S DSP to long glucans may mimic the 
binding of WT laforin to long phosphoglucan. Therefore, these data suggest that 
laforin preferentially binds to long phosphorylated glucan substrates, but a single 
dimer prefers to dephosphorylate only one glucan at a time even if it is associated 
with two separate glucan chains. 
D/A and C/A mutants are commonly used for substrate trapping. In our case, 
however, laforin C266S demonstrates product-trapping properties. It was unclear 
to us whether phosphate-scavenging was unique to the C266S mutant or common 
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in other catalytically incompetent mutants. We therefore performed titrations of 
DP24 with the mutants D235A and C266A. While D235A produced a similar 
binding curve to WT laforin, C266A exhibited a large shift with high concentrations 
of DP24 and a high apparent Bmax (Figure 4.13a, Table 4.2). However, binding 
was still negatively cooperative (Table 4.2). None of the other catalytic mutants 
exhibited the large shift of C266S and C266A. We also generated double mutants 
and found that mutation of R272 in addition to C266 abolished this large ΔTm and 
prevented phosphate scavenging (Figure 4.12b,c). Mutation of both D235 and 
C266 were stabilizing, raising the baseline Tm to 53°C, but the Tm in the presence 
of DP24 was still 66°C, similar to C266S, and the protein still scavenged 
phosphate (Figure 4.13b,c). The double mutant C169A/C266S was destabilized 
like C169A, but still exhibited a large ΔTm with DP24, and the protein scavenged 
phosphate. These data indicate it is the association with phosphate that causes 
the very large shift in the presence of DP24. This further corroborates the 
hypothesis that laforin preferentially binds long glucans that are phosphorylated.  
To determine how the association of phosphate impacts protein dynamics, we 
performed hydrogen deuterium exchange (DXMS) experiments on laforin C266S 
versus WT laforin. Interestingly, most peptides in C266S exhibited significantly 
less deuteration, indicating they were less solvent accessible (Figure 4.14a). A 
few peptides exhibited slightly increased deuteration in C266S compared to WT 
laforin (Figure 4.14a). The peptide containing C266S (257-275) was not identified 
due to the presence of the mutation. Peptides that were significantly less 
deuterated were part of the D-loop, R-motif and recognition domain (Figure 
4.14b). These data suggest the regions framing the active site have closed in over 
the bound phosphate in C266S. We also performed DXMS experiments on WT 
and C266S in the presence of glycogen. The maximum percent change upon 
binding with glycogen was determined for each protein, and they were graphed 
together for comparison (Figure 4.14c). Interestingly, both WT and C266S 
exhibited similar changes in deuteration upon binding in the CBM. However, 
peptides in the DSP domain of WT and C266S laforin exhibited distinctly different 
deuteration changes. Multiple peptides in WT exhibited a major change in 
deuteration, particularly in the recognition domain and a peptide between the PTP-
loop and R-motif (Figure 4.14c). However, C266S did not exhibit such large 
changes in deuteration in these regions, again suggesting that it is already in a 
more compact conformation (Figure 4.14c). In C266S, the DSP domain appears 
to undergo significantly less conformational change in the DSP domain than in WT 
laforin upon glycogen binding (Figure 4.14d).  
Furthermore, AUC experiments on WT and C266S show that WT produces a 
broader peak than C266S and a very minor monomeric fraction (Figure 4.14e). 
These data also indicate that WT and C266S laforin are conformationally distinct. 
These results also suggest that the dissociation constant for dimerization is lower 
in C266S compared to WT laforin, i.e. the C266S mutation produces a stronger 
dimerization interaction.  
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Cumulatively, these data suggest that the C266S mutation induces a significant 
conformational change in laforin that changes the way that it binds to glucans and 
phosphate. This conformational change is likely to also alter the ability of laforin  
to interact with other proteins. Malin is an E3 ubiquitin ligase that binds laforin, and 
some results suggest that a malin-laforin complex then ubiquitinates other proteins 
(175, 176, 188, 310). The malin-laforin complex has been shown to ubiquitinate 
enzymes involved in glycogen metabolism including glycogen synthase, glycogen 
debranching enzyme, and Protein Targeting to Glycogen (PTG), an indirect 
activator of glycogen synthesis. Malin deficiency also causes LD so it has been 
hypothesized that the common functions of the malin-laforin complex are more 
relevant to LD instead of the laforin glycogen phosphatase activity (159, 188). This 
hypothesis is supported by the finding that overexpression of laforin C266S in 
laforin-deficient mice rescues the LD phenotype (159, 189). However, it is possible 
that laforin C266S rescues the LD phenotype due to the preservation (or increase) 
of laforin C266S binding to malin, overcoming the lack of catalytic activity.  
To assess this hypothesis, we tested how the multiple laforin catalytic mutants 
affected the interaction of laforin with its binding partners, malin and PTG using a 
directed yeast two-hybrid assay. Laforin C266S enhanced both interactions by 
nearly two-fold (Figure 4.14f). In contrast, C266A and R272A reduced the PTG 
interaction by 35-62% and nearly abolished the interaction with malin. D235A 
minimally affected the malin interaction but reduced the PTG interaction by 63%. 
Since C266A and C266S do not have the same effects, it is not the bound 
phosphate that enhances laforin interaction with malin and PTG. Both C266A and 
C266S associate with phosphate and display high-affinity binding to long 
oligosaccharides (Figure 4.13). However, only C266S exhibits positive 
cooperativity, not C266A (Table 4.2). Furthermore, only C266S enhances the 
interaction of laforin with malin and PTG (Figure 4.14f). In contrast, laforin C266A, 
has a reduced Tm (Figure 4.2b), and fully or nearly abolishes the interaction of 
laforin with its protein substrates (Figure 4.14f). Therefore, it is likely that the 
conformation and positive cooperativity exhibited by C266S are linked to the 
enhanced interaction with laforin binding partners. These data demonstrate that 
laforin C266S possesses unique biophysical properties that enhance its binding 
to malin and PTG and suggest an alternative explanation for how laforin C266S 
rescues the LD phenotype in mice that are lacking laforin. 
4.3 Discussion  
 The protein phosphatases are classified into completely separate superfamilies 
that independently evolved from distinct ancestral folds (546). The Cx5R active 
site motif is unique to the PTP superfamily (532). Alternatively, serine/threonine 
phosphatases utilize an entirely different catalytic domain that coordinates metal 
ions (547). The motifs utilized by the serine/threonine phosphatases involve 
multiple histidine residues and aspartic acid residues which vary by family. In 
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contrast, the haloacid dehalogenase phosphatase superfamily is characterized by 
a Rossmann-like fold, magnesium dependence and the active site sequence 
DxDx(V/T) (548). Herein, we show that laforin has only a single catalytic triad that 
adheres to the classic Cx5R motif of the PTP family. We define the unique 
architecture of the laforin active site in the context of the glucan phosphatase 
family. We show that laforin forms a DSP-DSP dimer interface and that residues 
at this interface contribute to the allostery between subunits and cooperative 
binding. Finally, we show that the laforin C266S mutant scavenges phosphate, 
exhibits unique binding properties and dynamics, and enhances the interaction of 
laforin with its protein substrates.  
The PTP consensus motif is comprised of a D/C/R triad where the aspartic acid 
is 30 residues upstream from the Cx5R active site (549). The proposed second 
triad is comprised of a cysteine and arginine that are only 1 residue apart and an 
aspartic acid 26 residues downstream from the arginine. It is evolutionarily unlikely 
that laforin would contain a second active site that does not adhere to the extended 
PTP consensus motif. Furthermore, catalysis is structurally implausible since the 
aspartate of the proposed non-classic triad is part of an α-helix instead of a flexible 
loop, and these residues do not reside in a positively charged pocket (Chapter 3). 
Finally, our experimental evidence demonstrates that mutation of any of the 
primary triad residues, D235, C266 or R272, completely ablates catalytic activity, 
while mutation of residues of the second triad does not (Figure 4.2). These data 
demonstrate that the laforin C266S protein does not maintain residual activity. 
Data from both crystal structures supports a DSP-DSP interface (Figure 4.1), the 
purified CBM does not dimerize (Figure 4.5), and mutations of residues at the 
DSP-DSP interface residues alter dimer-dependent cooperativity (Figure 4.6) 
(190).  
 The laforin active site shares similarity with other members of the glucan 
phosphatase family, but it also differs in multiple ways. Like SEX4 and LSF2, a 
conserved tryptophan in the recognition domain (laforin Y146) is critical for the 
glucan phosphatase activity of laforin (Figure 4.3, 4.4). Indeed, the laforin 
recognition domain is essential for activity, since laforin T142A and the purified 
DSP domain lacking the recognition domain both lack phosphatase activity 
(Figure 4.4, Chapter 3) (454). Additionally, laforin contains an aromatic residue 
within the R-motif that interacts with glucan, similar to SEX4 (Figure 4.3). 
However, unlike SEX4, laforin does not exhibit a preference for the C3 or C6 
position and mutation of this residue does not change specificity (Figure 4.4e) 
(184, 207). Interestingly, the glucans at the laforin active site interact with the V-
loop residues W196 and D197, but W196 is not essential for activity like the V-
loop aromatics of SEX4 and LSF2. Furthermore, the D-loop residue is a 
methionine (M239) in laforin rather than a phenylalanine. Both the shape and 
hydrophobicity of M239 are required for maximal activity (Figure 4.4d,e). The 
glucan is set further back in the laforin active site compared to SEX4 and LSF2, 
so the methionine may position the glucan more deeply in the catalytic pocket. 
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 Strikingly, laforin C266S scavenges phosphate from its E. coli host while WT 
laforin and other catalytic mutants do not, and this requires coordination by R272 
(Figure 4.8, 4.13c). Among the PTPs, C/S and D/A mutants are often used for 
substrate trapping (538, 539, 550). Although to our knowledge phosphate 
scavenging by other PTPs has not received significant attention, the combination 
of the scavenged phosphate with laforin's preferred substrate (long glucans) at the 
active site may mimic substrate-trapping by laforin C266S. It is not yet clear 
whether phosphate scavenging is unique to laforin or common among the glucan 
phosphatases. Despite the general assumption that substrate-trapping mutants 
retain the same structural and binding properties as their wild-type counterparts, 
conformational and dynamic differences in such mutants have been reported for 
other PTPs. The conformation of the PTP-loop in the apo structure of the PTP1B 
C/S mutant is dramatically different than in the apo structure of the WT enzyme 
(550). However, in the ligand-bound PTP1B WT and C/S structures, the PTP-
loops adopt the same conformation. In WT PTP1B, the active site cysteine exists 
in a thiolate form, so the lack of charge in the C/S mutant could account for this 
conformational difference in the apo structure. The importance of a negative 
charge is supported by studies of a C/D mutant that possesses a PTP-loop 
conformation similar to the WT enzyme, but with a much lower catalytic turnover 
number (551). Although we observed conformational differences between the 
PTP-loops of the isolated DSP domain and full-length protein, this was likely not 
due to charge differences since both structures had the C266S mutation and a 
bound oxyanion (Figure 4.1). Instead, the difference may be due to the presence 
of the recognition domain and/or binding to a glucan, which likely pushes the 
oxyanion further into the active site. 
 The movement of the D-loop is also quite different in C/S mutants of other 
PTPs. Studies have shown that the D-loop of WT PTP1B, YopH and SHP2 
fluctuates between open and closed configurations, although the molecular details 
of this motion vary between enzymes (552-556). DXMS experiments on PTP1B 
show that the D-loop is less solvent accessible in the C/S mutant than in WT (550). 
The reduced solvent accessibility is likely due to locking of the D-loop in the open 
configuration, since closure would be sterically blocked by the altered PTP-loop. 
The C/S mutant of YopH also displayed reduced solvent accessibility of the D-
loop (557). However, molecular dynamics simulations showed that the YopH C/S 
mutant spends more time in the closed conformation than the WT enzyme, which 
favors an open configuration, consistent with spectroscopic data (552).  
 The laforin DXMS studies demonstrate that laforin C266S also has reduced 
solvent exposure in the D-loop (Figure 4.14a,b). Upon binding to glycogen, the 
D-loop of WT and C266S exhibit an identical increase in deuteration (Figure 
4.14c). This result suggests that both enzymes favor the open configuration and 
that the change in deuteration upon glycogen binding is induced by D-loop closure. 
The DSP-DSP dimer interface increases by over 100 Å when the D-loop is open 
(Table 4.1, Figure 4.6). The AUC results suggest higher affinity at the dimer 
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interface of C266S than in WT laforin (Figure 4.14e). Therefore, like PTP1B, the 
laforin C266S D-loop may be locked in the open configuration, which increases 
interfacial surface area. Only upon glucan binding would it close, as in the crystal 
structure. 
Interestingly, laforin WT and C266S exhibit nearly identical deuteration 
changes in the CBM region upon binding to glycogen (Figure 4.14c,d). In contrast, 
there are major differences in the binding-induced deuteration changes in the DSP 
domains. Some of the regions in the DSP domain of glucan-free laforin C266S are 
much less solvent-exposed than in the WT enzyme; upon glucan binding, these 
regions also exhibit a smaller change in deuteration (Figure 4.14a-d). These data 
suggest that laforin C266S favors a conformation that, for the WT protein, is only 
induced by carbohydrate binding. Furthermore, the effect observed in the DSP 
must be allosteric since there is abundant evidence that glucan binding is 
mediated exclusively by the CBM (Chapter 3) (190, 285). These results are 
particularly profound because laforin C266S is also the only catalytic mutant found 
to enhance the interaction of laforin with malin and PTG (Figure 4.14f). Laforin 
C266S also interacts more strongly with other binding partners such as pyruvate 
kinase by yeast two-hybrid assay (524). Therefore, it is likely that the 
conformational rigidity induced by glucan binding also enhances laforin's function 
as a scaffold. Thus, laforin is more likely to bind to malin and PTG when it is 
associated with a glycogen molecule.  
The effects of phosphate on cooperative binding by C266S are difficult to fully 
interpret. This phenomenon calls for further investigations using additional 
techniques. However, allosteric effects on phosphatase activity induced by glucan 
binding have been previously reported. While glucans inhibit the generic 
phosphatase activity of laforin (where para-nitrophenylphosphate is used as 
substrate), laforin W32G, a mutation with abolished glucan binding, does not 
display this inhibition (508). The positive cooperativity of C266S binding to DP24 
when it is associated with only one phosphate molecule suggests the laforin dimer 
may have a dual function: while one subunit dephosphorylates, the other subunit 
recruits malin and/or other proteins. This hypothesis leads to a very reasonable 
model: when laforin binds a long, phosphorylated glucan, in the process of 
dephosphorylating this glucan it also recruits malin and other proteins such as 
glycogen synthase and PTG. Ubiquitination of glycogen synthase and PTG by the 
laforin-malin complex may lead to slowing of glycogen synthesis and/or allow for 
remodeling by glycogen branching enzyme. Indeed, glycogen remodeling 
following exhaustive exercise is delayed in laforin-deficient mice, suggesting 
laforin plays an integral role in the remodeling process (160).  
Some have suggested that the glycogen phosphatase activity of laforin is 
irrelevant to LD. This hypothesis is flawed based on previously published work 
and data presented here. First, glucan phosphorylation is ubiquitous among the 
plant and animal kingdoms (139). Plants, algae and higher eukaryotes all possess 
glucan phosphatases, and although the source of glycogen phosphate has not 
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been identified in mammals, glucan dikinases have been identified in plants and 
algae. Secondly, glucan phosphorylation is essential for proper synthesis and 
degradation of plant and algal starch (139). Phosphate disrupts the formation of 
glucan α-helices by inducing steric hindrance (193). Cycles of phosphorylation and 
dephosphorylation are necessary for solubilizing the crystalline starch surface so 
that it can be broken down by plant amylases. It is possible – even likely – that in 
mammals, phosphate is also introduced (by an unidentified kinase) to prevent α-
helix formation. This event may be especially important during glycogen super-
compensation, when glycogen levels exceed basal levels upon refeeding after 
hypoglycemia or exercise (368-370). During this period of rapid re-synthesis, 
glycogen contains longer chains that at resting state (135, 160). The longer chains 
result because glycogen synthase extends glucan chains faster than glycogen 
branching enzyme can remodel them. Phosphate may be introduced during this 
super-compensation stage to prevent α-helices from forming and prevent 
glycogen from precipitating. Phosphates could then be removed upon glycogen 
remodeling; this may be the dual role facilitated by laforin. Furthermore, the 
catalytic residues of laforin are highly conserved among the higher vertebrates. If 
laforin's only role was to act as a scaffold, it would likely be a pseudophosphatase 
with the vestige of a PTP motif rather than an active phosphatase. Indeed, multiple 
members of the PTP family are pseudophosphatases, such as Styx, the Leukocyte 
common antigen-related (LAR) receptor PTP, and 6 out of the 14 known members 
of  the myotubularin family (532). Finally, even in malin-deficient mouse models 
when laforin is fully functional, glycogen is both hyperphosphorylated and 
abnormally branched. These results suggest that hyperphosphorylation and 
abnormal branching are correlated and are likely functionally related. 
Glycogen degradation can proceed via two pathways: the major pathway is via 
cytosolic glycogenolysis facilitated by glycogen phosphorylase, and the second 
pathway is via lysosomal hydrolysis facilitated by acid α-glucosidase (Chapter 1). 
Laforin is a cytosolic protein that dephosphorylates glucans in vitro and 
dephosphorylates muscle glycogen during exercise-induced glycogenolysis (160, 
173, 174, 184). Laforin also interacts with other enzymes of the cytosolic glycogen 
synthesis and degradation pathways: malin, PTG, glycogen synthase, and 
glycogen debranching enzyme. The laforin-malin complex may promote glycogen 
remodeling by ubiquitinating these enzymes (188). However, defective autophagic 
flux is a recurring theme in LD and recent studies point to a role of laforin and 
malin in glycophagy (179, 182, 291, 312). Malin incorporates K63-linked ubiquitin 
into its substrates, which is linked to autophagy rather than proteasomal 
degradation (303, 306). Furthermore, in cell culture, laforin and malin form a 
complex with the autophagy-related protein p62 (307). p62 is binds to polyubiquitin 
moieties via its ubiquitin-associated (UBA) domain and interacts directly with LC3 
(558, 559). Additionally, malin was shown to ubiquitinate p62 in a laforin-
dependent manner, and p62 enhanced laforin ubiquitination by malin (307). 
Furthermore, p62 expression induced the colocalization of malin and laforin with 
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the autophagosome marker LC3. These data strongly suggest that laforin and 
malin are involved in the selective autophagic degradation of glycogen via the 
lysosome. Hyperphosphorylated, aberrantly branched glycogen molecules may 
be shunted toward the glycophagy pathway when they become too precipitation-
prone for the cytosol.  
Laforin is therefore likely to have multiple roles related to both cytosolic 
glycogenolysis and lysosomal glycophagy (Figure 4.15). In the cytosol, laforin is 
likely to both dephosphorylate glycogen and form a ubiquitin complex with malin. 
Glycogen synthase (GS), glycogen phosphorylase, PTG, debranching enzyme 
and branching enzyme are all cytosolic enzymes. Laforin and malin may form a 
complex and ubiquitinate some or all of these enzymes, leading indirectly to 
glycogen remodeling by changing the ratio of the activities of these enzymes. 
Although laforin C266S does not have phosphatase activity, it can still interact with 
malin to form a ubiquitination complex (Figure 4.15). In fact, this interaction is 
actually enhanced by C266S (Figure 4.15). When glycogen molecules escape 
this cytosolic remodeling and become hyperphosphorylated and precipitation-
prone, they may be targeted for glycophagy by laforin and malin. Laforin 
preferentially binds to substrates with longer chains, and this is particularly evident 
for laforin C266S (Figure 4.11, 4.12). The laforin-malin complex may promote the 
ubiquitination of p62, which also interacts with ubiquitin moieties on laforin 
introduced by malin (Figure 4.15). This would promote the assembly of LC3 and 
the autophagy machinery around the aberrant glycogen molecule. This molecule 
would then be deposited in the lysosome where it is degraded at low pH by acid 
-glucosidase (GAA) (Figure 4.15).  
While Laforin C266S is catalytically inactive, our data demonstrate that it 
possesses an enhanced ability to interact with laforin binding partners. This 
enhanced interaction may rescue the LD phenotype in mice overexpressing laforin 
C266S due to its ability to bind carbohydrates and form a ubiquitination complex 
with malin. This ubiquitination complex may still promote glycogen remodeling in 
the cytosol and/or facilitate the recruitment of autophagic machinery for lysosomal 
glycogen degradation. 
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Table 4.1  Comparison of DSP molecules and interfaces in 4R30 and 4RKK. 
Structural comparisons between DSP domains (amino acids 153-329) in each 
PDB file were determined using the DALI server (467). Residues not common to 
both structures were excluded from the comparison. Interfacial atoms, residues 
and surface area were determined using PDBePISA (464). 
 
Structural comparison of DSP domains 
Analysis of major intermolecular 
interfaces 
PDB 4R30 4RKK  Interface 
4R30A: 
4R30C 
4R30B: 
4R30D 
4RKKA: 
4RKKC 
Chain A B C D A C  Chain A B A 
4
R
3
0
 
 
A 37 0.2 0.2 0.1 1.7 1.7 R
M
S
D
 (Å
) 
Atoms 116 117 90 
B 36 37 0.1 0.2 1.7 1.8 Residues 32 31 27 
C 35 35 37 0.2 1.8 1.8 Chain B D C 
D 35 35 35 37 1.7 1.8 Atoms 119 115 93 
4
R
K
K
  A 27 27 27 27 37 0.1 Residues 32 32 28 
C 27 27 27 27 36 37  Area (Å2) 1100.6 1084.5 879.95 
  DALI Z-score      
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Table 4.2 Apparent binding coefficients from DSF titration experiments with 
various substrates. 
Binding coefficients were determined using the Prism software (Graphpad). Units 
for Bmax are °C. Units for Kd are mM for phosphate, DP7 and DP24; for glycogen, 
Kd units are mg/ml. 
 
Figure Protein Substrate Phosphate Bmax  Hill 
coefficient 
Kd 
4.6e WT DP24 0 mM 9.863 0.4966 0.4828  
I229A DP24 0 mM 6.237 0.9339 0.01829 
 
L251A DP24 0 mM 8.926 0.5945 0.09913 
 
F321A DP24 0 mM 9.45 0.608 0.1357 
4.6f C266S DP24 0 mM 15.83 1.744 0.09227 
 
F321C DP24 0 mM 7.082 0.6101 0.0713 
4.10a C266S Phosphate varied 9.459 0.4905 0.05471 
4.11a,b WT DP7 0 mM 11.79 0.6406 14.71 
  
DP7 0.1 mM 13.23 0.5884 21.41 
  
DP7 1 mM 15.46 0.5322 35.31   
Glycogen 0 mM 5.407 0.9633 0.6001 
  
Glycogen 0.1 mM 6.055 0.7914 0.7724 
  
Glycogen 1 mM 7.01 0.6111 1.05   
DP24 0 mM 9.182 0.4946 0.4092 
  
DP24 0.1 mM 9.73 0.4754 0.5048 
  
DP24 1 mM 9.872 0.4787 0.4927 
4.11c,d C266S DP7 0 mM 11.23 0.6362 9.942 
  
DP7 0.1 mM 9.343 0.6267 15.58   
DP7 1 mM 12.72 0.5107 63.78 
  
Glycogen 0 mM 16.51 0.7495 2.951 
  
Glycogen 0.1 mM 10.42 0.776 6.004   
Glycogen 1 mM 2.861 1.53 1.247 
  
DP24 0 mM 17.8 1.335 0.04648 
  
DP24 0.1 mM 13.37 0.993 0.3474   
DP24 1 mM 18.84 0.5556 5.486 
4.13a WT DP24 0 mM 9.669 0.4993 0.5124 
 
C266S DP24 0 mM 15.32 1.293 0.0653  
C266A DP24 0 mM 17.56 0.6763 0.07973 
 
D235A DP24 0 mM 15.44 0.4026 1.308 
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Figure 4.1 Comparison of glucan-free DSP domain (PDB: 4R30) and glucan-
bound full-length laforin (PDB: 4RKK) structures. 
 (a) The four molecules in the asymmetric unit of the 4R30 crystal structure 
(amino acids 153-331) colored by chain. Sulfate is shown as yellow spheres. (b) 
The two molecules in the asymmetric unit of the 4RKK crystal structure (amino 
acids 1-329) colored by chain and domain. Phosphate is shown as orange 
spheres. Chain B consists of bound glucans. (c) Superimposed DSP domains 
forming the common interface between 4R30 and 4RKK. (d) Superimposed 
single DSP domains of 4R30 and 4RKK. DSP motifs are labeled. (e) Glucan at 
the active site in 4RKK. (f) Residues of the classic catalytic triad and the second 
triad proposed by Sankhala et al. in 4R30 and 4RKK. The difference in position 
of D235 between the two structures is shown. In (d, e, and f), phosphate and 
sulfate are shown in orange and yellow, respectively.  
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Figure 4.2 Characterization of putative and proposed catalytic residues at 
the laforin active site.  
(a) 5-10 μg of purified proteins were analyzed via SDS-polyacrylamide gel 
electrophoresis (PAGE). Protein was visualized by staining with Coomassie blue. 
(b) Mutant stability and binding to short glucans (DP7) determined via differential 
scanning fluorimetry (DSF). (c) C3- and C6-phosphate released from radiolabeled 
starch. Average of triplicate reactions ± SD are shown in (b,c).  
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Figure 4.3 Sequence and structural comparison of DSPs in the glucan 
phosphatase family. 
(a) Alignment of the DSPs of the glucan phosphatase family. DSP motifs and key 
residues are labeled. (b) Ligplot+ generated representation of hydrophobic and 
hydrophilic protein-glucan interactions at the CBM and active site in the glucan 
phosphatases (466). Maltohexaose is shown in green and hydrogen bonds are 
shown in black. Glucose moieties are numbered from the non-reducing end to the 
reducing end, which are indicated. Invariant CBM residues, DSP motifs and their 
corresponding key residues are highlighted.  
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Figure 4.4 Contributions of active site residues to laforin stability, binding 
and activity.  
(a) Stick representation of residues interacting with glucan at the laforin active site 
(PDB: 4RKK). (a) 10-20 μg of purified proteins were analyzed via SDS-PAGE with 
Coomassie staining. (c) Mutant stability and binding to short glucan (DP7). (d) 
Glycogen phosphatase activity of active site mutants. (e) C3- and C6-
dephosphorylation of radiolabeled starch by active site mutants. In (c, d and e), 
the average of triplicate reactions ± SD are shown. 
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Figure 4.5 Oligomeric state of the laforin CBM.  
(A) C(S) and (B) c(M) plots from AUC experiments on the purified laforin CBM. 
Mapp indicates apparent molecular weight.  
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Figure 4.6 Residues of the DSP-DSP dimer interface contribute to 
cooperativity.  
(a) Comparison of the dimer interface in 4R30, where the D loop is open, and 
4RKK, where the D loop is closed. (b) Purity of dimer mutants determined by SDS-
PAGE and Coomassie staining. (c) Stability and binding to DP7 determined by 
DSF. (d) C6-P, C3-P and glycogen dephosphorylation relative to WT laforin. (e,f) 
Effects of dimer mutants on binding to DP24 compared to WT and C266S. (g) 
Oligomerization of laforin dimer mutants determined by native PAGE. (h) 
Sedimentation coefficient of dimer mutants compared to WT laforin. In (e, f, c, and 
d), the average of triplicate reactions ± SD are shown.  
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Figure 4.7 Comparison of WT and C266S binding to glucans.  
DSF titration experiments were performed with (A) DP7 and (B) glycogen. Average 
of triplicate reactions ± SD are shown.
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Figure 4.8 C266S laforin scavenges phosphate from E. coli.  
(a) Visualization of phosphate in the soluble and insoluble protein fractions after 
the addition of malachite green reagent. (b) Quantification of phosphate in WT 
laforin and mutants. (c) Protein purity during C266S purification determined by 
SDS PAGE with Coomassie staining. (d) Visualization and quantification of 
phosphate during control and stripped purifications of C266S laforin from E. coli. 
Flow through (FT) and elution (E) are from the immobilized nickel affinity 
chromatography step. Average of triplicate reactions ± SD are shown. 
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Figure 4.9 Effects of sugars and phosphate binders on C266S phosphate.  
(a) Phosphate content of 100 μg C266S after 1 hour incubation with various sugars 
and PiBind resin. Blank controls were included to check for phosphate 
contamination. (b) Phosphate content of 100 μg C266S after dialysis with PiBind 
and phosphate binders. 
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Figure 4.10 WT and C266S binding to phosphate and γ-cyclodextrin (γCD).  
(a) WT and C266S phosphate binding curves determined by DSF. (b) WT and 
C266S binding to 50 mM γCD with various concentrations of phosphate. Data from 
(b) are shown as black dots in (b) for reference. Averages of triplicate reactions ± 
SD are shown. 
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Figure 4.11 The effect of phosphate on WT and C266S binding to various 
carbohydrates.  
(a) Absolute Tm and (b) ΔTm of WT binding to DP7, glycogen and DP24 with 
increasing phosphate. (c) Absolute Tm and (d) ΔTm of C266S binding with 
increasing phosphate. Averages of triplicate reactions ± SD are shown. 
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Figure 4.12 Model of phosphate-induced cooperativity switch.  
(a) Binding of DP7 to a CBM of WT (or C266S) laforin reduces the affinity of the 
adjacent CBM for glucan. (b) Binding of DP24 to WT reduces the affinity of the 
adjacent CBM for DP24. (c) Binding of DP24 to the CBM of C266S associated 
with a single phosphate enhances the binding of the adjacent CBM to DP24. (d) 
Binding of DP24 to the CBM of C266S associated with two phosphates prevents 
the binding of the adjacent CBM to glucan. Regions involved in glucan binding are 
based on the location of maltohexaose molecules in the crystal structure and 
previous DXMS experiments with glycogen (190).   
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Figure 4.13 Glucan binding and phosphate scavenging of catalytic mutants.  
(a) DP24 titration with catalytic mutants. (b) Stability and binding of catalytic 
mutants to DP7 and DP24. (c) Phosphate scavenging of catalytic mutants 
determined by malachite green assay. In (a, b), averages of triplicate reactions ± 
SD are shown. 
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Figure 4.14 C266S is conformationally distinct from WT laforin and 
interacts more strongly with malin and PTG. 
(a) Maximal percent change in deuteration of amino acids in WT laforin versus 
C266S. Negative change indicates decreased deuteration in C266S compared to 
WT. (b) Peptides with significantly decreased deuteration in C266S were mapped 
onto one subunit of the laforin crystal structure (4RKK). (c) Maximal percent 
change in deuteration upon WT and C266S binding to glycogen. Negative change 
indicates decreased deuteration in the presence of glycogen. Peptides with a 
significantly different deuteration change in WT binding to glycogen compared to 
C266S are indicated with asterisks: * indicates a difference of >10%; ** indicates 
a difference of >30%. (d) Peptides with a significant difference in deuteration 
change upon glycogen binding mapped onto the crystal structure (4RKK). In (b) 
and (d), the missing peptide is labeled in red. (e) C(S) plots from AUC experiments; 
both WT and C266S were run at ~0.3 mg/ml (OD ~0.5). (f) Binding of catalytic 
mutants to malin and PTG by yeast two-hybrid assay. Averages of triplicate 
reactions ± SD are shown. 
  
135 
 
 
Figure 4.15 A model for C266S-mediated rescue of laforin deficiency in LD.  
Modified from the schematic proposed by Irimia et al. (160) based on recent data 
from our group and others. C266S laforin ablates phosphatase activity but 
enhances the laforin-malin interaction and interaction with other proteins. 
  
 
 
 TARGETING PATHOGENIC LAFORA BODIES IN LAFORA 
DISEASE USING AN ANTIBODY-ENZYME FUSION 
5.1 Introduction  
The progressive myoclonic epilepsies (PMEs) are a group of inherited 
disorders characterized by recurrent seizures, myoclonus, and progressive 
neurological decline. There are currently no treatments for PMEs, and anti-
epilepsy drugs are palliative at best (560). Lafora disease (LD; epilepsy, 
progressive myoclonus type 2, EPM2) is a severe form of PME that typically 
manifests with tonic-clonic seizures and myoclonic jerks in the early teen years 
followed by rapid neurological deterioration, increasingly severe and frequent 
epileptic episodes, dementia and death within ten years of onset (OMIM: 254780). 
LD is caused by mutations in the EPM2A or EPM2B genes that encode laforin, a 
glycogen phosphatase, and malin, an E3 ubiquitin ligase that ubiquitinates 
enzymes involved in glycogen metabolism (reviewed in (167)). LD is 
distinguishable from other PMEs by the presence of cytosolic polysaccharide 
inclusions known as Lafora bodies (LBs) most notably in the brain, where they are 
found in neuronal cell bodies and dendrites and astrocytic processes, and in other 
tissues such as muscle, heart, and liver (322, 324, 325). Among the PMEs LD is 
uniquely considered a non-classical glycogen storage disease (GSD) (165, 166). 
Independent studies from multiple groups demonstrate that Epm2a-/- and Epm2b-
/- mice recapitulate disease symptoms with respect to LB formation, 
neurodegeneration, neurological impairments, and susceptibility to epilepsy (177-
181, 561, 562). 
LBs, which form in the absence of functional laforin or malin, are comprised of 
abnormal polysaccharide referred to as polyglucosan. The term polyglucosan 
refers to any glucose polymer that is abnormal, and other types of polyglucosan 
bodies have been described in some GSDs (79). Unlike glycogen, LBs are water-
insoluble, hyperphosphorylated, contain long glucose chains, and range in size 
from a few microns to up to 35 or 40 μm (158, 168, 169, 209). Dr. Gonzalo 
Rodriguez Lafora first described these inclusions in patient autopsies, noting their 
histochemical similarity to plant starch (321). Decades later Sakai and colleagues 
isolated these inclusions from patient tissue and showed that LBs are indeed 
structurally more similar to starch than to glycogen (168, 169). Plant starch and 
LBs both contain significantly more covalently bound phosphate and longer glucan 
chains than mammalian glycogen (168, 208, 210). Loss of laforin or malin function 
results in the transformation of glycogen molecules into hyperphosphorylated 
polyglucosan molecules with an altered chain length distribution, and these 
aberrant molecules, prone to precipitation, accumulate to form LBs (188). How 
laforin and malin prevent this process is still being defined.  
Results from multiple labs have established that accumulation of polyglucosan 
drives neurodegeneration in both LD and non-LD models. Glycogen synthase is 
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the only mammalian enzyme able to catalyze glucose polymerization in vivo. 
Epm2b-/- mice lacking glycogen synthase (Gys1) in the brain are devoid of 
cerebral glycogen and LBs, exhibit no neurodegeneration, have normal 
hippocampal electrophysiology, and do not display an increased susceptibility to 
kainate-induced epilepsy (182). A similar phenotypic rescue was observed when 
Gys1-/- mice were crossed with Epm2a-/- mice (293). Furthermore, Epm2b-/- mice 
lacking just one Gys1 allele in the brain have reduced glycogen and also show 
near complete rescue of these phenotypes (182). Epm2a-/- and Epm2b-/- mice 
lacking Protein Targeting to Glycogen (PTG), a protein that promotes glycogen 
synthesis, also exhibit reduced LB accumulation, and neurodegeneration and 
myoclonic epilepsy are resolved in these animals (293-295). These results 
demonstrate that decreased or complete absence of the glycogen synthesis 
machinery ablates LB formation, neurodegeneration, and epilepsy in LD mouse 
models. The reverse has also been observed: overexpression of a constitutively 
active form of glycogen synthase in otherwise wild type animals drives 
neurodegeneration in both flies and mice (563). The accumulating polysaccharide 
in transgenic animals overexpressing glycogen synthase is a polyglucosan (i.e. 
abnormal) rather than normal glycogen (261). Collectively, the aforementioned 
studies illustrate that cerebral LB accumulation is pathogenic. These studies have 
both elucidated the molecular etiology of LD and have made LBs an obvious 
therapeutic target (564).  
These studies have motivated ongoing efforts to develop a targeted therapy 
(i.e. precision medicine) for LD (565). One form of precision medicine that has 
been successful with GSDs is the introduction of exogenous replacement 
enzymes. Enzyme replacement therapy has proven effective for Pompe disease 
(OMIM: 232300), an inherited GSD (566). Pompe patients are deficient in the 
lysosomal enzyme that degrades glycogen, acid -glucosidase (GAA), and are 
currently treated with a recombinant human form of this protein known as rhGAA 
or alglucosidase alfa (Myozyme®, Lumizyme®, Genzyme) (566, 567). The uptake 
of rhGAA is a receptor-mediated endocytic process that targets rhGAA to the 
lysosome. However, there is a significant portion of cytosolic glycogen in Pompe 
patients, and since rhGAA only targets lysosomal glycogen, those with large pools 
of cytoplasmic glycogen do not respond well to the current therapy (568). In LD, 
LBs are entirely cytosolic. Histological studies from patient tissues report that LBs 
are not membrane bound, and this observation has been confirmed in mouse 
models (179, 452, 569, 570). Thus, a therapeutic enzyme degrading LBs must be 
delivered to the cytosol.  
Although cytosolic targets remain challenging for protein therapeutics, 
antibody-based delivery platforms provide a means for penetrating the cell 
membrane (reviewed in (571)). The monoclonal anti-DNA autoantibody 3E10 and 
its antigen-binding (Fab) and variable domain (Fv) fragments can be fused to an 
enzyme to facilitate cytosolic delivery in multiple cell types (572-574). This 
antibody-enzyme fusion (AEF) strategy has proven successful for the replacement 
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of a cytosolic enzyme and rescue of X-linked myotubular myopathy in mice (575). 
A Fab-GAA fusion has similar efficacy to reduce glycogen in Pompe mice with the 
additional advantage of targeting both lysosomal and cytosolic glycogen and is 
now in Phase 1/2 clinical trials (576, 577). Rather than utilizing the AEF platform 
to deliver a replacement enzyme, we generated an AEF designed to penetrate 
cells and degrade pathogenic LBs. Herein, we show that an AEF comprised of the 
humanized 3E10 Fab fragment and pancreatic α-amylase degrades LBs in vitro, 
degrades glycogen and polyglucosan in situ, and reduces LB load in vivo.  
5.2 Results  
5.2.1 Construction of an antibody-enzyme fusion (AEF) that degrades starch 
An important consideration in designing an LB-degrading enzyme is that LBs 
are less sensitive to enzymatic hydrolysis than normal glycogen. Resistance to 
digestion with diastase (a generic term for enzymes that degrade polysaccharides) 
is a defining feature of LBs and one factor that differentiates LBs from glycogen 
(570, 578). However, in routine histological preparations, embedded sections are 
only incubated with diastase for 15-30 minutes prior to staining. Early studies 
reported that LBs in tissue sections can be digested by a 5-10 hour incubation with 
pancreatic α-amylase and γ-amylase (i.e. amyloglucosidase), but they are 
somewhat resistant to digestion by β-amylase or glycogen phosphorylase (168, 
169, 579).  
 Glycogen, starch, and LBs are all polysaccharides with different properties. LBs 
are considered more similar to starch than glycogen due to their insolubility, 
elevated phosphate levels, and the increased chain length of their constituent 
glucose chains. We hypothesized that starch could serve as a proxy for LBs in a 
screen to identify a candidate therapeutic enzyme. We screened a panel of 
amylases to determine which possessed robust activity against starch, and 
therefore would likely degrade LBs. We found that only α-amylases showed 
significant activity, and pancreatic α-amylase had the highest capacity to degrade 
starch (Figure 5.1a). Pancreatic α-amylase is naturally secreted by the human 
pancreas for digestion of carbohydrates in the gut, cleaving α-1,4 linkages to yield 
maltose, maltotriose and low molecular weight oligosaccharides. It has previously 
been shown to digest LBs in tissue sections (579). Thus, pancreatic α-amylase is 
a putative candidate for degrading LBs.  
 An AEF designated VAL-0417 was generated by fusing the humanized 3E10 
IgG1 Fab heavy chain fragment with human pancreatic α-amylase and then 
coexpressed in HEK293-6E cells with the corresponding light chain as a secreted 
heterodimer (Figure 5.1b). The fusion was purified from HEK293-6E cell 
conditioned media by affinity chromatography, and the purity was determined by 
reducing and nonreducing SDS-PAGE (Figure 5.1c). The addition of β-
mercaptoethanol (BME) dissociated the heavy and light chains, producing two 
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distinct bands of 75 and 25 kDa; in the absence of BME a single 100 kDa band 
was observed, corresponding to the intact Fab-amylase fusion. The specific 
activity of an α-amylase can be tested using a substrate that consists of seven 
glucose moieties and a chromophoric para-nitrophenyl moiety that is capped with 
an ethylidine group to block the action of other hydrolytic enzymes (Figure 5.1d) 
(580). Using this substrate, the specific activity of VAL-0417 was determined to be 
10.5 units/mg.  
 VAL-0417 activity was then tested against plant starch. After a 2-hour 
incubation, VAL-0417 degraded starch in a dose-dependent manner: 5 μg of 
enzyme released 61 μg of soluble glucan product (Figure 5.1e). We employed 
scanning electron microscopy (SEM) to visualize the effects of degradation on the 
starch granules. In the absence of enzymes, starch granules had a smooth, 
polyhedral or subspherical appearance (Figure 5.1f). Overnight treatment with 
VAL-0417 produced cavities in the granule surface, representing areas of active 
hydrolysis, and numerous partially degraded granules were visible (Figure 5.1f). 
When the ratio of VAL-4017 to starch was reduced by 10-fold, amylolysis was less 
extensive: fewer partially degraded particles were visible and most granules were 
only decorated with small pits (Figure 5.2). Other groups have similarly observed 
"pitting" of starch granules with α-amylase and other amylolytic enzymes (581, 
582).  
 
5.2.2 Isolation and characterization of LBs from LD mice 
Polysaccharides (both glycogen and LBs) are typically purified from Epm2a-/- and 
Epm2b-/- mice based on a method described by Pflüger in 1909 where the tissue 
is heated in strong KOH and the glycogen is precipitated with alcohol (16, 583). 
The isolated particles are 15-65 nm in size when visualized by transmission 
electron microscopy (209), orders of magnitude smaller than the intact LBs 
observed in fixed tissue sections, and the method does not separate LBs from 
glycogen. It is well-established that heating changes the physiochemical 
properties of starch, leads to granule swelling, and enhances its sensitivity to 
enzymatic degradation (584). Therefore, it is likely that this protocol disrupts the 
native structure of LBs, intermixing the individual polyglucosan constituents of LBs 
with normal glycogen molecules. We developed a procedure for isolating pure and 
native LBs from tissue so that we could test the sensitivity of LBs to VAL-0417 
degradation. A study from the 1960s showed that native LBs could be isolated 
from patient brain tissue by centrifugation steps and successive treatments with 
proteolytic enzymes (169). We designed a similar method for isolating native LBs 
from the brain, heart and skeletal muscle of Epm2a-/- mice (Figure 5.3a, see 
Section 2.1.3). Our procedure separates soluble glycogen (present in the 
supernatant) from the insoluble LBs (Figure 5.4, see Section 2.1.5). Final LB 
yields from each tissue type corresponded to ~30% of the total polysaccharide 
detected in the original tissue homogenate (Figure 5.3b,c).  Phosphate content of 
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the final LBs from skeletal muscle was 5-fold higher than phosphate in normal 
muscle glycogen, which is in agreement with published results (Figure 5.3d) 
(209). Iodine spectral scans of the purified LBs were compared to those of 
commercial glycogen and amylopectin, the major component of plant starch to 
which LBs are most similar (Figure 5.3e). While glycogen has a peak maximum 
at ~440 nm when stained with Lugol's iodine, amylopectin has a right-shifted 
spectrum and a peak maximum at 560 nm due to its reduced branching (147). The 
spectra of the purified LBs were also shifted toward longer wavelengths, with peak 
maxima at 510-520 nm (Figure 5.3e). These data indicate that the purified LBs 
are less branched than glycogen, consistent with previous reports on Epm2a-/- 
and Epm2b-/- mice (180, 209).  
 Final LB preparations were also stained with Lugol's iodine and examined by 
light microscopy. Minimal tissue debris was observed and the LBs tended to clump 
(Figure 5.3f,g,h). LBs from different tissues also had noticeably distinct 
morphologies. Brain LBs were generally spherical, sub-spherical or irregularly 
shaped (Figure 5.3f), and a range of sizes were observed: the maximum diameter 
of a single LB ranged from 1-10 μm, most being 2-4 μm (Figure 5.4a). These 
preparations also had a significant amount of granular material that stained less 
intensely with iodine; small amounts of this material were visible throughout the 
slide, but appeared to form a large aggregate in some fields of view (Figure 5.4d). 
Similar PAS-positive granular material has been reported in fixed tissue sections 
from patient brain biopsies or LD mice, which are referred to as dust-like particles, 
or simply "dust" (326, 570, 585, 586).  
 Heart LBs were more often ellipsoid or ovoid in shape, frequently with pointed 
ends, although some were sub-spherical like the brain LBs (Figure 5.3g). Heart 
LBs also ranged in diameter/length from 1-10 μm, most of them being 2-4 μm 
(Figure 5.4b). Dust-like particles were also observed among the heart LBs, 
although no masses of granular material were observed as with the brain LBs 
(Figure 5.4e). LBs have been reported in LD patient cardiac tissue: in fixed and 
stained tissue sections, they are irregularly shaped or elongated with pointed ends 
(585, 587-589). Although these reports do not discuss dust-like particles in the 
heart, they appear to be present in the micrographs, particularly in the studies that 
involve immunostaining with an LB-specific antibody (587, 588). PAS-stained 
cardiac sections from malin KO mice show LBs of similar shape and size and 
diastase-resistant granular material (178, 179). LBs from skeletal muscle were the 
smallest and most homogenous in size and shape: the vast majority were ellipsoid 
and 1-3 μm long (Figures 3.3h, 3.4e). There appeared to be virtually no dust in 
these preparations. In LD patients, LBs are reported to similarly range in diameter 
from 0.2-2 μm in skeletal muscle (326).  
 We also utilized SEM to visualize the purified LBs. We found that washing LBs 
in ethanol and allowing them to dry in a vacuum concentrator, the method used 
for visualization of starch granules, caused the LBs to aggregate and form very 
large clumps after being applied to carbon tape (Figure 5.5). It was difficult to 
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distinguish individual LBs within the clumps against the similarly textured carbon 
tape. As an alternative drying method, LBs were diluted in water, applied to a 
mounted silicon wafer and lyophilized prior to visualization. This method proved 
satisfactory. Micrographs showed that LBs from all three tissues had a similarly 
textured appearance (Figure 5.6), in contrast to the smooth surface of starch 
(Figure 5.1f). As observed via light microscopy, individual brain LBs up to 10 μm 
in diameter were observed, which were spherical or irregularly shaped (Figure 
5.6a). Ovoid and ellipsoid LBs from heart and small ellipsoid LBs from skeletal 
muscle were also consistent with our light micrographic observations (Figure 
5.6b,c). Visualization of skeletal muscle LBs at very high magnification (30,000×) 
revealed the fine texture of the bodies (Figure 5.6d). 
 
5.2.3 Degradation of LBs by VAL-0417 
Native LBs purified from different tissues possess unique morphology. To 
determine if VAL-0417 could degrade the different types of LBs, we incubated 50 
μg of Epm2a-/- LBs from brain, heart and skeletal muscle with VAL-0417 and 
observed a consistent dose-response effect: 1 μg VAL-0417 released 6-9 μg of 
glucan into the soluble fraction, indicating 12-18% of the LBs had been degraded 
(Figure 5.7a). Increasing the dose to 10 μg of VAL-0417 released over twice as 
much, 15-19 μg of glucan, corresponding to 30-38% of the total substrate. A small 
amount of soluble glucan (5 μg or less) was observed in the untreated samples, 
so we visualized the soluble fractions of untreated and treated LBs by light 
microscopy. We observed some LB fragments in the soluble fraction of the 
untreated and treated brain LBs that did not sediment with centrifugation (Figure 
5.8). We have observed that harsh mechanical agitation in vitro causes LBs to 
fragment, so the occasional fragments found in the soluble fraction result from the 
mild agitation that is necessary to keep the LBs in suspension during incubation 
with VAL-0417.  
 We also purified LBs from skeletal muscle of 12-month-old Epm2b-/- mice and 
found they were indistinguishable from Epm2a-/- skeletal muscle LBs in 
appearance, size and iodine spectra (Figure 5.9). We observed a comparable 
dose-response effect of VAL-0417 on Epm2b-/- LBs: 1 μg and 10 μg VAL-0417 
released 16% and 32% of the total, respectively (Figure 5.10a). In a similar 
experiment, we incubated LBs with 10 μg VAL-0417 overnight and then visualized 
the product by staining the insoluble fraction with Lugol's iodine. Untreated LBs 
had no change in appearance and seemed fully intact after the overnight agitation, 
but VAL-0417 treatment led to fewer iodine-positive LBs and the appearance of a 
filamentous degradation product (Figure 5.10b).   
 Previous work has shown that various proteins are associated with LBs in vivo 
(179, 586). Our purification protocol removes these proteins, so it is possible that 
an intact protein coat could inhibit LB degradation by VAL-0417. To test this 
possibility, we measured LB load in crude muscle homogenates after incubation 
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with VAL-0417 using iodine absorbance. While virtually no absorbance was 
detected at 550nm in the WT samples with or without VAL-0417 treatment, 
treatment of the Epm2a-/- samples with VAL-0417 reduced iodine absorbance by 
>50%, indicating substantial LB degradation (Figure 5.10c).  
  Since VAL-0417 is a potential therapeutic, it is important to define the soluble 
product(s) it releases from LBs. Pancreatic α-amylase is reported to release 
glucose, maltose, maltotriose and other short oligosaccharides (590). Amylolytic 
products can be separated and quantified via high-performance anion-exchange 
chromatography coupled with pulsed amperometric detection (HPAEC-PAD). We 
digested LBs from Epm2a-/- skeletal muscle with VAL-0417 for a total of 168 hours 
with additional enzyme added every 24 hours. At 24-, 48- and 72-hour time points, 
the soluble fractions of LB digestions were removed for HPAEC-PAD analysis. At 
all 4 time points, maltose and glucose were the major degradation products, 
followed by small amounts of oligosaccharides with 3, 4, 5 and 6 degrees of 
polymerization (DP-3, 4, etc., where each DP corresponds to one glucose unit) 
(Figure 5.10d, 5.11). Quantitation of the glucose and maltose peaks showed that 
maltose levels remained constant throughout degradation and glucose levels 
increased steadily over the 168-hour experiment (Figure 5.10e). Cumulatively, 
these data demonstrate that VAL-0417 robustly digests brain, heart and muscle 
LBs in vitro. It is not inhibited by endogenous proteins in muscle homogenates, 
and its degradation products are primarily glucose and maltose, with a few short 
oligosaccharides. 
 
5.2.4 VAL-0417 uptake and polysaccharide degradation in situ  
To degrade LBs in vivo, VAL-0417 must penetrate and remain active inside 
cells. Cell penetration of the parent 3E10 mAb and its fragments require functional 
expression of the membrane equilibrative nucleoside transporter 2 (ENT2), which 
is involved in a nucleoside salvage pathway and is ubiquitously expressed in 
rodents and humans (591-593). VAL-0417 uptake and activity were assessed in 
two cell lines: fibroblast-derived Rat1 cells accumulating normal glycogen and 
HEK293 cells engineered to accumulate polyglucosan (HEK293-PTG/PP1Cα) 
(Figure 3.12; see Section 2.1.11). After a 20-hour treatment with increasing 
doses of VAL-0417, cells were washed, lysed, and probed for ENT2 and VAL-
0417. ENT2 protein levels were stable in both lines, though Rat1 cells have slightly 
higher levels, and were unchanged with increasing concentrations of VAL-0417 
(Figure 5.13a). Western analysis of VAL-0417 using an antibody for AMY2A 
revealed a dose-dependent increase in protein levels (Figure 5.13a). 
Polysaccharide per well (glycogen in Rat1 cells and polyglucosan in HEK293-
PTG/PP1Cα cells) in the treated cells was also measured. Both Rat1 and 
HEK293-PTG/PP1Cα lines displayed a dose-dependent decrease in total 
polysaccharide, reductions of 30% and 26% of the untreated control, respectively 
(Figure 5.13b). Thus, VAL-0417 is both taken up by cells and degrades glycogen 
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and polyglucosan in situ. 
 
5.2.5 In vivo uptake of VAL-0417 and LB reduction in Epm2a-/- mice 
We have shown that VAL-0417 degrades LBs in vitro, penetrates cultured cells, 
and degrades glycogen and polyglucosan in situ. We next tested VAL-0417 uptake 
in an in vivo setting and biodistribution after peripheral injections. We performed 
intramuscular (IM) injections of VAL-0417 to determine if it can be detected in the 
injected muscle and other tissues and if it is quickly degraded and/or cleared. We 
injected 0.6 mg VAL-0417 into the left gastrocnemius muscles of WT C57BL/6 
mice, then 2 and 24 hours post-injection, euthanized the mice and collected right 
and left gastrocnemii, right and left quadriceps, heart, liver, and brain. The same 
tissues were also collected 2 hours post-injection from control mice treated with 
phosphate-buffered saline (PBS). We designed a sandwich enzyme-linked 
immunosorbent assay (ELISA) to specifically detect VAL-0417 in tissue 
homogenates with very low background. At the 2-hour VAL-0417 post-injection 
time point, 3200 ng of VAL-0417 per mg protein (15% of the injected amount) was 
detected in the injected (left) gastrocnemius (Figure 5.14a). After 24 hours, VAL-
0417 levels dropped by 20-fold (to 151 ng per mg protein), 0.7% of the initial 
injected amount. At 2 hours, low levels of VAL-0417 (2-9 ng per mg protein, 0.02-
0.1% of the injected amount) were detected in the other muscles, heart, liver, and 
brain, indicating some VAL-0417 had entered circulation. After 24 hours, VAL-
0417 levels nearly returned to baseline in muscles, liver, and brain, but remained 
constant in the heart. Since blood circulates the entire body of a mouse within 
minutes, the very high levels of VAL-0417 in the injected muscle 2 and 24 hours 
post-injection strongly suggest that VAL-0417 is taken up by cells rather than 
being immediately cleared. The low levels of VAL-0417 in non-injected tissues 
indicates VAL-0417 entered the circulation. In mice, ENT2 expression levels are 
high in brain, muscle and heart, and low in liver (592). It is possible that these 
tissues took up a small amount of VAL-0417 from the circulation that was mostly 
cleared by 24 hours. ENT2 levels were probably not limiting since VAL-0417 levels 
were similar regardless of tissue differences in ENT2 expression. It is notable that 
VAL-0417 levels remained constant in heart even after 24 hours. 
 We next tested whether IM injections of VAL-0417 reduced polysaccharide 
levels in vivo in Epm2a-/- mice. To determine polysaccharide levels in individual 
muscles, we utilized the Pflüger method rather than our native LB protocol 
because the Pflüger method recovers ~100% of the polysaccharides, enables 
more accurate and sensitive measurements from small amounts of tissue, and 
yields both normal glycogen and LBs. 10-month-old WT and Epm2a-/- mice were 
injected in the right gastrocnemius with either 0.6 mg VAL-0417 or PBS. Three 
injections were performed over the course of one week, on days 1, 4, and 7, and 
on day 8 the mice were euthanized. The injected muscles were collected for total 
polysaccharide quantification. Polysaccharide levels in the WT mice were similar 
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regardless of treatment, and consistent with reported skeletal muscle glycogen 
levels for C57BL/6 mice (Figure 5.14b) (209). In Epm2a-/- animals, VAL-0417 
treatment reduced polysaccharide levels by 53% relative to the PBS-treated 
controls (Figure 5.14b). These data indicate that in vivo, VAL-0417 does not 
decrease normal glycogen levels, but degrades LBs in Epm2a-/- mice.  
 Intravenous (IV) injections are sometimes preferable to IM injections to achieve 
rapid and extensive bioavailability of the drug to various tissues, but the preferred 
route depends on the drug (594). We tested whether a high dose of VAL-0417 
administered intravenously could reduce LBs in the heart. Like skeletal muscle 
and brain, heart tissue has a very high LB load, and cardiac abnormalities have 
been reported in both LD mice and patients (595-597). Furthermore, our 
biodistribution experiment indicated there was less turnover of VAL-0417 in the 
heart compared to other tissues (Figure 5.14a). Four injections of either PBS or 
XX mg VAL-0417 were performed over the course of two weeks, on days 1, 5, 8 
and 13. The mice were euthanized on day 14, and hearts were removed and 
flushed with PBS. A small section of tissue was excised for fixation and periodic 
acid-Schiff (PAS) staining, and the remaining tissue was flash frozen and analyzed 
for polysaccharide content via the Pflüger method. 
 The glycogen content of the heart in WT animals is very low in comparison to 
skeletal muscle (598). We found that polysaccharide levels in PBS-treated WT 
animals were undetectable. Very low levels were detected in the WT animals 
treated with VAL-0417, which was not significantly different than the PBS-treated 
levels (Figure 5.14c). Since there was a delay prior to freezing the heart tissue in 
order to remove tissue for fixation, rapid post-mortem glycogen degradation may 
account for the absence of heart glycogen in the WT animals. In contrast, 
polysaccharide levels in the PBS-treated Epm2a-/- mice were very high in 
comparison to the WT animals and were reduced by 67% after the two-week 
treatment regimen with VAL-0417 (Figure 5.14c).   
 Results from the fixed, PAS-stained heart sections were consistent with 
quantification via the Pflüger method. PAS-positive deposits, i.e. LBs, were 
abundant in PBS-treated Epm2a-/- tissue (Figure 5.14d). Epm2a-/- tissues 
treated with VAL-0417 showed a marked reduction in LBs (Figure 5.14d). No LBs 
were observed in WT tissues regardless of treatment (Figure 5.14e). HALO image 
analysis software was used to quantify the staining results. Similar to the 
biochemical analysis, we observed a 63% reduction in the average staining 
intensity of PAS-positive deposits in Epm2a-/- tissue with VAL-0417 treatment 
(Figure 5.14f). WT animals displayed undetectable levels, consistent with the 
biochemical results (Figure 5.14f). Since LBs in the Epm2a-/- mice are cytosolic, 
these data indicate that after IM or IV injection, VAL-0417 penetrates cells, 
remains active, and degrades LBs in vivo.  
 Cerebral LB accumulation drives epilepsy and neurodegeneration in LD (182). 
Most drugs do not cross the blood-brain barrier, so any therapy targeting cerebral 
LBs must be deliverable directly into the CNS. There are multiple routes of drug 
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administration to the CNS that bypass the blood-brain barrier. The intrathecal (IT) 
route involves injection of the drug directly into the spinal cord or the subarachnoid 
space. Drugs can also be injected directly into the ventricles of the brain via 
intracerebroventricular (ICV) injection. Both IT and ICV are considered safe and 
well-tolerated drug delivery routes in both pediatric and adult populations, but the 
procedures have different risks and benefits (599).  
 We first tested IT versus ICV administration of either PBS or VAL-0417 in WT 
mice over a period of 3 days. The IT catheter was surgically implanted intrathecally 
at the lumbar region. The ICV cannula was implanted in the cerebral lateral 
ventricle. The IT catheter and ICV cannula were each attached to an osmotic 
pump, through which a continuous infusion of VAL-0417 (0.08 mg/day) or PBS 
was administered for 3 days. Mice were sacrificed on the fourth day and brains 
were removed and sectioned as shown (Figure 5.15a). Homogenates from each 
section were used in ELISA assays to detect VAL-0417 levels (Figure 5.16a) and 
amylase assays were used to quantify VAL-0417 activity (Figure 5.16b). Little to 
no ELISA signal was detected in tissue treated with PBS either by IT or ICV, and 
amylase activity in the tissue was very low. In tissues treated with VAL-0417, VAL-
0417 levels detected by ELISA were markedly higher with ICV administration 
compared to IT. In most slices, amylase activity was also higher with ICV treatment 
of VAL-0417, with the exception of slice 6. After ICV administration, VAL-0417 
levels and activity were nearly equivalent in all slices, indicating this route 
facilitates homogenous distribution of the drug throughout the brain. In contrast, 
after IT administration VAL-0417 levels and activity were high only in the most 
caudal sections, which are nearest the brain stem. Since LBs are abundant 
throughout the cortex and cerebellum, a thorough distribution is necessary and 
thus ICV administration is preferable to IT. Furthermore, these data are indicative 
of cellular uptake of VAL-0417 in the brain, since the drug was not cleared in the 
period after infusion (day 3) and before euthanasia (day 4). These data also 
demonstrate that the drug remains active after uptake.  
 To target cerebral LBs, we administered VAL-0417 directly into the cerebral 
lateral ventricle of 5-month-old Epm2a-/- mice. A continuous infusion of VAL-0417 
(0.08 mg/day) or PBS was administered for 28 days via the ICV cannula and 
pump. Mice were then euthanized, and brains were removed and sectioned as 
shown (Figure 5.15a). Polysaccharides were isolated from each section, 
quantified, and normalized to protein levels. Polysaccharide levels relative to 
protein content were lowest in the rostral section and highest in the caudal section 
(Figure 5.15b). This is the first-time polysaccharide distribution across different 
brain regions has been quantitated in Epm2a-/- mice, and is consistent with the 
high levels of LBs observed in histological sections from brainstem and cerebellum 
(179, 180, 325). Treatment with VAL-0417 reduced the polysaccharide load in all 
sections, with statistical significance in the two most caudal sections that contain 
the highest glucan load (Figure 5.15b). We also quantified whole brain 
polysaccharide relative to tissue weight (Figure 5.15c). Polysaccharide levels in 
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PBS-treated animals are consistent with what has been previously reported for 
Epm2a-/- animals of this age, i.e. 3-4 times higher than WT levels (2 μmol 
glucose/g tissue) (159, 209). Treatment with VAL-0417 reduced total brain 
polysaccharide in the Epm2a-/- mice by 43% (Figure 5.15c), only 2-fold higher 
than normal brain glycogen levels. 
5.3 Discussion  
LD is caused by mutations in one of two genes both encoding enzymes that 
impact glycogen structure. Efforts from multiple labs have shown that LBs are the 
pathogenic epicenter of LD and removal of LBs has become a therapeutic target 
for treating LD (564). In this study, we combine insights from the fields of antibody-
based therapeutics, GSDs, carbohydrate metabolism, and LD to design an AEF 
that degrades LBs in vitro, penetrates cells and reduces polysaccharide levels in 
situ, and decreases polysaccharide load in vivo via both IM and ICV injection. This 
is the first time a significant LB reduction has been achieved in adult LD mice by 
the use of a drug. 
 Antibody-based drugs have made a major impact on the treatment of cancer, 
autoimmune and inflammatory diseases with worldwide revenues of ~$89 billion 
in 2016 (600). Antibody-based drugs are typically whole IgGs designed to bind 
and block receptors, deplete target cells, downregulate a receptor or initiate 
signaling. Bispecific antibodies, antibody fragments and antibody-drug conjugates 
(ADCs) are also being developed across multiple diseases, further expanding the 
diversity of therapeutics utilizing antibody targeting  (600-603). Herein, we report 
a novel class of antibody-based drugs with a similar construction to ADCs: 
antibody-enzyme fusions (AEFs). Rather than delivering a cytotoxin, AEFs deliver 
an enzyme to a specific target. The antibody or antibody fragment is essential both 
for targeting and cellular penetration. AEFs have recently been reported for the 
treatment of two congenital disorders: a muscle wasting disorder known as X-
linked myotubular myopathy and the GSD Pompe disease. In the first study, the 
deficient lipid phosphatase myotubularin fused to an Fv fragment was delivered 
by intramuscular injection and improved muscle function in a mouse model of 
myotubular myopathy (575). In the second, a Fab fragment fused to GAA delivered 
intravenously reduced glycogen load and alleviated pathology in GAA-deficient 
mice (576). These two studies illustrate that enzyme replacement therapy, which 
can be problematic for cytosolic enzymes, can be enhanced by fusion of the 
replacement enzyme with a cell-penetrating antibody fragment. We now 
demonstrate that VAL-0417, an AEF comprised of a Fab fragment fused to 
pancreatic α-amylase, degrades LBs and reduces polysaccharide loads in vivo. 
Unlike the previous two studies, VAL-0417 does not replace a missing enzyme, 
but rather delivers a natural human enzyme to a new target. Since LBs are 
structurally similar to plant starch, and -amylase naturally degrades dietary 
starch in the human digestive tract, -amylase is a logical choice for the VAL-0417 
147 
 
payload. 
 It is important to distinguish normal glycogen from polyglucosan. Polyglucosan 
bodies (PGBs) have historically been defined as "small, non-membrane-bound 
cytoplasmic structures composed largely of unusual glucose polymers" (261). 
They are typically a pathological feature of GSDs, although PGBs known as 
corpora amylacea are a hallmark of normal aging and neurodegenerative 
disorders (79). PGBs are not found in all GSDs, and not all PGBs are identical 
with respect to physiochemical structure. The abnormal polyglucosan found in 
Cori's disease is characterized by short outer chains, while the polyglucosan of 
LD, Anderson disease, Adult Polyglucosan Body Disease, and Tarui disease 
contain very long chains (261, 604). The Pflüger method, originally designed to 
purify normal glycogen, also precipitates polyglucosan. Herein we refer to Pflüger-
isolated material as polysaccharide, since it contains both glycogen and 
polyglucosan. Furthermore, the Pflüger method includes a boiling step that 
solubilizes polyglucosan and destroys LB superstructure, which is not included in 
our LB purification procedure. LBs (and PGBs) may be considered a higher-order 
structure of polyglucosan. The LB purification protocol we designed does not 
destroy the native LB structure and separates LBs from normal, soluble glycogen.  
 LBs from the different tissues displayed varied morphologies. Brain LBs were 
the most irregular in size and shape, included dust-like particles, and reached the 
largest size. LBs from brain exhibited the greatest variation in size, consistent with 
clinical observations: LBs from patient brain micrographs are 3-40 μm and LB 
dust-like granules are even smaller (322, 326). A recent microscopic study of 
Epm2b-/- mice showed that astrocytic LBs are on average smaller than neuronal 
LBs, more irregularly shaped, and clustered, while neuronal LBs are larger, more 
spherical, and isolated (324). LBs in the heart were also surprisingly large and 
included some dust-like particles. LBs from skeletal muscle appeared well 
organized: they were very small and homogenous in shape, and no dust-like 
particles were present. It is not clear why such variation in LB size and shape 
exists in the brain and heart, in contrast to the homogeneity found in skeletal 
muscle. One possibility is that LB size is limited by the dimensions of the cell or 
subcellular region it occupies. For example, in patients, canines, and mice, LBs 
can be found in the cell bodies of Purkinje neurons, which can be up to 40 μm in 
diameter (326, 586, 605). In astrocytes, LBs are typically found in processes that 
can be very long but are only a few microns wide at most (324, 325). However, 
cell size constraints do not explain the difference between heart and skeletal 
muscle LBs, since cardiac and skeletal myocytes are similar in size. It is well 
known that glycogen metabolism is remarkably different in astrocytes, neurons, 
cardiomyocytes and skeletal myocytes. Skeletal myocytes may sequester LBs 
more efficiently than cardiomyocytes, in smaller, discrete units. In brain and heart, 
the dust-like particles may represent a pre-aggregated form of polyglucosan, while 
the larger particles may represent polyglucosan aggregates that have been 
sequestered and compacted by the cell. Active cellular sequestration of 
148 
 
polyglucosan has been proposed to explain the large, dense, and spherical LBs 
observed in some neurons (586).  
 Although LBs from all three tissues had iodine spectral peak maxima at similar 
wavelengths, indicative of similar degrees of branching, the higher amplitude of 
the spectra of brain and heart LBs suggests that they may contain longer chains 
compared to LBs from skeletal muscle (147, 148). Indeed, Nitschke et al. showed 
using HPAEC-PAD that in Epm2a-/- and Epm2b-/- mice, brain glycogen had a 
more exacerbated shift in chain length distribution than muscle glycogen (159). 
Although the brain is most severely affected in LD and a neurological phenotype 
predominates, heart failure and arrhythmia have been reported in LD patients, and 
Epm2a-/- and Epm2b-/- mice have metabolic cardiomyopathy (595-597). 
Glycogen metabolism is variable with tissue type: glycogen synthase and 
glycogen phosphorylase have tissue-specific isoforms that are disparately 
regulated by cellular signals (113); the ultrastructure of glycogen is different under 
different metabolic conditions and in different organs (337, 373); subcellular 
glycogen pools are variable (239); and both phosphate levels and average chain 
length differ with species and tissue type (133, 164). Due to these differences, the 
LBs may be more pathological in brain and heart than in skeletal muscle. 
Conversely, different cell types may be more sensitive to the presence of the LBs, 
and/or the metabolic perturbations induced by the LBs may have distinct 
consequences in different organs. Tissue-specific differences are important to 
consider throughout the clinical development of VAL-0417. ICV administration of 
VAL-0417 may attenuate neurological symptoms, but cardiac, liver and/or 
muscular pathology may require treatment by intravenous or intramuscular 
injection of VAL-0417.  
 We found that VAL-0417 primarily releases maltose and glucose from LBs, and 
glucose levels gradually increased over time, as expected for an -amylase. 
Cytosolic free glucose would likely be phosphorylated to produce glucose-6-
phosphate, entering central carbon metabolism. Although maltose is not 
considered a typical participant in intracellular energy utilization, studies have 
shown that maltose can be transported into and out of cells and metabolized in 
cell culture and humans after intravenous infusion (606, 607). The small 
oligosaccharides (DP-3, DP-4, etc.) would likely remain cytosolic and inert until 
they are further metabolized to glucose and maltose. Importantly, IM injections of 
VAL-0417 in Epm2a-/- mice reduced the polysaccharide load (i.e. LBs and 
glycogen) to WT levels but did not decrease glycogen levels in WT skeletal 
muscle. In contrast, we observed that VAL-0417 reduced glycogen levels in cell 
culture. It should be noted that the cell culture studies were performed in high 
glucose media, known to promote glycogen accumulation in cultured cells. Thus, 
it is possible that a reduction in polysaccharides with VAL-0417 treatment is only 
detected when the polysaccharide accumulates above a baseline level, as 
glycogen accumulates in cultured cells or LB in LD tissues. When glycogen levels 
drop below a certain threshold due to degradation by VAL-0417, the cellular 
149 
 
machinery may respond to restore those levels. Glycogen is likely to be 
maintained at a certain baseline level in vivo in muscle, and this may explain why 
no change was observed in WT muscle treated with VAL-0417. The observation 
that VAL-0417 reduced polysaccharide levels in Epm2a-/- muscle and brain 
indicates LBs are degraded in vivo. We have initiated further studies to define the 
metabolic changes invoked by VAL-0417 in WT and LD mice. 
 Given these exciting results, we are now performing pre-clinical experiments 
with VAL-0417 to define the minimal in vivo efficacious dose, the therapeutic 
window for treatment, and the necessary dosing frequency. We have established 
a robust VAL-0417 ELISA-based quantitation method that will be utilized to define 
the pharmacokinetic and pharmacodynamic parameters. Further, we are actively 
developing biomarkers that could be used to assess VAL-0417 treatment efficacy 
and monitor ongoing therapy. In the current study, we observed dramatic effects 
with VAL-0417 in brain of 6-month old mice and muscle of 10-month old mice. 
Moving forward, we will define the range of doses that most effectively clear LBs 
in animals at various ages as well the dose that effectively prevents the 
appearance of LBs in younger animals.  
 We have demonstrated that VAL-0417 is a putative precision therapy for LD, 
an intractable epilepsy. Currently, >30% of epilepsies, including LD, are resistant 
to available antiseizure drugs (ASDs) and are known as refractory epilepsies 
(608). More than 35 different iterations of ASDs have been discovered over the 
past 150 years with most of them acting primarily on ion channels or 
neurotransmitters. Due to this focus on one mode of action, the high proportion of 
refractory epilepsies has remained constant since the 1850s (608, 609). The 
underlying causes of these refractory epilepsies must be identified in order to 
develop more effective therapies. As the molecular basis of LD has been defined, 
we have now developed an AEF that targets its underlying cause. As molecular 
etiologies in other epilepsies become clear, precision therapies, possibly also 
utilizing the AEF platform, become feasible. LD is also a non-classical GSD. There 
are over 14 different types of GSDs characterized by glucan accumulations, and 
1 in 20,000 people have some form of GSD though the individual types are 
considered rare (165, 610). While the glycogen in some GSDs is of normal 
structure like in Pompe disease, other GSDs such as Cori disease and Andersen 
disease are characterized by polyglucosans, like LD (165). Two AEF drugs (VAL-
0417 and Fab-GAA) have now been shown to target, respectively, cytosolic 
polyglucosan (the present study) and normal glycogen in both the cytosol and 
lysosome (576). These drugs could be repurposed and/or modified to target 
glycogen in other GSDs. Not only is VAL-0417 the first drug with the potential for 
providing a significant clinical benefit to LD patients, it is an example of a precision 
therapy and expands the repertoire of antibody-based drugs that can be used to 
treat human disease.  
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Figure 5.1 The antibody-enzyme fusion VAL-0417 degrades starch, a proxy 
for LBs.  
(A) Degradation of starch by a panel of amylases. 1 mg of starch was incubated 
with 5 μg of amylase overnight with constant agitation, then soluble and insoluble 
fractions were separated by centrifugation. Degradation product in the soluble 
fractions was quantified by measuring glucose equivalents (i.e. glucan). Reactions 
were performed in triplicate and data shown are means ± SD. (B) Schematic 
representation of VAL-0417. The gene encoding the human IgG1 Fab heavy chain 
fragment (H) was fused to AMY2A, encoding human pancreatic α-amylase, and 
coexpressed with the gene encoding the human light chain (L) in HEK293-6E 
cells. Heavy and light chain signal peptides were included to facilitate proper 
folding and assembly of the Fab fragment. The predicted molecular weight of each 
polypeptide is shown. (C) Purity of VAL-0417 assessed by reducing (+BME) and 
nonreducing (-BME) SDS-PAGE. (D) Chemical structure of the α-amylase-specific 
substrate E-G7-pNP. Reducing (inner) and non-reducing (outer) ends of the 
substrate are shown. (E) Degradation of 1 mg starch after a 2-hour incubation with 
increasing amounts of VAL-0417, expressed as glucan released in the soluble 
fraction. Mean ±SD of triplicate reactions are shown. (F) Scanning electron 
micrographs of starch granules in the absence of treatment and after overnight 
treatment with VAL-0417. Samples were visualized at 2kV by an FE Quanta 250 
scanning electron microscope.  
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Figure 5.2 Starch degradation with different VAL-0417:starch ratios.  
(A) Degradation with low ratio (10 μg VAL-0417, 1 mg starch). (B) Degradation 
with high ratio (10 μg VAL-0417, 100 μg starch).  
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Figure 5.3 A novel protocol for isolating native LBs from LD mice.  
(A) LB purification scheme. (B) Polysaccharide was purified at different steps in 
the protocol via the Pflüger method and quantitated via glucose measurement 
following hydrolysis. Initial tissue weights and total polysaccharide at each step 
are shown. (C) Polysaccharide yields normalized to tissue weight. Triplicate 
samples were removed from each fraction and each measured in triplicate. Mean 
±SD are shown. (D) Phosphate content of LBs from skeletal muscle and normal 
rabbit muscle glycogen. Mean ±SD of triplicate measurements are shown. (E) 
Normalized iodine spectra of purified LBs compared to commercial liver glycogen 
and amylopectin. Spectra shown are an average of 3 replicates. (F) Brain, (G) 
heart, and (H) skeletal muscle LBs stained with Lugol's solution and visualized 
using a Zeiss Axioimager Z1. 
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Figure 5.4 Iodine staining of LB purification fractions.  
(A) 50 μL samples were removed from homogenate, supernatant, and pellet 
fractions during preliminary LB purifications from skeletal muscle, boiled for 30 
minutes, and clarified by centrifugation. 30 μL of the clarified sample was diluted 
with 15 μL water and stained with 50 μL 1x Lugol's solution in a microplate. 
Commercial liver glycogen and amylopectin were also stained as controls. (B) 
Concentration vs. iodine absorbance at 550 nm of Pflüger-isolated polysaccharide 
from skeletal muscle at each step of the purification scheme. Mean ±SD of 
triplicate reactions are shown. 
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Figure 5.5 Size distribution of LBs purified from different tissues and 
appearance of dust-like particles. 
Frequency distribution of LBs from each tissue type: (A) brain (total count: 473), 
(B) heart (total count: 247), and (C) skeletal muscle (total count: 252). Two fields 
of view from (D) brain and heart (E) LB preparations containing numerous dust-
like particles are shown. Black boxes indicate areas that have been magnified and 
are labeled correspondingly (e1, e2, etc.). Occasionally very large bodies were 
observed (10-20 μm). They were difficult to distinguish from tightly packed clumps, 
so they were excluded from the size distribution histograms.   
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Figure 5.6 Scanning electron micrographs of LBs from brain, heart and 
skeletal muscle, washed in ethanol, dried, and applied to carbon tape.  
Samples were visualized at 2kV under high vacuum by an FE Quanta 250.  
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Figure 5.7 Scanning electron micrographs of isolated LBs.  
Scanning electron micrographs of LBs purified from brain (A), heart (B), and 
skeletal muscle (C) shown at identical scale. LBs from skeletal muscle are shown 
at a higher magnification in (D). Samples were visualized at 2 kV using an FE 
Quanta 250.  
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Figure 5.8 Soluble fractions of untreated and treated BrLBs after 
degradation reactions.  
Samples from the soluble fractions and total reactions were stained with Lugol's 
solution and visualized using a Zeiss Axioimager Z1. 
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Figure 5.9 Purification of LBs from skeletal muscle of 12 month old Epm2b-
/- mice.  
(A) LB purification yields. Mean ± SD of triplicate measurements are shown. (B) 
Epm2b-/- LBs stained with Lugol's solution and visualized by light microscopy. 
(C) Comparison of size distribution of skeletal muscle LBs from Epm2a-/- and 
Epm2b-/- mice. (D) Normalized iodine spectra of Epm2b-/- and Epm2a-/- skeletal 
muscle LBs. The spectral data are an average of 3 replicates. 
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Figure 5.10 VAL-0417 degrades LBs in vitro.  
(A) Degradation of 50 μg LBs from different tissues after overnight incubation 
with 0, 1, or 10 μg VAL-0417. (B) LBs from different tissues after overnight 
incubation +/- 10 μg VAL-0417. Insoluble fractions were resuspended post-
degradation, stained with Lugol's solution, and visualized using a Nikon Eclipse 
E600. (C) Iodine absorbance in pellet fractions after incubation of WT and 
Epm2a-/- skeletal muscle homogenates +/- 25 μg VAL-0417. In (A), (C), and (E) 
mean ± SD of triplicates are shown. (D) HPAEC-PAD chromatogram of 
degradation product after incubation with VAL-0417 for 168 hours. Peak 
identities were determined based on the elution profile of degradation buffer and 
glucan standards. The chromatogram is representative of triplicate experiments, 
and glucose/maltose quantification from the replicates is shown in (E). (E) 
Quantification of glucose and maltose at various time points throughout the 
degradation reaction of LBs with VAL-0417. Product released are expressed as a 
percentage of total LBs.  
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Figure 5.11 HPAEC-PAD chromatograms of control samples and additional 
time points from LB degradation with VAL-0417. 
(A) Overlay of control chromatograms: degradation buffer only (black line), LBs 
only (red line), and a mixture of 1 μg glucose and 1 μg maltose standards for 
quantitation (blue line). A small amount of maltose and low molecular weight 
oligosaccharides were detected in the LB control. Additional time points from the 
168 hour LB degradation experiment with VAL-0417: (B) 24 hours, (C) 48 hours, 
and (D) 72 hours. Each chromatogram is representative of triplicate 
chromatograms. Small shifts in retention time (≤1 min) are typical between 
HPAEC-PAD runs. (E) Maltrin100, a mixture of low molecular weight 
oligosaccharides, was used as a standard for verifying degrees of polymerization 
(DP), i.e. number of glucose units. 
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Figure 5.12 Polysaccharide levels relative to protein concentration in three 
cell lines.  
Polysaccharide content of Rat1, HEK293, and HEK293 stably expressing PTG 
and PP1Cα. Data are expressed as the mean of 12 replicates ± SE.  
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Figure 5.13 VAL-0417 uptake and polysaccharide reduction in cell culture. 
(A) Rat1 cells and HEK293 cells stably expressing PTG and PP1Cα after 20-hour 
treatment with increasing concentrations of VAL-0417. VAL-0417 levels were 
assessed by Western blotting using an anti-AMY2A antibody. ENT2 levels were 
also quantified by Western blotting. (B) Polysaccharide level per well in Rat1 and 
HEK293-PTG/PP1Cα cells after 20-hour treatment with VAL-0417. Data shown 
are a mean of 4 measurements ± SE. Statistical significance is indicated: * p ≤ 
0.05, ** p ≤ 0.01, *** p ≤ 0.001.   
163 
 
 
 
Figure 5.14 VAL-0417 reduces LB load in vivo after intramuscular (IM) or 
intravenous (IV) injection.  
(A) Biodistribution of VAL-0417 levels determined by sandwich ELISA after IM 
injection of WT mice with PBS or 0.6 mg VAL-0417. (B) Quantification of 
polysaccharide in the injected gastrocnemii of WT and Epm2a-/- mice after 3 IM 
injections of PBS or VAL-0417 administered over the course of one week. (C) 
Quantification of polysaccharide in the heart of WT and Epm2a-/- mice after 4 IV 
injections of PBS or VAL-0417 administered over a two-week period. 
Polysaccharides in (B) and (C) were isolated via the Pflüger method and quantified 
by glucose measurement following hydrolysis. (D, E) PAS-stained heart tissue of 
WT (D) and Epm2a-/- (E) mice after IV treatment regimen. Intensely staining PAS-
positive deposits are LBs (purple). Tissues were counterstained with hemotoxylin 
(blue). (F) Quantification of PAS staining using HALO image analysis software.  
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Figure 5.15 Comparison of intrathecal (IT) versus intracerebroventricular 
(ICV) administration in WT mice. 
 (A) Distribution of VAL-0417 levels using the sandwich ELISA in PBS- and VAL-
0417-treated WT brain slices after intrathecal (IT) or intracerebroventricular (ICV) 
infusion. (B) Distribution of VAL-0417 activity in the same slices measured using 
the BioVision amylase activity assay. Data shown are a mean of 3 measurements 
± SE. 
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Figure 5.16 VAL-0417 reduces LB load in vivo after continuous ICV 
infusion.  
(A) Representative photograph of six 2.0 mm coronal sections. Blue dye was 
injected through the cannula into the lateral ventricle to verify its location within 
slice 2. (B) Polysaccharide content normalized to protein content in Epm2a-/- brain 
slices after 28 days of continuous ICV infusion of VAL-0417 or PBS. (C) Total brain 
polysaccharide normalized to tissue weight of PBS and VAL-0417 treated Epm2a-
/- mice. In (B) and (C), at least three technical replicates were performed for each 
isolated slice to determine an average per slice per animal, and data shown are 
the mean from each treatment group ± SE. The numbers of animals in each 
treatment group (n) are shown. Statistical significance is indicated: ns p > 0.05, * 
p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001. 
 
 
 
 
 
 
 THE STRUCTURE OF LAFORA DISEASE POLYGLUCOSAN 
BODIES  
6.1 Introduction 
Polyglucosan bodies (PGBs) are a common feature of glycogen storage 
disorders (GSDs), neurodegenerative diseases, and physiological aging (79, 80, 
611). PGBs range in size from 2 to 50 μm in diameter, and unlike the proteinacious 
inclusion bodies of neurodegenerative diseases they are primarily made of an 
abnormal glucose polymer called polyglucosan (261). Subtle chemical and 
ultrastructural differences distinguish the PGBs of various pathologies (79). What 
unites them is their chemical resemblance to mammalian glycogen and plant 
starch, the two major forms of glucose storage in living organisms (139). 
 Starch-like structures in the brains of elderly patients were first described in 
1836 by J. E. Purkinje, who named them corpora amylacea (literally "starch 
bodies"). In 1854, Rudolf Virchow observed a substance in the diseased nervous 
system that stained with iodine in a manner similar to plant starch, coining the term 
"amyloid" (612). It was later discovered that many amyloid deposits were 
proteinacious, so the term now typically refers to the inclusions of Alzheimer's and 
other amyloidoses (613, 614). But corpora amylacea and the later-described 
PGBs are, in fact, true amyloid: in addition to their similarity in size and shape and 
staining characteristics to starch, they are comprised primarily of insoluble glucose 
polymers containing significant amounts of phosphate (79, 615, 616). Since 
glycogen synthase is the only enzyme able to catalyze glucose polymerization in 
mammals, PGBs are considered a pathological result of aberrant glycogen 
metabolism (80, 114, 261). 
 Like other PGBs, LBs from tissues of Lafora disease (LD) patients were 
described as starch-like in the early- and mid-1900s based on their chemical and 
structural characteristics (169, 321). A peculiar link between carbohydrate 
metabolism in humans and plants was made when it was discovered that laforin 
is a functional analog of a plant protein called starch excess 4 (SEX4) (183). SEX4 
deficiency in plants leads to a starch excess phenotype whereby the plants 
synthesize a glucan that they cannot efficiently break down. Thus, the plant 
phenotype is very reminiscent of the LBs found in LD patients and mouse models 
(208, 617). It was later shown that polysaccharides purified from LD muscle and 
brain tissue had an abnormal chain length distribution (CLD) compared to wild-
type glycogen, increased levels of covalent phosphate monoesters, and that 
laforin can remove this phosphate (158, 159, 209, 210). These important studies 
provided quantitative evidence that the polysaccharide in LD tissues resembles 
plant amylopectin, the branched component of starch, on a molecular level, and 
that phosphate is involved in its metabolism. To our knowledge, comparable 
structural studies on purified polyglucosan from other diseases have not yet been 
conducted.  
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 The polysaccharides from Epm2a-/- and Epm2b-/- mice that have been 
characterized in vitro were purified based on a method first described in 1909 by 
Pflüger for purifying glycogen, in which the tissue is boiled in KOH and the 
polysaccharides are precipitated with ethanol (16, 583). The method does not 
separate glycogen from the LBs, and the Pflüger-purified polysaccharides differ in 
morphology from LBs observed via microscopy in LD tissue sections. Analysis of 
the Pflüger-purified particles by transmission electron microscopy (TEM) showed 
that they are larger and more aggregated than wild-type glycogen (209), but they 
are still much smaller (15-65 nm) than the micron-sized LBs observed in tissue 
sections. Another group showed that the average molecular weights of the 
Pflüger-purified particles from Epm2a-/- and Epm2b-/- mice were only 2- to 3-fold 
larger than glycogen, again much smaller than LBs observed in tissue sections 
(158). Thus, purification of LBs by the Pflüger method does not separate LBs from 
glycogen and likely changes the morphology of the LBs. It is conceivable that LBs 
are aggregates of polyglucosan (i.e. abnormal polysaccharide) molecules, and 
that the Pflüger method breaks apart the LBs and intermixes the polyglucosan 
molecules with normal glycogen particles. In the case of starch, many studies have 
shown that the application of heat and moisture results in solubilization and 
irreversible disruption of the starch granular structure (618). However, the 
deconstruction of LBs to polyglucosan molecules has not been investigated.  
 An enormous body of work has been performed to define the chemical, physical 
and structural properties of different types of starch, which vary depending on plant 
species and tissue type (reviewed by (145)). One of the major features that 
distinguishes starch from glycogen is its semi-crystalline, lamellar organization, 
which can be detected with X-ray scattering techniques such as wide-angle and 
small-angle X-ray scattering (WAXS and SAXS, respectively). Treatment of starch 
granules with mild hydrochloric acid, a process known as lintnerization, 
preferentially hydrolyzes the amorphous regions, leaving crystalline regions intact 
and providing valuable information about granule architecture (619-621). Despite 
the similarities between PGBs and starch, comparable methods have not yet been 
applied to investigate the structure of PGBs.  
 We have described a procedure for isolating native LBs from Epm2a-/- and 
Epm2b-/- mice using a novel protocol that does not rely on the Pflüger method 
and separates native LBs from glycogen (Chapter 3). Analysis of these LBs by 
light microscopy and scanning electron microscopy showed that native LBs from 
brain, heart, and skeletal muscle have distinct sizes and morphologies, ranging 
from 2 to 10 μm or more, depending on tissue type. In the present study, we use 
methods previously utilized to characterize starch to investigate the 
physiochemical and structural characteristics of LBs isolated from different 
tissues. Combining these methods with thermal, mechanical and chemical 
treatments to disassemble LBs allows for a model of how polyglucosan molecules 
aggregate to form LBs in LD. Although not all PGBs are identical, the corpora 
amylacea of aging and neurodegeneration and the PGBs of various GSDs bear 
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striking similarities to LBs. PGBs may represent a common pathological 
phenomenon resulting from misregulated glycogen metabolism, which has 
particularly detrimental consequences in the brain.   
6.2 Results 
6.2.1 Confocal micrographs of iodine-stained LBs  
 Lugol's iodine is a chemical stain that has been used for over a century to detect 
and differentiate polysaccharides such as glycogen, amylose and amylopectin. 
Lugol's iodine intercalates within the glucan chains to form a chromophoric 
complex that provides information about polysaccharide architecture. Amylose, 
which is α-1,4 linear chains, produces a deep blue-black color with Lugol's iodine, 
due to the very stable association of the triiodide ions with the long helical chains 
(622). Since amylopectin contains branches in addition to helix-forming glucan 
chains, it produces a less stable complex with triiodide, giving a reddish-purple 
color. Stained amylose and amylopectin maximally absorb around wavelengths of 
650 nm and 550 nm, respectively (148). Since glycogen contains shorter chains 
and more frequent branching than amylopectin, it stains poorly with Lugol's iodine, 
and yields an absorbance maximum at 440 nm, although this varies slightly 
depending on glycogen source, i.e. glycogen from different tissues and/or 
organisms (151).  
 LBs, corpora amylacea, and other PGBs stain brown or purplish-brown with 
Lugol's iodine, suggesting they have a branching degree that is more similar to 
amylopectin than glycogen (616, 623, 624). We showed that native LBs isolated 
from skeletal muscle, heart tissue, and brain of Epm2a-/- mice stained intensely 
reddish-brown in Lugol's iodine, with an absorbance maximum at 510-520 nm 
(Figure 5.3). The iodine-stained LBs not only absorb at this wavelength, but they 
also produce red fluorescence when excited by a 561 nm confocal laser. Confocal 
microscopy has previously been used as a sensitive method for visualizing starch 
granules in vitro and in planta (625, 626). Z-stack images of iodine-stained starch 
granules visualized using the TRITC channel and differential interference contrast 
(DIC) at high magnification show that only the smooth, outer edge of the granule 
is stained (Figure 6.1a, 6.2a,b). This staining pattern suggests the iodine does not 
penetrate beyond the outer edge, which is not surprising given the densely 
packed, semi-crystalline interior of starch granules.  
Isolated LBs from Epm2a-/- skeletal muscle (SmLBs) have a characteristic 
ovoid morphology and are typically 1-3 μm in length (Figure 5.3h, 5.5c). Like 
starch, they also fluoresce brightly with 561 nm excitation after iodine staining, but 
they stain more thoroughly, suggesting their smaller size and less dense interior 
facilitates greater penetration of the triiodide ions (Figure 4.1b, 6.2c,d). LBs 
isolated from Epm2a-/- hearts (HtLBs) are larger in size (typically 2-4 μm, up to 10 
μm in length) and often more elongated than SmLBs (Figure 5.3g, 5.5b). They 
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also stained homogenously with iodine, with visible interior texture and a brighter 
rim (Figure 6.1c, 6.2e,f). The textured surface of the LBs was evident using DIC 
and consistent with what we observed via scanning electron microscopy (Figure 
5.7). Brain LBs (BrLBs) were also larger in size (typically 2-4 μm, some >10 μm in 
diameter) and varied in morphology more than skeletal muscle and heart LBs. 
Some LBs were very round and homogenously stained, with a bright rim and 
textured appearance, similar to heart LBs except that they are not typically 
elongated (Figure 6.1d). Some LBs had a very jagged edge with a dark core 
(Figure 6.1e). Since both LB types were of comparable size, the lack of central 
staining in Figure 6.1e suggests that some bodies had a more densely packed 
center, like that of starch. Iodine-positive dust-like granules were also evident 
around LBs from heart and brain (Figure 6.1, 6.2), consistent with our previous 
observations (Figure 5.5).  
Distinct types of LBs have been observed in fixed brain tissue from LD 
patients and mouse models. Van Hoof's type I LBs have been described as 
homogenous and uniformly granular, while type II LBs have a dense core that 
stains more intensely with the carbohydrate-specific stain periodic acid-Schiff 
(PAS) (452, 570, 586). By TEM, type I LBs contain ramifying and randomly 
arranged, finely curved fibrils; in type II LBs, the fibrils are densely packed in the 
core, and were surrounded by radiating, less densely packed fibrillar layer (452). 
Small, dust-like granules appeared to be made of the same material as type I LBs. 
It is possible that the bodies in Figure 6.1d and e correspond to types I and II, 
respectively. Smaller, amorphous and granular BrLBs would likely also be type I.  
 
6.2.2 Differences in chain length distribution (CLD) between LB types 
 In addition to the distinct morphologies of LBs from different tissues, data from 
our lab and others suggest that the CLD of LBs also varies depending on tissue 
origin (Chapter 5) (159). Polysaccharides purified via the Pflüger method from 
Epm2a-/- and Epm2b-/- skeletal muscle contain significantly more glucan chains 
with 14-36 degrees of polymerization (i.e. DP14-DP36), than polysaccharides 
from wild-type (WT) mice, and significantly fewer short chains (DP5-11). This shift 
in CLD was even more exacerbated in polysaccharides purified from Epm2a-/- 
and Epm2b-/- brain. As mentioned before, the Pflüger method does not separate 
glycogen from LBs, and thus the CLD represented a mixture of glycogen and LBs, 
not pure LBs. We showed that in our native LB purification, a low-speed 
centrifugation step after tissue homogenization separates the LBs and glycogen 
into pellet and supernatant fractions. Importantly, only the pellet fraction stains 
reddish-brown with iodine, indicative PGBs and not glycogen (Figure 5.4). All 
purified LB types maximally absorbed Lugol's iodine at 510-520 nm, suggesting 
they have a similar degree of branching, but equivalent amounts of LBs produced 
peaks of varying amplitude: BrLBs produced the highest amplitude, followed by 
HtLBs, then SmLBs. The higher amplitude of BrLBs suggests that they contain 
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even longer chains than HtLBs and SmLBs (147, 148), consistent with previous 
findings (159).  
 In order to define these parameters for native LBs, we determined the CLD of 
purified SmLBs, HtLBs, and BrLBs using fluorescience-assisted capillary 
electrophoresis (FACE) (Figure 6.3). Samples were enzymatically debranched 
then linear oligosaccharides fluorescently labeled and separated using Beckman 
Coulter PA800 plus instrument equipped with a laser induced fluorescence 
detector. BrLBs had the highest proportion of long chains: 13.8% of the detected 
oligosaccharides had a length of 10 glucose units (i.e. 10 degrees of 
polymerization, DP10) or more (Figure 6.3). HtLBs had a lower proportion of long 
chains: 7.8% of the detected oligosaccharides were DP10 or longer. SmLBs had 
the lowest proportion of long chains, with only 2.0% of the detected 
oligosaccharides being DP10 or longer. These data demonstrate that native LBs 
in the different tissues have varying CLD, and that BrLBs are more amylopectin-
like than HtLBs and SmLBs.  
 
6.2.3 LBs are B-type crystallites lacking long-range order 
 Unlike glycogen, starch granules possess both short- and long-range order, 
which can be measured by X-ray scattering techniques. Short-range order refers 
to repeating units on the sub-naonometer scale, i.e. the crystalline double helices 
formed by the long glucan chains in the unbranched regions of amylopectin. Wide-
angle X-ray scattering (WAXS) is used to probe sub-nanometer-sized structures 
and has been widely utilized to study crystallinity in starch and other polymers 
(627, 628). Long-range order refers to the alternation of crystalline and amorphous 
lamellae, which have a repeat distance of 9-10 nm (145, 628). Small-angle X-ray 
scattering is better suited for measuring these nanometer-sized distances (627). 
We utilized WAXS and SAXS to define the order of native, purified LBs. 
Crystallinity content and type of helical packing can be determined from WAXS  
patterns. In starch, amylopectin double helices crystallize in two different ways 
depending on the starch species (i.e. potato, corn, etc.), called A- or B-type 
polymorphs (143). Helices of A-type crystals are densely packed into a monoclinic 
unit cell that contains very little water. In the B-type crystal, the double helices form 
a hexagonal channel that fills up with water, rendering a polymorph that is more 
open and hydrated. Both SmLBs and BrLBs produced a WAXS pattern with an 
unambiguous B- type ring distribution (Figure 6.4a,b). This result is in sharp 
contrast to the typical scattering halos produced by amorphous samples such as 
glycogen or phytoglycogen, a soluble, glycogen-like polymer synthesized by 
isoaymlase-deficient plants (Figure 6.4c) (629). A scattering profile generated 
from the rotational average of the 2D patterns show characteristic B-type 
reflections at diffraction angles of 5.5, 16.6, 21.7 and 23.6° for SmLBs and BrLBs 
(Figure 6.4d) (142, 630). Peaks at approximately 15, 17, 18 and 23° are typical of 
A-type crystals (631) and WAXS studies of normal glycogen produce no distinct 
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peaks (632). These data clearly illustrate B-type crystallinity in both types of LBs.  
While WAXS data is presented as a function of diffraction angle (2θ), SAXS 
data is presented as a function of the scattering vector, q (628). The scattering 
vector is related to the wavelength of the incident radiation (λ) and the scattering 
angle (2θ). It can be converted to distance of the repeating unit (d) in real space 
using Bragg's law:  
 
𝑞 =
4𝜋
𝜆
sin 𝜃 =
2𝜋
𝑑
 
 
SAXS studies were performed on SmLBs and BrLBs. Potato amylopectin starch, 
a genetically modified starch that lacks amylose, was used as a positive control 
(633). The starch produced a SAXS diffraction pattern with two distinct rings: a 
large, outer ring, and a small, inner ring (Figure 6.5a). SmLBs produce a 
diffraction pattern with an outer ring that lacks the small, inner ring (Figure 6.5b). 
The outer ring represents a reflection at q = 4 nm-1 in the 1D scattering profile 
(Figure 6.5c). This ring is equivalent to the innermost ring on the WAXS diffraction 
pattern. From this value of q, a repeating distance, d, of 1.6 nm is calculated. This 
value is the distance between the helices in the B-type crystal. The inner ring of 
the starch diffraction pattern represents a reflection at q = 0.76 nm-1. This converts 
to a repeating distance of 8.3 nm, representing the lamellar repeats. SmLBs lack 
this reflection for lamellar repeats (Figure 6.5c).  
When starch is heated, the short-range and long-range order from the packing 
of amylopectin helices and lamellar units are lost (634). WAXS and SAXS 
experiments on cooked starch produce an amorphous scattering pattern. As the 
starch cools, the amylopectin retrogrades, gaining B-type crystallinity over time. 
Helices form from intra- and intermolecular interactions, and aggregate randomly 
into networks (635). The lamellar periodicity of the native starch granule never 
returns (636). In this way, LBs are quite similar to retrograded amylopectin. They 
are composed of crystalline glucan chains that are arrayed in a random, 
disordered fashion.   
  
6.2.4 Effects of mechanical, thermal and chemical treatments on LBs  
 These data illustrate that LBs are comprised of long glucan chains that are 
crystalline. As discussed in the introduction, the Pflüger method (which involves 
both thermal and chemical treatment) converts micron-sized LBs to nanometer-
sized polyglucosan particles that are on the same scale as glycogen particles. We 
previously showed that degradation of LBs with an amylolytic enzyme releases an 
iodine-positive filamentous material (Figure 5.10b). Since modification of starch 
and other polysaccharides by mechanical, thermal, chemical, or enzymatic means 
provides structural insights, we sought to explore the effects of various treatments 
on LB structure by light microscopy and iodine staining.  
 Untreated SmLBs are uniformly small and ovoid and stain intensely with Lugol's 
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iodine (Figure 6.6a). As previously described, all LB types have a tendency to 
clump (Chapter 5). We found that mild sonication (5 x 5 seconds at 25% 
amplitude) disrupted SmLB structure almost entirely (Figure 6.6b). After this 
treatment, most of the LBs were fragmented into clumped, lace-like networks of 
polyglucosan material that only lightly stained with Lugol’s. Only a few intact 
SmLBs were left associated with the polyglucosan networks. This result is quite 
different from what has been observed with starch granules: treatment of starch 
granules with ultrasonication for minutes or longer produces only mild disruption 
of granular structure (637).  
 Previously, we found that native LBs are solubilized after a short period of 
boiling (15-30 minutes), which facilitated the iodine absorbance spectral scans 
(Chapter 5). However, we did not visualize the effects of boiling on a microscopic 
level. For the present study, we heated SmLBs in water for 30 minutes at 95°C 
and found that the bodies were completely converted to the polyglucosan lacy 
networks (Figure 6.6c). The resulting material after heating appeared very similar 
to the material produced by sonication, except that no intact SmLBs were 
observed after the heat treatment. The clumps of material were even more 
dispersed with longer heating (2 hours at 95°C), and very small, freely floating 
particles with a diameter of approximately 0.2-0.6 μm were more abundant 
(Figure 6.6d). 
 In the Pflüger method, tissue is heated at 95°C in 30% KOH for 2 hours, and 
then the polysaccharide is precipitated three times with 2 volumes of cold ethanol 
and then re-dissolved in water. LiCl is also added with the ethanol to ensure 
complete precipitation (209). The successive precipitation steps remove impurities 
and residual KOH. The effects of the Pflüger method on LB structure could be 
attributed to one or more components of the protocol: (1) heat in an aqueous 
environment, (2) heating in 30% KOH, and/or (3) precipitation with ethanol and 
LiCl. The results in Figure 6.6b and c demonstrate that heat alone is not sufficient 
to completely disassemble LBs. The SmLBs that were precipitated with ethanol 
and LiCl three times following a 2-hour boil in water were more difficult to 
resuspend in water: the white pellet did not easily go into solution, and flakes of 
polysaccharide were visible. Using light microscopy, this material contained 
intensely staining aggregates, filamentous structures and granular particles 
(Figure 6.6e). The aggregates were more amorphous and less compact than 
control SmLBs, but stained with a similar intensity, suggesting that the 
polyglucosan became re-crystallized with precipitation. However, it did not reach 
the compact, elliptoid form of native SmLBs. In contrast, LBs that were boiled in 
30% KOH for 2 hours and then precipitated three times with ethanol and LiCl were 
very easily resuspended in water and produced no visible precipitate. This material 
did not contain intensely-staining aggregates with Lugol's solution and only a few 
small clumps of polyglucosan material were visible (Figure 6.6f). Thus, boiling in 
KOH instead of water fully disassembles the LBs into polyglucosan, and in these 
alkaline conditions the polyglucosan is much less prone to re-aggregate upon 
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ethanol/LiCl precipitation.  
 Treatment with heat or the Pflüger treatment was also applied to BrLBs and the 
product was visualized via light microscopy. As expected, control BrLBs were 
larger and more irregularly shaped than SmLBs and stained just as intensely with 
Lugol's iodine (Figure 6.6g). A 30-minute heat treatment in water did not 
completely convert BrLBs to polyglucosan networks; some BrLBs remained intact 
but were always surrounded by the lace-like material (Figure 6.6h). As with the 
SmLBs, Pflüger treatment released a large amount of small granular particles, but 
more lace-like polyglucosan was still present in these samples than in the Pflüger-
treated SmLBs (Figure 6.6i). These samples were also easy to resuspend after 
precipitation.  
 Image thresholding was used to quantitate LBs, LB-like aggregates and 
polyglucosan in treated samples. In the recorded micrographs, intact LBs were 
very dark grey or black, with grey values of 50 or less (Figure 4.6j,k). 
Polyglucosan networks or particles appeared in lighter shades of grey, with values 
between 51 and 140 (Figure 6.6k,l). Pixel counts from multiple micrographs 
showed that the vast majority of intensely-staining LBs were disrupted by 
sonication and boiling in water for 30 minutes (Figure 6.6m). No intact LBs were 
found in the SmLB samples that were boiled in water for 2 hours or the Pflüger-
treated samples. Interestingly, the high intensity observed in control samples (53% 
of counted pixels) could be partially restored by ethanol treatment after a 2-hour 
boil in water (25% of counted pixels). These results clearly demonstrate that 
crystalline LBs undergo a structural transition to polyglucosan networks in the 
presence of heat, and they can be fully dispersed with the Pflüger method. Without 
KOH, ethanol precipitation causes polyglucosan to re-aggregate and form dense, 
LB-like structures.   
To capture the appearance of the transition from native LB to lace-like 
polyglucosan, SmLBs were heated at 95°C for 1 or 5 minutes, immediately flash 
frozen in liquid nitrogen, thawed, and stained with Lugol's iodine. Light microscopy 
with a color camera was utilized to capture the stained appearance of the native 
and treated LBs. Control, native LBs stained bright reddish-brown in Lugol's iodine 
(Figure 6.7a). Samples that were heated for 1 minute displayed numerous 
amorphous, red-brown gel-like structures in addition to small fragments of lightly 
stained lacy polyglucosan (Figure 6.7b). By 5 minutes, only lace-like 
polyglucosans were visible, and no gel-like structures were observed (Figure 
6.7c). These results are strongly reminiscent of gelatinization, the irreversible 
order-disorder transition that starch undergoes when heated in water 
characterized by swelling, increased viscosity and a loss of crystallinity (638). 
These results strongly suggest that like starch, LBs gelatinize at high 
temperatures, corresponding with a loss of crystallinity.  
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6.2.5 Transmission electron microscopy and lintnerization of LBs 
 The particles that were dispersed after extensive heating or Pflüger treatment 
were less than 1 μm in diameter (Figure 6.6d,f,i), but still large enough to observe 
by light microscopy, which has a resolution of about 100 nm. Glycogen particles 
are smaller, however, typically 15-35 nm in diameter, and visible only by electron 
microscopy (73, 337). It is assumed that the basic unit of LBs is an abnormally 
branched glycogen molecule, but this would be approximately 10-fold smaller than 
the smallest particles in Figure 5. To further study the structure of LBs, boiled 
SmLBs and Pfluger-purified polysaccharide from skeletal muscle of Epm2a-/- and 
WT mice were analyzed by transmission electron microscopy (TEM). Electron 
micrographs of boiled SmLBs showed very large, round bodies ranging in 
diameter from less than 20 nm to over 100 nm (Figure 6.8a,b). Smaller particles 
were also present but were less prominent than the larger bodies. Large spherical 
particles were not observed in the Pfluger-purified polysaccharide from Epm2a-/- 
or WT mice (Figure 6.8c,d). Epm2a-/- mice showed only very small particles 
ranging in diameter from 6-20 nm (Figure 6.8c), while WT particles showed a 
normal distribution for glycogen particles, ranging from 15-30 nm in diameter 
(Figure 6.8d). Tagliabracci et al. also reported smaller particles in young Epm2a-
/- mice and very similarly large, round aggregates in older mice after purification 
with the Pflüger method (209). These data strongly suggest that the particles in 
Figures 6.6 and 6.8a and b are still aggregates of smaller polyglucosan molecules, 
which are the most basic unit of LB structure.  
Lintnerization is the process of treating starch with mild hydrochloric acid (HCl) 
at sub-gelatinzation temperatures for long periods of time in order to study its 
crystalline structure (143, 639). The amorphous regions of the starch granule 
hydrolyze relatively early during lintnerization, while the crystalline regions are left 
intact. This effect is due to the protection of glucose residues and glycosidic 
linkages within the water-excluding helices, which are not easily penetrated by the 
hydrogen ions (639, 640). The morphology and properties of the resulting lintners 
vary with species, amylose content, and starch allomorph (475, 640, 641).  
BrLBs and SmLBs were treated with 2.2N HCl for 5 days at 36°C and then 
imaged by TEM. The BrLB and SmLB lintners were very similar in morphology, 
both appearing as lace-like networks (Figure 6.8e-h). Similar lace-like networks 
have been reported for lintnerized potato starch, particularly waxy potato starch, 
which exhibit B-type crystallinity (641). This is in contrast to A-type waxy maize 
starch or barley starch lintners, which form polyhedral-shaped, platelet 
nanocrystals, reflective of A-type helix packing (475, 640). The LB lintners 
appeared to be composed of knobby fibers with a diameter of 5-9 nm and larger 
10-20 nm subunits, consistent with the size of potato starch lintners (641). The 
thickness of the fibers is also consistent with the diameters of the individual 
particles observed in 7C. These data indicate that the polyglucosan particles 
associate with one another via intermolecular crystalline helical interactions to 
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form a network or necklace-like pattern. Interestingly, retrograded amylopectin, 
amlylopectin that has been reprecipitated after gelatinization, takes on a very 
similar necklace-like appearance under the electron microscope, and over time 
the molecules associate to form networks (635). This is a spontaneous process 
and therefore the association and precipitation of polyglucosan particles into 
networks is similarly likely to be spontaneous. 
6.3 Discussion 
In this study, we defined the architecture of LBs, the hallmark PGBs of a fatal 
childhood epilepsy, using techniques previously utilized to define starch structure. 
LBs from different tissues not only vary in gross morphology, but they contain 
distinct differences in CLD profile, which may have important pathological 
implications. Additionally, LBs possess B-type crystallinity, but they lack the 
hierarchical arrangement of starch and contain randomly arrayed crystalline fibrils. 
The results highlight that the methods utilized to purify and analyze LBs must be 
taken into account as the methodology can dramatically alter the polyglucosan 
structure. Furthermore, the terminology used to describe the purified structure 
should be carefully considered. We propose a model of their hierarchical structure 
and formation based on these results. This model and the results are likely highly 
relevant to understanding PGBs found in other diseases and pathologies.  
 
6.3.1 LB architecture depends on cellular origin 
 LBs form as a result of aberrant glycogen metabolism, which varies with tissue 
type. Although glycogen metabolism has been most thoroughly studied in liver and 
muscle, most cell types have the capacity to make glycogen, and it is regulated 
and utilized differentially depending on the tissue (113). Liver glycogen is utilized 
to maintain blood glucose during fasting; in muscle, glycogen utilization fuels 
muscle contraction during exercise. Glycogen metabolism in the heart is unique; 
paradoxically, cardiac glycogen is preserved under metabolic stress (374). In the 
brain, although it exists in low levels, glycogen is a dynamic participant in the 
sleep-wake cycle, learning and memory, and synaptic plasticity (80, 127, 128).  
Not only is glycogen differentially regulated, but its structure depends on its 
cellular origin. TEM studies show that in skeletal muscle, glycogen exist solely as 
small particles of 42 nm or less in diameter, known as β-particles. In liver, β-
particles associate to form rosettes known as α-particles up to 300 nm in diameter 
and are believed to release glucose more slowly (374). In the heart, glycogen 
exists in both forms. In the brain, only β-particles have been described under 
normal conditions although α-particles in the central nervous system have been 
associated with glycogen storage diseases (354, 355, 642). Phosphate content 
and average chain length of glycogen also depends on tissue type. Glycogen 
phosphate is 10-times higher in skeletal muscle than in liver, although the 
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relevance of glycogen phosphate is not yet clear (163, 167). Studies from the mid-
1900s demonstrated that the average chain length of liver glycogen is slightly 
higher than muscle glycogen (47, 133, 643). Chromatographic techniques for 
chain length profiling with very high resolution appeared in the 1990s, and it was 
demonstrated that glycogens from different sources had varying profiles although 
they were all asymmetrically unimodal (155, 156).  
Given these observations, it is not surprising that LBs from different tissues 
have distinctly different morphologies and CLD profiles, and therefore should be 
considered different LB 'types'. LB shape may simply be a product of the 
constraints of the cell type where it was formed. However, the differences in CLD 
underscores the tissue-specific differences in regulating glycogen structure. 
Indeed, the pathological consequences of these differences are intriguing. Since 
neurological symptoms dominate in LD patients, the brain is considered to be the 
most sensitive to glycogen perturbations. However, our results suggest that an 
additional factor could also contribute to neuronal and astrocytic sensitivity to 
glycogen perturbations. We found that brain LBs exhibit an exacerbated shift in 
chain length. Therefore, these LBs may actually be more toxic than heart and 
skeletal muscle LBs. In contrast, polyglucosan in the muscle, which has a CLD 
that is closest to normal glycogen, may be the least toxic. Anecdotally, we have 
observed that native, purified BrLBs clumped more frequently, followed by HtLBs, 
and then SmLBs, and the denatured polyglucosan from BrLBs was the most prone 
to precipitation. The severity of the clinical features of LD correlates with the shift 
in the CLD profile of LBs from the corresponding tissue. Seizures, cognitive deficits 
and neurodegeneration are the initial and most prominent clinical manifestations 
of the LD in both mice and humans (167, 326). However, cardiac abnormalities 
have also been reported in mouse models and patients (595, 596). Muscular 
complications in LD patients such as ataxia, dysarthria, spasticity, and rigidity are 
generally attributed to neurological deterioration (326, 644). LD mice only display 
mild muscle weakness and decreased motor coordination (177, 561). Reports 
about LBs in liver are also inconsistent: although liver abnormalities and PAS-
positive material have been reported in LD patients, they are not generally called 
LBs and hepatic disease is not typical (526, 645). In mouse models, LBs appear 
to accumulate more slowly in liver than in brain (177, 211).  
As we have mentioned, two types of BrLBs have been observed in LD patients 
and mouse models, often referred to as Van Hoof's type I and type II. It is possible 
that CLD may vary between the BrLB types, but they are inseparable using our 
purification method. A recent quandary has arisen regarding the cellular origin of 
BrLBs. For decades, LBs have been reported to exclusively populate neurons in 
LD patients (reviewed in (79)). Recently, two independent groups discovered LBs 
in both astrocytes and neurons in Epm2a-/- and Epm2b-/- mice (324, 325). Augé 
et al. showed that neuronal and astrocytic LBs were immunologically distinct, and 
that astrocytic LBs were identical to corpora amylacea. They suggested that Van 
Hoof's types I and II LBs correspond to astrocytic corpora amylacea and neuronal 
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LBs, respectively. Since we have observed distinct morphologies and CLD in LBs 
originating from cardiac and skeletal myocytes, it is reasonable to speculate that 
two distinct morphologies of BrLBs could correspond to their different cellular 
origins. 
 
6.3.2 Proposed model for LB architecture and formation 
We have described three levels of polyglucosan architecture in our study: the 
native LB, the polyglucosan network, and the polyglucosan particle. The largest 
entity is the native LB, ranging in diameter from 2-10 μm or more (Figure 6.9a). It 
is comprised of crystallized polyglucosan particles with B-type crystal packing, 
where double helices form a hexagonal unit with a water-filled interior channel. It 
is very likely that some double helices are formed from adjacent chains within the 
same polyglucosan molecule (intramolecular interactions), while others may be 
formed from chains from two different polyglucosans (intermolecular interactions). 
For most LB types, crystalline units are randomly arranged, in stark contrast to the 
lamellar structure of starch granules. The exception may be the dense core of type 
II BrLBs, which EM studies suggest are composed of radially arranged fibrils.  
The second structural entity is the polyglucosan network that emerges when 
intact LBs are boiled, mechanically agitated, or lintnerized (Figure 6.9b). These 
networks resemble potato lintners and retrograded (i.e. re-precipitated) 
amylopectin, both of which exhibit B-type crystallinity (635, 641). Since 
amylopectin and LD polysaccharide are both infrequently branched 
polysaccharides with long glucan chains capable of crystallizing, it is not surprising 
that the two polysaccharides would associate in a similar network formation. The 
networks are composed of knobby fibers between 5 and 20 nm in diameter. The 
morphology has been described as resembling a necklace, where the "pearls" are 
laterally packed helical bundles connected by longer amylopectin chains (635). In 
the case of LD, it is likely that molecules associate via intermolecular helical 
interactions to form these necklace-like fibers (Figure 6.9b). 
The third structural entity is the polyglucosan particle (Figure 6.9c). This 
particle is presumably an aberrantly branched glycogen β-particle, with such long 
chains that it crystallizes. We have shown that polyglucosan particles are best 
dissociated with Pflüger treatment, due to heating in KOH. Indeed, alkaline 
treatment increases the solubility of both glycogen and starch (646, 647), and 
certain forms of these polysaccharides (desmoglycogen or 'fixed' glycogen and 
resistant starch) can only be solubilized with alkali (648, 649). This is likely simply 
because alkali solutions disrupt hydrogen bonding (650). 
In starch, the crystalline, double helical conformation of glucan chains prohibits 
their access by degrading enzymes (139). Presumably, the long chains of 
polyglucosan particles take on a similar conformation and prevent them from being 
degraded by the glycogenolytic machinery (188). As a result, polyglucosan 
particles accumulate, potentially associating into networks inside of cells like the 
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ones we observed in vitro (Figure 6.6). Aggregation and network formation likely 
occur spontaneously, similar to the natural retrogradation of amylopectin after it is 
cooked. It is possible that the cell, detecting an unknown and potentially toxic 
species, sequesters the polyglucosan particles and networks into non-membrane-
bound inclusions that become LBs. LBs have been shown to be decorated with a 
variety of proteins involved in glycogen metabolism, ER stress, ubiquitin, and 
autophagy and delineated by cytoskeletal elements in vivo (179, 586). Thus, the 
formation of this structural entity may not be entirely spontaneous; cellular 
mechanisms may assist in polyglucosan sequestration. We showed that ethanol 
precipitation of LBs after boiling in water led to some polyglucosan clumps that 
stained as intensely as native LBs. This treatment may in some way resemble the 
process of polyglucosan sequestration and compaction that occurs in cells. The 
shape and size of the LB is probably dictated by the internal constraints of the cell 
type where it forms, but may also be influenced by the CLD of the constituent 
polyglucosan and/or effects of surrounding molecules.  
The random arrangement of fibrils and lack of higher order in LBs is not 
surprising, given that they are an aggregate that forms in response to a aberrant 
cellular mechanism. B-type crystallization is favored by longer chains and lower 
temperatures (651, 652). Even native A-type amylopectin takes on a B-type 
conformation after retrogradation, and A-type crystallites can convert to B-type 
with sufficient hydration (653, 654). A previous study showed that enzymatic chain 
elongation of glycogen produced dendritic particles with B-type crystallinity (655). 
Electron micrographs suggest that over time, double helical segments formed as 
a result of intra- and intermolecular entanglement of the extended glucan chains. 
It has been proposed that in LD, the lack of laforin or malin leads to an imbalance 
in glycogen synthase and phosphorylase activities, causing aberrant chain 
elongation (188). Thus, the entanglement and crystallization of artificially 
elongated glycogen as described by Putaux et al. may resemble what occurs in 
vivo in LD.  
 
6.3.3 Nomenclature: Polysaccharides, glycogen, polyglucosan, PGBs and LBs 
 We have endeavored to be precise with our terminology in this study. The term 
'polysaccharide' denotes any polymer of sugar molecules, and thus glycogen, 
amylopectin, amylose, and polyglucosan are all considered polysaccharides. The 
term 'polyglucan' refers only to polysaccharides containing glucose units attached 
by glycosidic bonds, and more specifically, α-polyglucans are those with α-1,4 an 
α-1,6 glycosidic bonds. Thus, all of the polysaccharides that we have discussed 
in this paper are also α-polyglucans. However, we have abstained from using the 
term 'polyglucan' due to its similarity to 'polyglucosan' and also since no other 
types of polysaccharides are discussed. 
 The polysaccharides purified from LD mice via the Pflüger method are 
frequently called 'glycogen', and LD mice are said to have increased glycogen in 
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their tissues. However, the Pflüger purified polysaccharides are actually a mixture 
of both normal glycogen and abnormal polysaccharides that we refer to herein as 
polyglucosan. The polyglucosan of LD is a precipitation-prone, crystalline 
polysaccharide with long chains. This structure does not fit the definition of 
glycogen, i.e. a soluble glucose polymer with ~13 glucose units per chain and 
regular branching (113). Therefore, we propose that the abnormal polysaccharide 
should be called polyglucosan rather than glycogen. In fact, studies of the 
polysaccharide content of insoluble vs. soluble 'glycogen' fractions in LD mice 
show that LD mice display an increase in the insoluble fraction (corresponding to 
polyglucosan), but the soluble fraction is equivalent to WT mice (178). Thus, LD 
tissues have approximately the same amount of soluble glycogen as WT mice, 
and the total increase in polysaccharide, is exclusively due to insoluble 
polyglucosan.  
We also want to clarify the difference between 'polyglucosan', 'polyglucosan 
bodies' (PGBs), and 'LBs'. We use the term polyglucosan to refer to any abnormal 
glucose polymer containing α-glycosidic linkages found in mammalian tissues, but 
its exact chemical characteristics vary with its pathological origin. The 
polyglucosan found in LD tissues is more phosphorylated and has a right-shifted 
CLD compared to glycogen. 'PGBs' refer to the compacted inclusions of 
polyglucosan observed in vivo, which can be isolated as intact entities (169, 616) 
(Chapter 5). Corpora amylacea and LBs are considered PGBs, but not all PGBs 
are exactly equivalent to LBs or corpora amylacea with respect to CLD and other 
structural elements. 'LBs' are the PGBs found in LD, which we have shown are 
crystalline and morphologically distinct based on tissue type.  
 
6.3.4 Similarities of LBs with other PGBs and amyloid and relevance to 
neurological disease 
PGBs of different pathologies are overall very similar but distinguishable by 
subtle ultrastructural and histochemical qualities. LBs are the only PGB to display 
a darkly staining central core with radiating fibrils visible by electron microscopy 
(79). The polyglucosan fibrils in LBs are somewhat thicker and more electron 
dense than those in the PGBs of GSD IV, a disease caused by a deficiency in 
glycogen branching enzyme (569). With Lugol's iodine, LBs are brown, corpora 
amylacea are purplish-brown, and the GSD IV PGBs are distinctly purple, 
indicating they contain very long glucan chains (616, 624). The PGBs of GSD IV 
do not stain with toluidine blue, in contrast to corpora amylacea and LBs, 
suggesting they have a much lower phosphate content (624). Corpora amylacea 
have even more phosphate than LBs (168). The data presented in the present 
study on LBs are likely to be very relevant to understanding the architecture and 
formation of other PGB types. It is likely that the aggregation of polyglucosan into 
networks and B-type crystallization are common features of PGBs. It will be very 
interesting to compare their CLD profiles and understand how their chemical 
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compositions affects their architecture and in vitro properties.  
The different levels of polyglucosan association (PGB, network, and particle) 
are analogous to the levels of protein aggregation in amyloid disorders. 
Polyglucosan particles aggregate into networks much like misfolded proteins 
aggregate into soluble amyloid oligomers. Eventually the polyglucosan compacts 
into PGBs, and soluble oligomers polymerize into fibrils and plaques, although 
these higher-orders structures are distinctly different (PGBs contain crystalline α-
helices, while amyloid contains β-sheets; polyglucosan fibrils are branched, but 
amyloid fibrils do not; PGBs are typically not birefringent, in contrast to amyloid; 
etc.). It is possible that for both types of inclusions, the intermediate aggregates 
are toxic, and the higher-order structures are reactionary, or even protective. 
There is a significant amount of evidence supporting the toxicity of soluble 
oligomers rather than amyloid fibrils (656, 657). Since LBs are often found in 
apparently healthy neurons, and degenerating neurons usually lack LBs, some 
have suggested that the sequestration of polyglucosan into LBs may be a 
protective mechanism in neuronal cells (177, 586). Corpora amylacea, which 
appear with aging and various neurological conditions, are also considered a 
protective response to age-related or pathological degeneration (611). It has been 
suggested that the corpora amylacea are a repository for hazardous cellular waste 
that can be cleared by the immune system (658). The observation that 
polyglucosan is a primary constituent of these alleged cellular 'trash bins' further 
supports their potentially toxic nature. 
Whether or not higher-order PGBs are themselves pathogenic or reactionary, 
studies indicate that polyglucosan accumulation is pathogenic at some level. 
Genetic ablation of glycogen synthase in the brain rescues the neurological 
phenotype in LD mouse models, and overexpression of glycogen synthase 
induces polyglucosan accumulation and neurodegeneration in WT flies and mice 
(182, 563). Similarly, inhibition of glycogen synthase eliminates PGBs and 
reverses neurological damage in a mouse model of GSD IV (262). Glycogen 
synthase ablation in WT mice also eliminates the formation of corpora amylacea 
with aging, and a reduction in glycogen synthesis eliminates polyglucosan 
deposits and increases lifespan in Drosophila (659). Further investigation will be 
necessary to understand how polyglucosan is sequestered as PGBs in vivo, why 
various forms of polyglucosan are pathological, and what can be done to alleviate 
their toxicity. 
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Figure 6.1 Representative z-stack images of iodine-stained starch and LBs.  
Starch (a), SmLBs (b), HtLBs (c), and BrLBs (d-e) were visualized by confocal 
microscopy using 561 nm (TRITC) channel and differential interference contrast 
(DIC). In (a), scale bar = 10 μm and panels represent 2 μm steps. In (b), scale bar 
= 2 μm and panels represent 0.4 μm steps. In (c-e), scale bar = 2 μm and panels 
represent 0.9 μm steps. 
  
182 
 
 
 
Figure 6.2 Additional z-stack images. 
Iodine-stained starch (a,b), SmLBs (c,d), HtLBs (e,f), and BrLBs (g,h). In (a,b), 
scale bars = 5 μm and panels represent 2.25 μm steps. In (c-h), scale bars = 2 
μm and panels represent 0.9 μm steps.   
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Figure 6.3 Chain length distribution of LB types determined by FACE.  
Degree of polymerization (DP) corresponds to the number of glucose units per 
linear chain.  
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Figure 6.4 Wide-angle X-ray scattering (WAXS) of LBs and phytoglycogen.  
(a-c) 2D WAXS diffraction patterns of BrLBs (a) and SmLBs (b) illustrate a B-type 
ring distribution. Phytoglycogen produces scattering halos without distinct rings 
(c). The corresponding 1D scattering profile for SmLBs is shown (d); grey arrows 
designate the B-type reflections.  
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Figure 6.5 Small-angle X-ray scattering (SAXS) of LBs and potato 
amylopectin starch.  
(a,b) 2D SAXS diffraction patterns of (a) SmLBs and (b) starch. (c) 1D scattering 
profile for both samples.  
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Figure 6.6 Effects of various treatments on the structure of LBs. 
SmLBs (a-f) and BrLBs (g-i) were stained with Lugol's iodine after each treatment 
and visualized by light microscopy. Control SmLBs (a); mildly sonicated SmLBs 
(b); SmLBs heated in water at 95°C for 30 minutes (c); SmLBs heated in water at 
95°C for 2 hours (d); SmLBs heated in water at 95°C for 2 hours, then precipitated 
3 times with 2 volumes cold ethanol and LiCl (e); SmLBs treated with the Pflüger 
method (2 hours at 95°C in 30% KOH) (f). Control BrLBs (g); BrLBs heated in water 
for 30 minutes (h); BrLBs treated with the Pflüger method (i).  Scale bar = 10 μm. 
Each inset is a 2.5x magnification of the boxed region. Thresholding was used to 
quantitate LBs (with high intensity staining) and polyglucosan (with low intensity 
staining) in micrographs. Examples of applied thresholds for (g-i) are shown in (j-
l). Pixels with high intensity (grey values 0-50) and low intensity (grey values 51-
140) were counted and shown as a percentage of total counted per micrograph. 
Pixels with grey values above 141 were considered background and not counted. 
The values shown are the averages of 9 micrographs ± standard error.   
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Figure 6.7 Structural transition of SmLBs during heating. 
Control SmLBs (a), SmLBs heated for 1 minute and flash frozen (b), and SmLBs 
heated for 5 minutes and flash frozen (c). After freezing, samples were thawed, 
stained with Lugol's iodine, and visualized using a light microscope with a Zeiss 
512 color camera. Scale bar = 10 μm. 
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Figure 6.8 Transmission electron micrographs of LBs exposed to various 
treatments. 
Boiled SmLBs (a,b), Pflüger-purified polysaccharide from Epm2a-/- mice (c) and 
WT mice (d), linterized BrLBs (e,g) and lintnerized SmLBs (f,h). Lintnerized 
samples were incubated in 2.2 N HCl at 36°C for 5 days and then visualized. 
Panels (a-f) are shown at equal magnification for comparison, while (g,h) are 
magnified 2.5x for detail. Scale bars = 40 nm. 
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Figure 6.9 A model for LB structure and formation.  
Blue arrows and text illustrate what was observed in vitro, and red arrows and 
text illustrate what may occur in vivo. 
 
 
 
 
 CONCLUDING REMARKS 
7.1 Summary 
Since its discovery in the 1800s, glycogen metabolism has received an 
enormous amount of scientific attention. At least four Nobel prizes related to the 
field of glycogen metabolism were awarded during the 20th century, and the topic 
occupies at least one chapter in nearly every biochemistry textbook. Since the 
1970s, the field has assumed to be an antiquated area of research, one that has 
been so extensively elucidated that research efforts should be directed elsewhere 
(103). This assessment is most certainly not the case. The role of glycogen in the 
brain is only beginning to be understood (80, 127, 128). Additionally, the intricate 
mechanisms of glycogen regulation are still being defined (137). Basic studies of 
Pompe and Lafora disease have revealed the importance of neuronal glycogen, 
glycogen structure and covalent phosphorylation, and glycophagy (167, 275). 
Novel GSDs are still being described as GSD type XV was only recently 
discovered (165, 240). Furthermore, with the exception of Pompe disease, 
therapies for GSDs are severely lacking. Lafora disease (LD), an atypical GSD 
causing severe epilepsy and early death, is one such disease.  
Genetic testing has been employed with increasing frequency to diagnose 
diseases, particularly in the epilepsy field (660). LD is no exception; a genetic 
diagnosis is essential due to the rarity and severity of the disease. As a result, the 
resolution with which scientists and clinicians can view the disease is improving. 
LD is no longer considered a homogenous disorder, but it is understood that 
genetics can modify or dictate clinical phenotype (328, 484, 488). There are many 
parallels between the fields of cystic fibrosis and LD, and like CFTR mutations, we 
have shown that LD missense mutations can be divided into classes with different 
molecular effects (Chapter 3). Our biochemical results pose a molecular 
explanation for milder forms of LD, and the pipeline that we have developed will 
facilitate characterization and classification of novel mutations within a matter of 
weeks. With LD therapies in preclinical development, personalized diagnoses and 
patient-specific treatments will become extremely beneficial in the near future. 
Despite multiple advances in the last decade, many gaps in our understanding 
of LD remain. Perhaps the most difficult question is why the lack of laforin or malin 
leads to aberrant glycogen structure and hyperphosphorylation. The relevance of 
laforin phosphatase activity has been challenged based on mouse models (159, 
188, 189). We discovered that the catalytically inactive laforin C/S mutant that is 
able to rescue the LD phenotype in mouse models dramatically changes the 
binding properties of laforin. Laforin C/S is a less dynamic protein that enhances 
the interaction of laforin with both glucan and protein substrates (Chapter 4). 
Before the work presented herein, the field assumed that the primary cause of LD 
in EPM2A mutant patients was a lack of laforin phosphatase activity. However, my 
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work has demonstrated that the primary deficiency of LD-causing laforin missense 
mutations is a lack of glucan binding and/or deficient protein-protein interactions, 
and not a defect in phosphatase activity (Chapter 3). While LD-causing mutations 
lead to destabilization and reduced glucan/protein interaction, the LD-rescuing 
mutation C/S leads to increased rigidity and enhanced glucan/protein interaction. 
These results strongly suggest that the primary role of laforin is to serve as an 
adaptor protein on the glycogen molecule. The similar phenotypes observed by 
malin- and laforin-deficient patients do indeed suggest that laforin and malin have 
overlapping functions, and the evidence for a laforin-malin complex is building 
(188). In fact, many RING-type E3 ubiquitin ligases function as dimers or part of a 
multi-subunit complex (661). Laforin and malin may function analogously to the 
Cullin-RING E3 ubiquitin ligase complexes, which consist of an elongated Cullin 
protein bridging a RING-containing E3 ligase with an adaptor and substrate 
receptor (662). However, the independent functions of laforin and malin must not 
be disregarded. The conservation and centrality of glucan phosphorylation to 
carbohydrate metabolism across multiple kingdoms reinforce the relevance of 
laforin phosphatase activity (139, 183, 185), as does the observation that even in 
malin deficiency, aberrantly branched glycogen is hyperphosphorylated (159, 178, 
180).  Furthermore, malin ubiquitinates glycogen phosphorylase independent of 
laforin (Sun, Dukhande, Gentry, unpublished data).  
History can attest to the enormous benefit of basic scientific studies for the 
development of novel therapies (663, 664). The similarities between LBs and plant 
starch led to the conception of a targeted fusion enzyme comprised of α-amylase, 
which naturally degrades starch in the human gut. We showed that this enzyme 
reduces LB load in muscle, heart and brain of LD mice (Chapter 5). An analogous 
enzyme designed to treat Pompe disease has shown great promise in phase 1/2 
clinical trials (577). Additional lines of therapy for LD are being developed by the 
same investigators who laid the initial biochemical groundwork in the LD field (328, 
564). The concerted efforts of basic scientists, clinicians, and the families of 
patients have accelerated progress toward therapies and a cure (665).  
Although LD is a rare disease, the work herein has applications beyond LD. 
Antibody-fusion therapy has the potential for treating an array of diseases, 
including most GSDs. Also, accumulated glycogen and/or polyglucosan bodies 
(PGBs) are found in some cancers and neurological diseases (79, 611, 666, 667). 
Although PGBs have been studied histologically, their fine structure and molecular 
composition have not been defined in a level of detail comparable to plant starch 
(145). We studied LBs using X-ray diffraction, microscopy, and chemical, thermal 
and mechanical means (Chapter 6). We discovered tissue-specific differences 
and postulate that both spontaneous precipitation and cellular sequestration 
contribute to LB formation. This study is broadly applicable since polyglucosan 
accumulation is pathogenic, and the formation of other types of PGBs may 
proceed in a similar manner.  
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7.2 Limitations and Future Directions 
 Although we have defined molecular defect(s) for most of the LD missense 
mutations analyzed, no defect was detected in 6 of the 27 mutations (E210K, 
P211L, E224I, K140N, G240S, and P246A) using our current suite of assays. 
E210, P211 and E224 are surface-exposed residues of the laforin V-loop that may 
represent a binding surface for additional laforin interaction partner(s). K140 may 
be a ubiquitination site, suggesting laforin ubiquitination is critical for preventing 
LD. It is not clear why S25P abolished the interaction of laforin with malin and 
PTG; however, S25 has been shown to be a site for phosphorylation by AMPK 
(313). Laforin and malin have also been shown to ubiquitinate the CBM-containing 
β-subunit of AMPK (303). These data suggest reciprocal regulation between 
AMPK and the laforin-malin complex. Further study will be required to identify the 
molecular defects of all missense mutations. A current limitation in studying the 
laforin-malin interaction in vitro is the inability to produce soluble recombinant 
malin using E. coli. This issue may be circumvented by alternative expression 
systems such as insect or mammalian cells. Knock-in mouse models of missense 
mutations will also be extremely useful for defining and treating mild forms of LD. 
These models are currently in development using CRISPR gene editing 
technology (328).  
 We have shown that laforin has a DSP-DSP dimer interface and that this 
interface is important for cooperative binding to glucan substrates (Chapter 4) 
(190). Our data suggest that cooperative binding may be specific for long, 
phosphorylated glucans, which is mimicked by the interaction of phosphate-bound 
C266S laforin with DP24. Phosphoglucan substrates are not readily available 
commercially, but they could be prepared by debranching amylopectin or purified 
LD polyglucosan. Furthermore, it is not clear if and how laforin phosphatase 
activity and binding to other proteins are coupled. We propose that one subunit 
may phosphorylate a glucan while the other binds to a protein. We also suggest 
that dimerization may be required for the malin interaction (Chapter 3). These 
speculations will need to be tested further.  
 It is not clear if and how laforin binds to branch points in glucans, although the 
multiple glucan molecules found at both binding sites in the glucan bound 
structure, as well as the location of W196, suggest a branch point interaction. 
However, laforin preferentially binds amylopectin-like or LB-like substrates, which 
have fewer branch points than glycogen. Again, testing this is limited by the 
availability of branched glucan substrates, which are difficult, although not 
impossible, to attain. It would also be interesting to monitor the dynamics of the 
laforin-glucan interaction. Obviously, a single dimer has two primary contact sites 
on the CBMs. Do these two sites alternate binding and releasing glucans, allowing 
laforin to "walk" across the surface of a glycogen molecule? Or does the entire 
dimer associate and dissociate from a glucan as a unit? The observation that 
laforin always colocalizes tightly with glycogen molecules in cell culture suggests 
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the former.  
 The emerging role(s) of laforin as a scaffolding molecule and/or adaptor protein 
for glycophagy need to be further defined. Crystal structures of laforin in complex 
with different glucan substrates and/or binding partners will be tremendously 
useful in understanding how laforin may assemble with malin other proteins on 
polyglucans. Again, such studies are limited by the availability of glucan substrates 
and recombinant proteins. However, structures of glycogen synthase, glycogen 
debranching enzyme, and the AMPK β subunit and partial structures of p62 have 
been determined (251, 264, 668-670). The ubiquitination of these proteins by 
malin may require direct binding by laforin (300, 303, 307, 455). 
We have shown that VAL-0417 reduces LB load of LD mice. However, the 
effect of the drug on neurodegeneration and epilepsy is difficult to assess using 
mouse models. As is the case for many neurodegenerative diseases, LD mouse 
models incompletely recapitulate the human phenotype. Although they do exhibit 
behavioral and neurophysiological impairments, LD mice do not have a reduced 
lifespan, comparable EEG abnormalities, or spontaneous grand mal seizures 
(177). To detect seizure susceptibility, kindling with convulsive agents is often 
employed (180, 182, 294, 562). Electrophysiological and behavioral changes are 
difficult to detect even in older mice (e.g. 6 months) corresponding to a 
developmental stage beyond the lifespan of most LD patients (30 years). There 
are canine models of LD that develop spontaneous convulsive seizures, but 
clinical features often develop later in life and the animals also do not die early 
(671, 672). Although additional preclinical development can be performed in mice 
or dogs, such as drug turnover rate, effective dosing range and toxicity levels, 
there are limitations to both models. Phase 1/2 clinical trials involving another 
antibody-enzyme fusion therapy for Pompe disease are currently underway, and 
our preliminary data indicate this drug also reduces LB load in LD mice (328, 577). 
Therefore, repurposing this drug for LD treatment is also a viable option, 
particularly since it has already entered the clinical stage. Treatment of LD with 
antibody-enzyme fusions will require direct injection into the CNS of patients to 
bypass the blood-brain-barrier. We showed that intracerebroventricular (ICV) 
injection achieves a better distribution than intrathecal injection of VAL-0417 
(Chapter 5). Implanted ICV devices are already utilized for safe, long-term drug 
administration to the CNS and are favored over repeated lumbar punctures (599). 
Clinical trials with LD patients would likely involve periodic injections via an 
implanted ICV device. To prepare for these clinical trials, a natural history study 
has already been initiated to define the natural course of the disease, establish a 
primary endpoint, and identify potential biomarkers that could be used to monitor 
treatment (328). 
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7.3 Conclusion 
 This work has contributed to the development of personalized diagnoses and 
therapies for LD and a better understanding of the molecular basis for LD. These 
studies highlight the importance of basic science research for therapy 
development and also the necessity for a deeper understanding of glycogen 
metabolism, particularly in the brain.  
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